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Abstract 
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in the 
world.  Identifying clinically relevant COPD phenotypes has the potential to reduce the 
global burden of COPD by helping to alleviate symptoms, slow disease progression and 
prevent exacerbation by stratifying patient cohorts and forming targeted treatment plans.  
In this regard, quantitative pulmonary imaging with hyperpolarized 
3
He magnetic 
resonance imaging (MRI) and thoracic computed tomography (CT) have emerged as 
ways to identify and measure biomarkers of lung structure and function.  
3
He MRI may 
be used as a tool to probe both functional and structural properties of the lung whereby 
static-ventilation maps allow the direct visualization of ventilated lung regions and 
3
He 
apparent diffusion coefficient maps show the lung microstructure at alveolar scales.  At 
the same time, thoracic CT provides quantitative measurements of lung density and 
airway wall and lumen dimensions.  Together, MRI and CT may be used to characterize 
the relative contributions of airways disease and emphysema on overall lung function, 
providing a way to phenotype underlying disease processes in a way that conventional 
measurements of airflow, taken at the mouth, cannot.  Importantly, structure-function 
measurements obtained from 
3
He MRI and CT can be extracted from the whole-lung or 
from individual lung lobes, providing direct information on specific lung regions.  In this 
thesis, my goal was to identify pulmonary imaging phenotypes to provide a better 
understanding of COPD pathophysiology in ex-smokers with and without airflow 
limitation.  This thesis showed: 1) ex-smokers without airflow limitation had imaging 
evidence of subclinical lung and vascular disease, 2) pulmonary abnormalities in ex-
smokers without airflow limitation were spatially related to airways disease and very 
mild emphysema, and, 3) in ex-smokers with COPD, there were distinct apical-basal lung 
phenotypes associated with disease severity.  Collectively, these findings provide strong 
evidence that quantitative pulmonary imaging phenotypes may be used to characterize 
the underlying pathophysiology of very mild or early COPD and in patients with severe 
disease. 
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CHAPTER 1 
INTRODUCTION 
Chronic Obstructive Pulmonary Disease (COPD) is characterized by progressive airflow 
limitation caused by a combination of airways disease and emphysema due to 
inflammatory responses in the lung to noxious particles (1).  The objective of Chapter 1 is 
to provide an overview of the global health burden imposed by COPD and the 
pathophysiology, symptoms and medical complications associated with the disease. 
Chapter 1 will also describe the conventional methodology for measuring pulmonary 
function and diagnosing COPD and discuss the use of pulmonary imaging for identifying 
clinically relevant COPD biomarkers and phenotypes. 
1.1 Chronic Obstructive Pulmonary Disease:  A Leading 
Cause of Death Worldwide 
Chronic obstructive pulmonary disease (COPD) affects 10% of the adult population 
worldwide (2).  A decade ago, COPD was the 4
th
 leading cause of death in the world.  At 
that time, based on global estimates of the rising use of tobacco smoke and biomass fuels, 
concomitant with the aging population, the World Health Organization (WHO) and 
others projected COPD to rise to the 3
rd
 leading cause of death in the world between the 
years 2020 – 2030 (1, 3).  Despite this threat, therapies and research efforts did not result 
in a reduced COPD mortality rate and it subsequently became the 3
rd
 leading cause of 
death in the world in the year 2010, a decade earlier than expected (4). 
 
Table 1-1.  Leading Causes of Death Worldwide in 2012 (Adapted from The 
World Health Organization Report 2014 (5)) 
Rank Disease Deaths (millions) % Deaths Worldwide 
1 Ischemic Heart Disease 7.35 13.2 
2 Cerebrovascular Disease 6.67 11.9 
3 COPD 3.10 5.6 
4 Lower Respiratory Infections 3.05 5.5 
5 Respiratory Cancers  1.60 2.9 
 
2 
 
 
 
COPD also causes life-altering disability to those affected and is expected to become the 
5
th
 leading cause of disability worldwide by the year 2030 making it one of the fastest 
rising disability threats in the world (Table 1-2). 
 
Table 1-2.  Worldwide leading causes of disability in 2004 and their predicted 
rank in 2030 (Adapted from ‘The Global Burden of Disease:  2004 Update, World 
Health Organization’ (3)) 
2004 Rank* Disease or Injury  2030 Rank* Disease or Injury 
1 Respiratory Infections  1 Depressive Disorders 
2 Diarrhoeal Diseases  2 Heart Disease 
3 Depressive Disorders  3 Traffic Accidents 
4 Heart Disease  4 Cerebrovascular Disease 
5 HIV / AIDS  5 COPD 
6 Cerebrovascular 
Disease 
 6 Respiratory Infections 
7 Premature birth  7 Hearing loss 
8 Birth trauma  8 Vision problems 
9 Traffic Accidents   9 HIV / AIDS 
10 Neonatal Infections  10 Diabetes 
13 COPD    
*Rank based on the disability adjusted life years (DALY), one DALY is equivalent to 
the loss of one year of full health 
 
Given the staggering statistics on the mortality and disability rates, it is not surprising that 
COPD also has the highest rate for hospital admissions and readmissions among chronic 
illnesses in the United States, Canada and Europe (Figure 1-1) (6, 7). 
Along with having a significant frequency of hospitalization, it is estimated that each 
hospitalized COPD exacerbation costs on average $10,000 CAN and the overall national 
economic burden for COPD hospitalizations ranges from $646 million to $736 million 
each year (8).  Unfortunately, these costs are expected to rise in tandem with the 
increasing burden of COPD disability over the next two decades. 
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Figure 1-1.  Hospitalizations and repeat hospitalizations by health condition 
Adapted from the Canadian Institute for Health Information (CIHI) (6) 
 
Collectively, these reports on the prevalence of COPD mortality, morbidity and disability 
have established that the burden of COPD is a global health issue.  At the same time 
however, epidemiological studies are showing that anywhere from 20-80% of individuals 
with impaired lung function consistent with COPD are not diagnosed nor treated for the 
condition (9, 10).  This may partly explain one reason why COPD is such a deadly and 
disabling disease as it suggests that individuals are not likely to seek care or treatment for 
their respiratory symptoms until their lung function has declined severely and may not be 
able to be adequately controlled with treatment or surgery.  As will be explained in more 
detail in this thesis, another explanation for the high mortality and disability rates of 
COPD is related to poor characterization of pulmonary pathophysiology of at-risk 
individuals who may be in the early subclinical stages. 
It has become obvious that there is room for improvement in regard to screening methods 
and diagnostic strategies for COPD.  In the following subsections of the Introduction I 
4 
 
 
 
will provide background knowledge on pulmonary pathophysiology in the healthy and 
COPD lung with emphasis on the varying contributions of airways disease and 
emphysema from patient to patient.  In the latter part of the introduction I will discuss 
conventional lung function testing and pulmonary imaging methods for characterizing, 
diagnosing and grading COPD.  Chapters 2, 3 and 4 are original research investigations 
focused on identifying clinically meaningful pulmonary imaging biomarkers and 
phenotypes to provide a better understanding of airflow limitation in ex-smokers with and 
without COPD.  Lastly Chapter 5, the Conclusion, will summarize the key pulmonary 
imaging findings from the studies in Chapters 2, 3 and 4 and discuss future work needed 
to address unanswered questions pertaining to pulmonary imaging abnormalities and their 
clinical relevance in ex-smokers with and without COPD. 
 
1.2 COPD:  A Heterogeneous Disease of the Lung 
COPD is an umbrella term that encompasses airways disease and emphysema.  Both 
airways disease and emphysema contribute differently to airflow limitation in each and 
every patient making the clinical presentation of COPD vary immensely among 
individuals who are demographically the same, who have the same smoking history and 
even among people with the same lung function and respiratory symptoms.  Decades of 
research has been put in to characterizing the pathophysiological and biochemical 
processes in the airways and lung parenchyma involved in lung function decline.  In this 
section I will discuss how pathophysiological changes to the airways and alveoli cause 
the irreversible airflow limitation characteristic of COPD 
1.2.1 Chronic Bronchitis 
Chronic bronchitis is characterized by extended periods of excessive cough and mucus 
and sputum production.  The inflammation triggered by noxious particles (from cigarette 
smoke or other pollutants) in the large or central airways (> 4mm in diameter) is the key 
cause of bronchitis.  The inflammatory response imposed by tobacco smoke triggers 
increased production of mucus and sputum with concomitant decrease in mucus 
clearance from the large central airways due to damage to the airway epithelial barrier.  
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There is also evidence that the bronchial walls thicken (causing the airway lumen to 
narrow) as a result of the abnormal accumulation of connective tissue within the medium 
and large airway walls (11).  Methods have been developed (12) to diagnose chronic 
bronchitis based on the ratio of mucus gland to bronchial wall thickness (Reid Index) 
however an clinical definition based on the frequency and duration an individual 
experiences of a debilitating cough is more commonly used (1).  
1.2.2 Small Airways Disease 
The airways < 2mm in diameter are the major site of airflow obstruction in COPD (13).  
These are airways (bronchioles) beyond the fourth generation of branching (Figure 1-2).  
As the bronchial tree branches non-dichotomously, the number of airways with each 
successive generation increases and so does their total cross sectional area (14).  The 
majority (75%) of airway resistance in the bronchial tree is attributable to the large 
(central) conducting airways (conducting airways > 2mm) while only a fraction of 
resistance is located in the small airways of the respiratory zone (15).  Therefore, the 
small airways contribute very little to overall airway resistance.  However, it is in these 
airways that disease can accumulate over long timeframes without having a significant 
effect on overall lung function and without causing noticeable respiratory symptoms (16). 
As already mentioned in 1.2.1, the introduction of toxins to airway epithelium increases 
mucus production, injures and impairs the mucociliary escalator and triggers an 
inflammatory response in the bronchi.  This is true for the small airways also.  The excess 
mucus and inflammatory markers (B cells, CD4 and CD8 lymphocytes) that are produced 
in response to the noxious particles accumulate and obstruct the small airways.  There is 
also evidence that a portion of mucus present in the small airways in COPD may actually 
be aspirated there from the large and central airways (15).  In addition to airway 
obstruction, the abnormal deposition of inflammatory cells and connective tissue in the 
small airway wall causes fibrosis of the airway wall and airway lumen obstruction in 
severe disease (13).  The progression of COPD with respect to lung function decline from 
mild to severe grades has been most closely associated with the thickening of the airway 
wall and surrounding compartments and less closely related to the degree of 
inflammation and mucus secretion within the small airways (13). 
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Figure 1-2.  Diagram of airway tree including the conducting and respiratory zones 
and showing the airway generations.  The conducting zone comprises the large and 
small central airways up to the 16
th
 generation that do not participate in gas exchange.  
The transition and respiratory zone comprise airways >17
th
 generation.  Surface area 
increases with airways generation and gas exchange processes occur in the respiratory 
bronchioles, alveolar ducts and sacs.  Reproduced from Respiratory Physiology:  The 
Essentials, 8
th
 Edition (14) 
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1.2.3 Emphysema 
Emphysema is defined as dilation and destruction of lung parenchyma distal to the 
terminal bronchiole (17) (see Figure 1-3).  In emphysema the airspaces involved in gas 
exchange enlarge and coalesce which reduces the surface area within the lung to carry out 
necessary gas exchange processes.  There are several subphenotypes of emphysema 
which are named according to the lung units that are involved.  Centrilobular, or 
centriacinar emphysema arises from damage and enlargement of the respiratory 
bronchioles (Figure 1-2 and 1-3) and is most commonly associated with cigarette 
smoking.  Centrilobular emphysema predominantly occurs in the apical-lung and it is 
postulated that this is a result of the elevated ventilation (V) – perfusion (Q) ratio (V/Q) 
in this part of the lung (14).  Since the ventilation largely outweighs perfusion (~3/1) in 
the apical lung, it is thought that noxious particles from cigarette smoke may be deposited 
in the distal airspaces without passing into the pulmonary circulation inducing 
inflammation and subsequent destruction of parenchynmal tissue.  A second form of 
emphysema, panlobular or panacinar emphysema, is more common in non-smoking 
related COPD and in particular alpha-1 antitrypsin deficiency (AATD).  AATD is an 
autosomal hereditary disorder and the panlobular emphysema characteristic of AATD 
destroys the structure of the entire distal bronchiole starting with the alveolar ducts and 
sacs and gradually degrading the structure of the respiratory bronchiole (Figure 1-2 and 
1-3) (18).  AATD is a result of reduced serum levels of alpha-1 antitrypsin, a protease 
that is responsible for protecting the lung from proteolytic activity of neutrophil elastase.  
The unchecked levels of neutrophil elastase result in destruction of the alveolar walls.  
AATD associated panlobular emphysema has been found to occur predominantly in the 
highly perfused basal-lung region where neutrophils and proteases are circulating within 
the blood (18).  Lastly, paraseptal emphysema is defined as dilation of the airspaces near 
or adjacent to the lung pleura and septa.  In paraseptal emphysema the most peripheral 
airspaces (Figure 1-2 and 1-3) are destroyed but typically these emphysematous lesions 
are asymptomatic and not associated with cigarette smoke but with lung trauma such as 
pneumothorax (19). 
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Figure 1-3.  Schematic of healthy, panlobular, centrilobular and paraseptal acini.   
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1.2.4 COPD – Asthma Overlap 
Although Asthma is not the direct focus of work presented in this thesis, a significant 
proportion of individuals who experience symptoms of COPD also exhibit symptoms 
consistent with Asthma.  This clinical presentation has recently been termed ‘Asthma-
COPD Overlap Syndrome (ACOS)’ and warrants explanation (20, 21).  While COPD 
encompasses both an airway and emphysema component, asthma is characterized by 
inflammatory and hyperresponsive airways.  Unlike in COPD, the airway obstruction in 
asthma is reversible with the use of inhaled corticosteroids and long-acting 
bronchodilators.  Although there are clearly defined clinical characteristics to stratify 
asthma and COPD patients (20), these guidelines fail to acknowledge the spectrum of 
ACOS.  This is an issue because based on these guidelines asthmatics are often excluded 
from large-scale and longitudinal COPD studies even if they are current- or ex-smokers.  
One study (22) found in a group of adults (> 55 yrs) with either COPD or asthma, 65% of 
subjects had overlap of asthma and COPD while only 16% and 21% of subjects had 
definite asthma or COPD respectively.  There are many possible origins of the ‘overlap’ 
between asthma and COPD and most likely the origin is different for every patient with 
ACOS.  It is widely known that asthma is most commonly diagnosed in childhood, but 
childhood respiratory disease is also closely linked to the development of impaired lung 
function and COPD later in life.  At the same time, cigarette smoking and an asthma 
diagnosis are risk factors for the development of COPD, and cigarette smoking alone 
promotes asthma.  Therefore there is substantial overlap even among the individual risk 
factors for asthma and COPD which may accumulate and increase the likelihood of 
developing just one of these diseases on its own (23, 24). 
1.2.5 COPD – Bronchiectasis Overlap 
Bronchiectasis is another chronic respiratory illness that has been closely linked with 
COPD.  It is characterized by persistent bronchial sepsis due to irreversibly damaged and 
enlarged bronchi (25).  The enlarged airways are injured in such a way that they are not 
able to clear mucus adequately.  Mucus builds up within the large and small bronchi 
promoting a cycle of repeated lung infections.  Each subsequent infection imposes more 
damage to the airways and a cyclical process ensues.  There are many causes of 
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bronchiectasis ranging from abnormal congenital etiology and childhood development 
disorders to poorly healed respiratory infections.  There is evidence that bronchiectasis is 
present in anywhere from 30% to 70% of patients with COPD (26-28) and those patients 
with concomitant COPD and bronchiectasis experience a more severe clinical course 
involving more hospitalizations and higher mortality (29).  It is unclear what the exact 
underlying mechanisms involved in the development of co-occurring COPD and 
bronchiectasis are.  It could be that the constant exposure to toxins in cigarette smoke 
repeatedly trigger respiratory infections promoting bronchiectic pathophysiology in the 
lungs of COPD patients.  Another hypothesis is that the airway obstruction presented in 
bronchiectasis due to mucus plugging imposes airflow limitation severe enough to 
warrant a COPD diagnosis (30).  It is not known for sure whether bronchiectasis is 
caused by COPD and repeated exposure to cigarette smoke or if the opposite is correct 
and COPD is a consequence of bronchiectasis pathophysiology.  It seems likely that the 
same is true for ACOS and the exact cause of concomitant bronchiectasis and COPD is 
different for each patient. 
 
1.3 COPD and Cardiovascular Disease 
Over the past two decades there has been increasing evidence that both COPD and 
cardiovascular disease, and in particular vascular atherosclerosis are closely related.  
Large-scale epidemiological and experimental studies (31-35) have established that 
cardiovascular diseases and complications are the leading cause of hospitalization among 
COPD patients and are second only to lung cancer as the leading cause of death.  
Therefore it is clear that there is a serious burden of cardiovascular disease in COPD 
patients.  Both COPD and cardiovascular disease share a common risk factor in cigarette 
smoke and air and gas pollution, however it is now known that the mechanistic link 
between cardiovascular and pulmonary disease pathophysiology extends beyond the 
toxicity imposed by inhaled toxins (32).  The ‘lung permeability’ theory was recently 
proposed (36) as a potential mechanism for atherogenesis (atherosclerotic plaque 
development) in COPD patients.  Figure 1-4 presents a schematic of this mechanism.  
This concept suggests that inflammatory stress similar to what occurs in COPD patients 
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might cause the alveolar – capillary layer to become increasingly permeable to 
inflammatory mediators.  These inflammatory markers, mainly the interleukins, are free 
to pass from the lungs into the systemic circulation where they trigger a secondary 
inflammatory response of procoagulant and inflammatory markers from the liver (C-
reactive protein, fibrinogen, serum amyloid protein) that promote atherogenesis at various 
locations throughout the body.  While this process may occur chronically in the inflamed 
COPD lung, cyclical insults of cigarette smoke would cause the alveolar – capillary layer 
to become chronically permeable, up-regulating the atherogenic response.  Given this 
mechanistic hypothesis it seems plausible that there is a dose-response relationship 
between the severity of lung disease and vascular disease and several studies (35, 37-41) 
have confirmed that this is the case.  The severity of atherosclerosis has been shown to be 
correlated with lung function decline whereby COPD patients have quantitatively more 
atherosclerotic plaque (37, 40, 42, 43) and more plaque that is vulnerable to rupture 
causing embolism and stroke (44).  However it is not known for certain if cardiovascular 
disease causes COPD or vice-versa, and the question about ‘which comes first’ cannot 
yet be answered with certainty (45).  What is known is that cardiovascular disease and 
acute ischemic events play one of the most important roles in the clinical course of 
COPD patients (46). 
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Figure 1-4.  Schematic of the mechanistic link between COPD and atherosclerosis. 
Reproduced with permission from ‘Imaging Evidence of the Relationship Between 
Atherosclerosis and Chronic Obstructive Pulmonary Disease’ Imaging in Medicine; DOI: 
10.2217/iim. 13.70, 2013 (47) 
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1.4 Subclinical COPD and Identifying Susceptible 
Individuals 
1.4.1 Undiagnosed, Early and Subclinical COPD 
Typically, individuals with COPD present with obvious symptoms of airflow limitation 
including chronic cough, breathlessness and wheezing.  These symptoms are related to 
the various contributions of airways disease and emphysema that reduce the ability to 
move air in and out of the lungs and participate in gas exchange.  However there are 
many ex- and current-smokers who experience respiratory symptoms and may or may not 
have airflow limitation consistent with COPD and never receive treatment for a 
pulmonary condition.  Ex- and current-smokers are most likely to encounter pulmonary 
function testing or be referred to a respirologist by a primary care provider only when 
pulmonary symptoms start to alter their exercise capacity and drastically impact their 
quality of life.  A study in the province of Ontario, Canada reported that up to 75% of ex- 
and current-smokers had impaired lung function consistent with COPD but had not 
previously sought medical help for respiratory illness; (9) this may have reflected the fact 
that most of these individuals could still carry-out day-to-day activities.  Unfortunately, 
other studies (48, 49) have recognized that COPD underdiagnosis is common in other 
countries as well.  There are several reasons COPD might go undiagnosed and untreated 
in the general population.  First, since lung function decline is a chronic process, it can 
take decades before obvious symptoms present.  At the same time, many ex- and current-
smokers often attribute impaired lung function to normal aging and not an indicator of 
respiratory illness.  Second, certain individuals may be ‘protected’ from being diagnosed 
with airflow limitation because of anatomical or comorbid conditions that prevent them 
from performing diagnostic pulmonary function tests (to be discussed in section 1.4.2).  
Lastly, as was previously mentioned in section 1.2.2, the small airways are the major site 
of airflow obstruction in COPD, but these airways only account for a fraction of overall 
airway resistance.  Given this, it has been speculated that disease processes can occur in 
the small airways or the ‘silent zones’ over very long timeframes without having a 
noticeable influence on lung function (16). Therefore it is likely that small airways 
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disease can accumulate without detection until a critical point is reached and overall lung 
function starts to decline rapidly. 
1.4.2 Airflow Limitation in Obese and Overweight Individuals 
Obesity, defined as a body mass index (BMI) greater than 30kg/m
2
,
 
and being overweight 
is a biomarker for dyspnea  which is one of the major and predominant symptoms of 
COPD (50).  Therefore, breathlessness in overweight individuals might be directly 
related to their obesity or a manifestation of an underlying and untreated lung condition 
such as COPD.  High BMI is associated with a decrease in functional residual capacity 
(FRC) and total lung capacity (TLC) due to the increase in adipose tissue in the thoracic 
trunk of affected individuals (51).  The smaller lung capacity combined with increased 
adipose deposits cause impaired movement of the diaphragm, and reduced chest wall 
compliance and ultimately both the forced expiratory volume in one second (FEV1) and 
forced vital capacity (FVC) decrease.  It has also been reported that the decrease in FVC 
is more severe than FEV1, leading to a subsequent increase in FEV1/FVC in these 
individuals (52, 53).  Therefore overweight and obese individuals might be ‘protected’ 
from developing airflow limitation based on the FEV1/FVC ratio due to extrapulmonary 
or anatomical impairment (50).  As a result, many overweight individuals may go 
untreated due to the absence of a COPD diagnosis (on spirometry) even though they may 
experience dyspnea that is attributable to airflow limitation and not solely a symptom 
associated with being overweight.  These individuals may make up a large percentage of 
people with ‘undiagnosed’ or very early or mild COPD.  At the same time, it is difficult 
to know for sure if the symptoms these subjects experience are secondary only to obesity 
or directly related to impaired lung function – this is postulated to be the primary reason 
obese or overweight individuals do not seek further treatment from a respirologist beyond 
the primary care setting. 
 
1.4.3 Identifying Individuals Susceptible to Developing COPD  
The Fletcher and Peto curve (Figure 1–5) that describes the natural history of COPD 
popularized the concept that both smokers and non-smokers alike, reach and maintain 
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maximum lung function during the first half of adulthood before lung function starts to 
decline (54).  Fletcher and Peto suggested that while both smokers and non-smokers 
experience a decline in lung function, smokers decline much more rapidly and develop 
airflow obstruction due to their rapidly declining trajectory.  The concept of rapid 
declining lung function in smokers has been confirmed more recently but the rate of 
change in lung function over time is now known to be highly variable (55).  Recently, the 
seminal findings of Fletcher and Peto were extended when it was suggested that there 
exists another group of individuals who develop COPD aside from ‘rapid decliners’.  
These individuals attain a low maximal lung function in adulthood and subsequently 
experience a rate of decline of lung function that is normal (similar to what is observed in 
non-smokers).  This study found that among COPD patients, approximately half 
experienced a rapid-decline in lung function leading to airflow limitation while the other 
half reached a low maximal lung function before declining at a normal rate (56).  This 
was an exciting finding because it suggested that lung function at young ages and 
maximally attained lung function in adulthood might serve as important biomarkers 
related to the development of COPD. 
At the same time, it is clear that identifying which ‘trajectory’ an individual follows may 
not be enough to identify who will develop COPD.  Many ex- and current-smokers have 
an ‘early’ or subclinical form of COPD that does not satisfy the criteria for a COPD 
diagnosis based on lung function or pulmonary symptoms.  Disease might accumulate 
‘silently’ (16) in the small airways (13) of the peripheral lung for many years without any 
symptomatic or lung function indications making it difficult to identify which trajectory 
an individual might follow (rapid decliner, normal decliner etc.).  The identification of 
early and subclinical COPD in individuals who smoke or who have smoked has many 
benefits with respect to treatment planning and lifestyle change recommendations.  
Concomitant with the objectives of any COPD treatment plan, which are to reduce 
recurrent respiratory symptoms and prevent exacerbation episodes, the identification of 
very early forms of the disease can help individuals and their health care team put 
together a targeted therapy strategy to achieve the most optimal outcome for a certain 
individual at the onset of disease. 
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Unfortunately, as discussed in section 1.4.1, many smokers develop respiratory 
symptoms over the span of several years but may not consider them significant enough to 
seek help from a primary care provider who could help kickstart a treatment plan.  In this 
way COPD progression may continue for decades before treatment begins at which point 
it may be in the severe and debilitating stages and be very difficult to manage.  
Furthermore, as will be described in more detail in section 1.5, conventional and gold-
standard pulmonary function tests for assessing lung function and diagnosing COPD do 
not fully characterize small changes in lung function that might indicate very early or 
subclinical disease progression.  Therefore the combination of very few individuals 
visiting the primary care setting along with poor characterization of small changes by 
gold-standard tools for diagnosing COPD makes the identification, treatment and 
longitudinal monitoring of COPD from the earliest stages extremely difficult in clinical 
practice. 
 
 
Figure 1–5.  Lung function decline over time in never-smokers, current-smokers 
and individuals who quit smoking.  Adapted from ‘The Natural History of Chronic 
Airflow Obstruction’ (54) and ‘Lung-Function Trajectories Leading to Chronic 
Obstructive Pulmonary Disease’ (56). 
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In the next section I will describe the methodology for measuring pulmonary function 
and diagnosing COPD.  An overview of these methods will highlight the inherent 
drawbacks of these conventional breathing tests for characterizing the early and 
subclinical forms of COPD – another potential reason the prevalence of unerdiagnosis 
and undertreatment of COPD is so high.  
 
1.5 Pulmonary Function Tests 
Established methods for measuring pulmonary function focus on the assessment of 
expiratory flow volumes through spirometry, lung volumes through plethysmography and 
the diffusing capacity of the lungs. 
1.5.1 Spirometry 
Spirometry tests measure the volume of air an individual inhales or exhales as a function 
of time.  Spirometry can be used to measure expiratory volumes and flow, although 
expiratory volumes are diagnostic for COPD.  In particular, the spirometry measurements 
of the forced expiratory volume in one second (FEV1) and the forced vital capacity 
(FVC) are the two most widely used measurements.  FVC is the maximal volume of air 
that can be forcefully exhaled from maximal inspiration while FEV1 is the maximal 
volume of air that is exhaled in just the first second of a forced expiration maneuver.   
The American Thoracic Society (ATS) and European Respiratory Society (ERS) have 
collaborated to publish standards for which spirometry testing worldwide should follow 
when collecting measurements (57).  First, since spirometry is the diagnostic test for both 
Asthma and COPD, measurements should always be collected by a trained and certified 
technician.  Second, the spirometry test to measure FEV1 and FVC is broken down into 
three distinct phases:  1) Maximal inspiration, 2) a ‘blast’ of exhalation and 3) continued 
exhalation until the end of the test.  Third, for the test to be considered acceptable, a 
minimum of three forced expiration maneuvers repeatable to within 0.15L of each other 
must be performed.  Lastly, ATS and ERS specify that the National Health and Nutrition 
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Examination Survey (NHANES III) reference standard equations be used to provide 
appropriate percent predicted spirometry values based on sex, age, height and ethnicity 
(58).  This allows measurements to be recorded on a ‘percentage predicted’ (%pred) scale 
from 0% to 100% (or higher) instead of interpreting raw volume measurements that vary 
greatly depending age, sex, height and ethnicity. 
The global initiative for chronic obstructive lung disease (GOLD) has deemed spirometry 
as the diagnostic tool for COPD and grading disease severity (1).  According to GOLD 
guidelines, assessing airflow limitation in an individual should be carried out after the 
administration of a short-acting inhaled bronchodilator.  A post-bronchodilator FEV1 
consistently below 70% of the FVC (FEV1/FVC < 70%) indicates that irreversible 
airflow limitation is present which warrants a COPD diagnosis.  Once an individual’s 
measurements fall below the FEV1/FVC < 70% threshold, their severity of airflow 
limitation is graded based on FEV1 percent predicted.  There are 4 grades of COPD 
disease severity as shown in Table 1-3 and severity increases with each grade. 
 
Table 1-3.  Grading of COPD severity based on post-bronchodilator spirometry 
GOLD Grade Severity FEV1/FVC < 70% and - 
GOLD 1 Mild FEV1%pred ≥ 80%  
GOLD 2 Moderate 50% ≤ FEV1%pred < 80%  
GOLD 3 Severe 30% ≤ FEV1%pred ≤ 50%  
GOLD 4 Very Severe FEV1%pred < 30%  
GOLD:  Global initiative for chronic obstructive lung disease, FEV1:  Forced 
expiratory volume in one second, FVC:  Forced vital capacity, %pred:  Percent of 
predicted value 
 
1.5.2 Plethysmography 
Plethysmography is used to measure lung volumes.  Similar to spirometry, the ATS and 
ERS have specified guidelines (59) for measuring eight lung volumes as shown in Figure 
1-6.  The inspiratory reserve volume (IRV) is maximum volume that can be inhaled from 
the end of normal inspiration.  The tidal volume (TV) is the volume of air an individual 
inhales or exhales during normal ‘tidal’ breathing.  The expiratory reserve volume (ERV) 
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is the volume of air that can be exhaled from end-expiration of tidal breathing.  The 
inspiratory vital capacity (IVC) is the volume of air that can be moved in and out of the 
lungs during full inspiration and full expiration.  The residual volume (RV) is the amount 
of air or gas that remains in the lungs after maximal expiration.  The inspiratory capacity 
(IC) is the maximum amount of air that can be inhaled from expiration during tidal 
breathing.  The functional residual capacity (FRC) is the sum of RV and ERV, it is the 
amount of air remaining in the lungs at end expiration of tidal breathing.  Finally, the 
total lung capacity (TLC) is the volume of air in the lungs after maximal inspiration.  
Figure 1-6 shows an inspiratory – expiratory curve with all lung volumes labelled. 
 
 
Figure 1-6.  Inspiratory – expiratory curve showing lung volumes measured by 
plethysmography. 
IRV:  Inspiratory reserve volume, TV:  Tidal volume, ERV:  Expiratory reserve volume, 
IVC:  Inspiratory vital capacity, RV:  Residual volume, IC:  Inspiratory capacity, FRC:  
Functional residual capacity, TLC:  Total lung capacity 
 
1.5.3 Diffusing Capacity of the Lung 
The diffusing capacity of the lung for carbon monoxide is commonly used to evaluate 
pulmonary microcirculation and diffusion of gases across the alveolar – capillary 
membrane.  There are two terms used for this measurement; the diffusing capacity for 
carbon monoxide (DLCO) and the transfer factor for carbon monoxide (TLCO).  While 
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both are acceptable, there is no concrete consensus as to which term is the correct one, 
although it has been suggested, but not agreed upon, that TLCO is more appropriate 
because the measurement does not solely reflect diffusion (60).  Throughout the rest of 
this Thesis the DLCO term will be used when referring to this measurement. 
To measure diffusing capacity a trained technician coaches an individual through a 
maneuver involving 1) full exhalation to RV, 2) maximum inhalation to TLC, 3) a ~ 10 
second breath-hold at TLC and 4) exhalation (61).  During the inhalation step the test 
subject will inhale a gas mixture of helium (~10%), carbon monoxide (~0.3%) and room 
air (~85-90%).  During the breath-hold step the carbon-monoxide and helium diffuse 
across the alveolar-capillary membrane throughout the lung.  Finally, after the breath-
hold the residual carbon-monoxide and helium is expired and this concentration is 
compared to the amount that was inhaled to estimate the amount of carbon monoxide that 
diffused into the pulmonary circulation.  One important consideration when collecting 
DLCO measurements is that the first bolus of air expired after the breath-hold was 
predominantly in the ‘anatomical dead-space’ of the large and central airways where gas 
exchange does not occur.  Therefore, technology for measuring DLCO discards this dead-
space air (the volume of which is known through an equation: 2.2ml • kg body weight) 
and only collects the air which was in contact with the respiratory zone.  In-line with the 
standardization of spirometry and plethysmography, the ATS and ERS have specified 
standards for the collection of DLCO – TLCO measurements as well (61).  
 
1.6 Measuring Exercise Capacity and Pulmonary Symptoms 
Measuring exercise capacity with a walk test and breathlessness and pulmonary 
symptoms through questionnaires can be used along with pulmonary function tests to 
better understand the impact of pulmonary function on daily activity. 
1.6.1 The Six-Minute Walk Test 
The six-minute walk test (6MWT) is an exercise test that is designed to measure the 
distance an individual can walk on a flat surface in six minutes (62).  The test is supposed 
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to reflect the exercise capacity of activities a person would experience in their daily lives.  
Importantly, the results of the six-minute walk test, the six-minute walk distance 
(6MWD) in COPD patients have been shown to be reproducible, correlate with frequency 
of exacerbation episodes and mortality in COPD (63).  
1.6.2 The St. George’s Respiratory Questionnaire 
The St. George’s Respiratory Questionnaire (SGRQ) is used to measure the impact of 
respiratory disease on an individual’s overall health, daily activities and perceived well-
being (64).  The questionnaire has four scores to rate the different components of 
respiratory disease: the symptoms score, the impact score, the activity score and the total 
score.  For each component score the values range from zero to one-hundred with higher 
scores being more severe.  Similar to other established measures of pulmonary function, 
SGRQ scores in COPD patients have been shown to be reproducible (64-66) and 
associated with other measures of pulmonary function (67). 
1.6.3 Modified Medical Research Council Dyspnea Scale 
The modified Medical Research Council (mMRC) dyspnea scale measures the impact of 
breathlessness on an individual’s daily activity.  The mMRC uses a straightforward scale 
of five grades ranging from 0 (no respiratory disability) to 4 (severe dyspnea with many 
limitations) to measure disability due to dyspnea (Table 1-4).  It has been found that 
mMRC dyspnea scores are related to disease severity and predict all-cause mortality in 
COPD patients (68, 69). 
 
Table 1-4.  Modified Medical Research Council (mMRC) Dyspnea Scale (Adapted 
from ‘Evaluation of Clinical Methods for Rating Dyspnea’(70))  
Grade Description 
0 Not troubled with breathlessness except with strenuous exercise 
1 Shortness of breath when hurrying on the level or walking up a slight hill 
2 Walks slower than people of the same age on the level because of 
breathlessness or has to stop for breath when walking at own pace on the 
level  
3 Stops for breath after walking ~100m or after a few minutes on the level 
4 Too breathless to leave the house or breathless when dressing or undressing 
 
23 
 
 
 
 
  
24 
 
 
 
1.7 The Role of Imaging to Study COPD 
Although FEV1 serves as the major endpoint for assessing the severity of airflow 
limitation and diagnosing COPD, it is clear that spirometry alone cannot fully 
characterize the heterogeneity of the disease.  As previously mentioned in Section 1.2, 
COPD is an umbrella term encompassing large and small airways disease and 
emphysematous tissue destruction of the lung parenchyma, and the extent of each of 
these abnormalities vary from patient to patient (71).  Therefore, simply measuring 
expiratory volumes at the mouth does not provide any regional information on lung 
pathophysiology nor indications on the relative contributions of airways disease and 
emphysema to lung function decline.  In this regard, thoracic computed tomography (CT) 
and pulmonary magnetic resonance imaging (MRI) have emerged as robust and reliable 
tools for in vivo imaging of COPD.  In recent years both CT and MRI have played 
important roles in advancing our knowledge on COPD heterogeneity and underlying 
pathophysiology and have simultaneously introduced the concept of radiological 
phenotyping to COPD to provide better stratification and targeted treatment options 
within COPD populations. 
1.7.1 High-resolution Computed Tomography of the Lung 
Conventional x-ray imaging is inherently limited to providing two-dimensional (2D) 
images of three-dimensional (3D) anatomical structures.  CT technology overcomes this 
drawback by rotating the conventional x-ray tube around a patient to construct a 3D 
volume of the region of interest.  The 3D volume created from the CT scan is made up of 
voxels (volume elements), each of which has a Hounsfield Unit (HU) associated with it 
based on the attenuation of x-rays through that region.  The HU scale uses water as a 
reference, where water has a HU = 0, air has HU = -1000 and solid structures such as 
bone have HU > +1000 (72).  Ultimately, CT provides 3D images of the anatomy based 
on density and since many tissues and organs within the body have different densities, 
good contrast can be achieved with conventional CT imaging. 
As described in Section 1.2, one pathophysiological phenotype of COPD is emphysema.  
When the alveoli are destroyed, alveolar ducts and sacs coalesce and the distal airspaces 
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enlarge to ultimately cause a decrease in parenchymal density.  Therefore, on CT images, 
emphysematous regions within the lung have attenuation values close to that of air (≤-
950HU) and appear darker than the higher density parenchyma surrounding them.  
Extensive research and debate is ongoing to determine an optimal HU threshold to define 
emphysema on CT.  Currently, the most commonly used HU threshold to identify 
emphysema is -950HU, whereby regions of the lung with attenuation ≤-950HU are 
considered to be emphysematous.  This threshold has been confirmed to correspond to 
emphysematous lesions on pulmonary histology of macroscopic (73) and microscopic 
(74) emphysema.  Figure 1-7 shows emphysematous lung regions ≤-950HU on CT in a 
healthy volunteer and a COPD patient.  It is important to note that other thresholds are 
also in use for the purpose of identifying mild emphysema (-910HU) and gas trapping on 
expiratory CT (-856HU) (75-77).  Another method for quantifying emphysema on CT is 
focused on the HU below which fifteen percent of all x-ray attenuation values fall (PD15).  
Using this method, the measurement of emphysema is a HU not a percent of the lung as it 
is with the threshold cutoff.  While both the threshold and percentile methods are widely 
used and considered appropriate for cross-sectional studies, the 15
th
 percentile analysis is 
recommended for longitudinal studies because it is less sensitive to changes in CT 
scanner technology that may occur over time (78).  At the same time, methods for 
quantitatively describing the size and distribution of emphysematous clusters (regions of 
RA950) on CT have also emerged (79).  The value of measuring these low attenuation 
clusters (LAC) relies on the concept that emphysematous lesions tend to coalesce and 
form larger clusters (bullae) as emphysema progresses.  The total number of 
emphysematous clusters (clusters of voxels <-950HU) is plotted against the cluster size 
in the log-log domain.  The slopes of the plots can then be described by the power law 
and the value of the slope is obtained by linear regression and used to quantify the LAC.  
In this manner subjects with early or mild forms of emphysema have smaller and more 
emphysematous clusters and subsequently have a more negative LAC (higher slope) 
while COPD subjects who have larger emphysematous bullae and fewer total clusters 
have a more positive LAC (flatter slope). 
Along with regionally mapping and quantifying emphysema within the lung, thoracic CT 
is also used to evaluate airway structure.  By measuring the cross section of the airways, 
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measurements of the airway lumen and wall thickness can be assessed.  The 
measurements of airway wall area percent (WA%) and lumen area (LA) were the first to 
be shown to significantly correlate with measures of lung function in COPD patients 
where the airway wall thickness increased and airway lumen area decreased as FEV1 
decreased (80).  However this early work focused predominantly on measuring the large 
and central airways which do not reflect the main site of airflow obstruction in COPD.  
Subsequent studies have transitioned to measuring higher generation airways (81), 
counting the number of airways visible on CT (82) and estimating small airway 
dimensions (83).  Figure 1-7 shows CT airway trees in a healthy volunteer and COPD 
patient.  Visibly, the COPD subject has few and thinner airways than the healthy subject. 
 
 
Figure 1-7.  Thoracic CT and segmented airway tree of a healthy volunteer and a 
COPD patient.   
Emphysema, or areas of the lung ≤-950HU on CT are shown in yellow.  Compared to the 
healthy subject, the COPD patient has more severe emphysema and fewer airways 
present as measured by CT. 
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Lastly, an important consideration for using CT to evaluate and monitor COPD is the 
radiation dose associated with each scan.  In COPD, longitudinal monitoring is necessary 
for evaluating disease progression or response to treatment or surgery.  The radiation 
dose associated with a single conventional chest CT is estimated to be ~7 mSv which is 
equivalent to 2.8yr of natural background radiation (84).  Therefore, if CT is the only 
option available for pulmonary imaging at a specific centre or within a region, it is clear 
that careful planning is required in order to longitudinally image a COPD patient because 
of the risk of radiation-induced cancers from cumulative dose of serial CT scans.  One 
potential solution to the burden of radiation dose associated with chest CT scanning is the 
further development of iterative reconstruction techniques and their incorporation into 
clinical use instead of, or along with, filtered back projection (FBP) reconstruction 
approaches.  Unlike FBP which is rapid and requires little computational processing, 
iterative approaches correct image data using a variety of models and require long 
computing times (85).  Current iterative reconstruction techniques can produce thoracic 
CT images of similar or better quality (based on signal-to-noise ratio) using a lower dose 
than images acquired using FBP (86).  The downside is that the reconstructive approach 
used during acquisition influences quantitative (and potentially qualitative) measurements 
of emphysema and airways disease.  Therefore, scientists and clinicians would need to 
meet and overcome the challenge of standardizing reconstructive approaches across 
academic centres where large-scale and long-term follow-up studies are ongoing in order 
to compare and concatenate data. 
1.7.2 Nuclear Medicine:  Ventilation Scintigraphy 
Single photon emission computed tomography (SPECT) is a tool that can provide 
information of pulmonary ventilation and perfusion through the use of radiolabeled 
aerosols and gases.  In SPECT, gamma radiation from an injected or inhaled 
radiopharmaceutical is received by detectors which convert the radiation into visible light 
that can be used to produce an image based on its spatial and quantitative information.  
For pulmonary ventilation imaging using SPECT, a radiolabeled aerosol or gas inhaled at 
the mouth during tidal breathing is used to provide gamma energy necessary to create 
ventilation images.  The most important consideration for ventilation imaging with 
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SPECT is the choice of which radiotracer to use.  Within the past thirty years 
99m
Tc-
Technegas aerosol has emerged as the most widely used radiotracer for pulmonary 
SPECT.  Other popular radiotracers used for pulmonary SPECT include 
99m
Tc labelled 
with diethylaminetriaminepentacetic acid (DTPA), 
133
Xe, and 
81m
Kr.  Unlike Technegas 
aerosol however, the laborious and expensive production along with their nuclear and 
physical properties have limited their use in ventilation studies.  
133
Xe has a half-life on 
the order of days and low gamma radiation energy which has deterred its routine use.  
81m
Kr on the other hand has an optimal gamma energy and short biological half-life 
making it suitable for ventilation imaging.  However the availability of rubidium 
generators required to produce the metastable Kr are limited, expensive and require 
almost daily replacement so the production of 
81m
Kr for ventilation imaging is often not 
feasible.  At the same time an important consideration acknowledged by physicists and 
clinicians using these techniques was the size of these radiotracers being inhaled.  
Particles larger than 2µm are predominantly deposited in the large and central airways 
whereas particles <1µm are deposited in the distal alveoli, therefore larger size 
radiotracers (>1µm) do not provide much information about distal lung regions when 
used for ventilation imaging.  
99m
Tc-DTPA particles are 1µm-2µm in size which has 
made it a popular alternative to 
99m
Tc-Technegas aerosol.  Technegas labelled with 
99m
Tc 
is a newer solid aerosol type radiotracer with particle sizes ranging from 0.005µm-0.2µm 
(87).  The small size combined with Compton-scattering predominant gamma energy and 
easy and inexpensive production have made it the radiotracer of choice for ventilation 
scintigraphy.  Several studies have compared the common radiotracers used for 
ventilation scintigraphy and have consistently reported superior results with 
99m
Tc-
Technegas (88-90).  Importantly, both 
99m
Tc-Technegas and 
81m
Kr have been shown to 
produce similar quality ventilation images (91), however Technegas is favored due to its 
inexpensive and efficient production. 
SPECT imaging of pulmonary ventilation has been used extensively for the assessment 
and diagnosis of pulmonary embolism but has not been widely exploited to evaluate and 
characterize COPD.  Unlike CT (Section 1.7.1) techniques, SPECT pulmonary structure-
function relationships and measurements in COPD are not as well established which has 
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limited its routine use in clinical practice and subsequently in large-scale epidemiological 
COPD studies. 
1.7.3 Pulmonary Magnetic Resonance Imaging 
Magnetic resonance imaging (MRI) is a tool that provides high-resolution images of the 
anatomy based on the magnetic properties of the protons in a tissue.  Unlike CT, MRI 
does not require the use of ionizing radiation from x-ray beams or any other forms of 
contrast making it an attractive option for pulmonary imaging at first glance.  However, 
the physical properties of the lungs are very different from other tissues in the body and 
pose unique challenges to generate clinically useful pulmonary images using 
conventional MRI methods. 
When a sample containing protons is placed inside an MRI machine, the nuclear 
magnetic moment of the protons within the sample or tissue align with the magnetic field.  
To collect the signal necessary to generate an image a radiofrequency pulse (RF) is 
applied which tilts the protons nuclear magnetic moments away from its axis in the 
magnet.  After this, the proton magnetization returns to its equilibrium state through 
longitudinal (T1) and transverse (T2) components of relaxation.  Relaxation causes a 
changing magnetic field which induces a voltage in a receive coil (Faraday’s Law of 
induction) that is spatially encoded to produce an MR image.  The signal intensity in an 
MR image is proportional to the proton density of the sample being imaged (92). 
The lungs have a tissue density that is approximately ten times lower than other tissues in 
the body, meaning they also have ten times lower proton density per gram of tissue 
compared to other tissues as well (93).  Therefore, assuming perfect imaging conditions, 
the achievable MRI signal of the lungs is still ten-fold weaker than other tissues.  
Secondly, the lungs are almost entirely made up of air – tissue boundaries.  Oxygen in 
room air is paramagnetic and in tissue it is diamagnetic and therefore there is a net 
magnetic susceptibility difference at each and every air – tissue boundary.  This magnetic 
susceptibility difference spread over millions of air – tissue boundaries produces a highly 
inhomogeneous local magnetic field in the lungs which causes extremely fast relaxation 
of the protons after the initial RF pulse and associated with this, rapid signal decay.  With 
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the combination of a low proton density and highly inhomogeneous local field within the 
lungs, conventional MRI methods such as those applied clinically to tissues like the brain 
or liver do not produce clinically relevant images of the lung parenchyma or airways.  
Until recently, this has limited the application of MRI to evaluate COPD predominantly 
to perfusion and hemodynamic studies using contrast-enhanced techniques (94).  Figure 
1-8 shows conventional MR images in a healthy individual and a COPD patient.  It is 
visibly obvious that the proton MR image does not provide a wealth of information on 
pulmonary parenchymal structure or function.  However, an emerging series of MRI 
pulse sequences, called ‘ultra-short echo time’ (UTE) pulse sequences have been 
developed (95) and optimized to capture the rapidly decaying MR signal in the lung 
before it is lost.  These UTE sequences are different from conventional proton MRI 
sequences in that they combine a fast RF pulse and rapid data acquisition steps to 
measure relaxation before it is completely lost.  Recent research with UTE sequences 
suggests that UTE pulmonary MRI is capable of producing images of similar quality to 
thoracic CT (96).  
Pulmonary MRI with hyperpolarized noble gases (
3
He and 
129
Xe) is another method of 
providing high-resolution images of the lungs that has gained traction in research settings 
over the past few decades.  This MRI method is based on previous nuclear physics 
research (97) that recognized the potential for capturing MR signal from polarized 
3
He 
and 
129
Xe in the gaseous phase.  This previous work showed that through a technique 
called ‘spin-exchange optical pumping’, collisions between 3He or 129Xe with gaseous 
rubidium could transfer angular momentum to the noble gas nuclei amplifying the 
achievable MR signal with these gases.  In the early stages this work focused on using 
129
Xe but became more common in 
3
He due its ease in MR imaging compared to 
129
Xe 
(98).  Currently however this area of MRI research is transitioning back to 
129
Xe owing to 
its lower cost and higher natural abundance over 
3
He.  Once the noble gas of choice is 
hyperpolarized, to collect images of the lungs an individual must inhale the gas and 
perform a short breath-hold while an MRI sequence collects the data.  Several methods 
exist for doing this but the most commonly used method is to coach the patient to breathe 
the gas in from a bag (99).  After a subject inhales the noble gas from the bag, there is an 
option of collecting ‘static-ventilation’ images or diffusion-weighted MR images, both of 
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which provide distinct measurements on lung pathophysiology.  Figure 1-8 shows 
3
He 
(cyan) and 
129
Xe (purple) static-ventilation MR images in a healthy volunteer and a 
COPD patient.  Compared to the healthy subject, the COPD patient exhibits markedly 
greater ventilation heterogeneity on both 
3
He and 
129
Xe images. 
 
 
Figure 1–8.  1H, 3He and 129Xe MRI of a healthy and COPD patient.   
Reproduced with permission from ‘Imaging Evidence of the Relationship Between 
Atherosclerosis and Chronic Obstructive Pulmonary Disease’ Imaging in Medicine; DOI: 
10.2217/iim. 13.70, 2013 (47). 
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Static-ventilation hyperpolarized noble gas images show which regions of the lung 
participate in ventilation.  Several studies have confirmed that static-ventilation MR 
images show that healthy non-smoking subjects without airflow limitation exhibit 
homogeneous ventilation signal throughout their lungs (shown in Figure 1-8 and 1-9) 
(100, 101).  In contrast, in subjects with COPD, it has been observed (101-104) that 
ventilation signal is heterogeneous with many regions within the lung not receiving any 
ventilation at all.  Importantly, these regions of signal void or ‘ventilation defects’ have 
also been shown to be reproducible over time (105). Ventilation defects have become 
central to image analysis techniques for quantifying disease on noble gas MR images 
since they are speculated to represent regions of the lung with underlying disease.  
Initially, visual grading of ventilated and unventilated regions was used to evaluate 
disease severity from noble gas MR images (101), but more recently, methods that 
normalize the volume of ventilation defects to the total thoracic cavity volume to 
calculate a ventilation defect percent (VDP) have become more common (106). 
Diffusion-weighted MRI is a tool that provides information on the movement of nuclei in 
a sample.  With regards to hyperpolarized noble gas MRI of the lung, diffusion-weighted 
methods have been harnessed to provide details on alveolar microstructure (107).  After 
the gas is inhaled, diffusion-weighted MRI pulse sequences can be applied to sensitize 
the data acquisition to the diffusion of gas within the alveoli.  Over a pre-specified time-
interval, the gas nuclei move within the airspaces, bouncing off the alveolar walls.  
Diffusion-weighted sequences provide information pertaining to the distance the nuclei 
travel per unit time within the airspaces.  Ultimately, this type of imaging is used to 
calculate the apparent diffusion coefficient (ADC) that reflects the amount of restriction 
of the gas nuclei in the distal lung airspaces.  These are valuable measurements for 
assessing structural changes to the lungs in COPD because emphysematous destruction is 
characterized by airspace enlargement.  Previous work (107-110) has established that 
noble gas MRI ADC measurements are correlated with lung function in COPD and 
importantly, the ADC measures of microstructure seem to be more sensitive to early- or 
pre-clinical changes to lung structure than conventional pulmonary function testing and 
CT (111).   
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Figure 1-9 shows 
3
He static-ventilation and diffusion-weighted MR images in a healthy 
subject and four COPD patients with increasing grades of severity.  In the healthy 
subject, the ventilation pattern is homogeneous throughout the lung with the lung 
periphery and contour of the diaphragm clearly visualized by the 
3
He gas.  Similarly, in 
the healthy subject the ADC map shows low ADC throughout the lung.  In contrast, in 
the COPD subjects the ventilation signal becomes increasingly heterogeneous with more 
and larger ventilation defects visible in more severe grades of disease.  Concomitant with 
the increasing ventilation heterogeneity, ADC maps get brighter (worse) indicative of 
worse microstructural emphysema with increasing disease severity.  
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Figure 1-9.  Static-ventilation (SV) and apparent diffusion coefficient (ADC) 
3
He 
MR images in a healthy volunteer and four COPD patients with increasing severity 
of airflow limitation.  
Reproduced with permission from ‘Imaging Evidence of the Relationship Between 
Atherosclerosis and Chronic Obstructive Pulmonary Disease’ Imaging in Medicine; DOI: 
10.2217/iim. 13.70, 2013 (47). 
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1.8 COPD Phenotypes 
It is now known that the relative contributions of airways disease and emphysema on 
airflow limitation vary greatly from patient to patient (71).  With this emerging 
knowledge, phenotyping COPD patients based on underlying pathophysiology has 
become an attractive concept as it would allow scientists and clinicians to stratify patients 
into distinct groups to study clinical features and form targeted treatment plans.  At the 
same time, advances in quantitative pulmonary imaging with CT and MRI have become 
the methods of choice for identifying distinct COPD phenotypes.  Since imaging is well 
suited to measure airway dimensions and quantify the severity of emphysema, imaging 
studies have focused on three phenotypes in particular; an emphysema – predominant 
phenotype, an airways disease – predominant phenotype and a mixed airways disease – 
emphysema phenotype.  Whether or not an individual phenotype predicts worse 
pulmonary function or outcomes is an area of active research but studies have shown 
distinct clinical features among different phenotypes (112).  For example, it has been 
shown that patients with predominant emphysema have worse exercise capacity, tend to 
have more exacerbations and have more rapid disease progression than patients with 
airways disease (113, 114).  While it has also been found that subjects with predominant 
airways disease exhibit worse overall symptoms including coughing and wheezing (114).  
However, a combination of both airways disease and emphysema appears to be 
associated with the highest risk of exacerbations and debilitating respiratory symptoms 
(113).  Interestingly the development of a predominant phenotype does not appear to be 
related to smoking history, whereby patients who have the same number of pack years 
may develop either emphysema or airways disease or a mix of the two.  Given this, it 
seems likely that there is an important genetic component which determines the 
phenotype individuals will develop during the course of the disease and several studies 
have provided evidence of this (115, 116). 
Along with whole-lung phenotyping methods, ‘regional’ emphysema phenotyping studies 
have also emerged (117-120).  These studies are motivated by the fact that patients with 
the same amount of emphysema show high heterogeneity in clinical features.  
Unfortunately, phenotyping patients based on the spatial location of emphysema has 
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yielded inconsistent results and the clinical relevance of emphysema distribution is still 
not entirely clear. 
Given that smoking history is not associated with the development of a particular COPD 
phenotype over another, it seems plausible that the different pathophysiological and 
biochemical construction of the lungs between males and females might be partly 
responsible for phenotype heterogeneity among cohorts.  Currently, more females than 
males have COPD.  It is not known for sure what has caused the drastic increase in 
COPD diagnoses among females over the past few decades, but one hypothesis attributes 
the rising incidence of COPD among females to their steadily increasing use of cigarette 
smoking since World War II (121).  In line with this theory, biochemical and 
epidemiological studies suggest that female lungs are more susceptible to the toxic effects 
of cigarette smoke than males (122).  With regards to COPD phenotypes, it has been 
found that females predominantly suffer from airways disease while males have more 
emphysema (123, 124).  A better understanding of the connection between COPD 
phenotype and sex might serve as a valuable endpoint to treat COPD, and sophisticated 
imaging techniques may provide valuable information on this relationship in the future 
(123, 125, 126). 
The two major goals of COPD therapy are 1) to alleviate respiratory symptoms and 2) to 
prevent or avoid exacerbation episodes.  Phenotyping COPD patients has the potential to 
do both of these things.  However, many questions remain unanswered with regards to 
the origins of COPD phenotypes in pre- or sub-clinical disease.  It seems likely that if we 
could develop a better understanding of the origins and progression of lung disease 
phenotypes as they occur in pre- or subclinical stages, we would be able to create patient-
specific treatment plans to better satisfy the two major goals of COPD therapy. 
 
1.9 Thesis Hypothesis and Objectives 
The prevalence and underdiagnosis of COPD and shortcomings of COPD treatments may 
be attributable to the paucity of information that exists on early- or subclinical structural 
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and functional changes to the lungs of ex- or current-smokers.  This may be partly due to 
the fact that imaging studies have focused on cohorts with diagnosed and established 
COPD to provide a better understanding of pathophysiology in disease and less on 
susceptible individuals without airflow limitation (127).  Furthermore, most histological 
investigations on the underlying origins of disease and disease progression have also been 
biased to post-mortem or post-surgical specimens of excised lung tissue from localized 
regions of the lung (13, 128, 129).  Therefore, there is little information available 
regarding susceptible groups of ex-smokers without evidence of airflow limitation.  This 
would help to provide a better understanding on pre- or subclinical COPD 
pathophysiology and perhaps strategies on how to treat it.  Pulmonary imaging with 
hyperpolarized 
3
He MRI and CT can provide high-resolution images and quantitative 
measurements of pulmonary ventilation, alveolar microstructure and macroscopic 
emphysema.  Therefore, the overarching goal of this thesis was to exploit sensitive and 
direct pulmonary imaging measurements in ex-smokers without airflow limitation to 
better characterize and phenotype early- or subclinical forms of COPD. 
As described in Section 1.3, there is strong evidence to support underlying mechanistic 
links between COPD and cardiovascular disease.  Studies investigating the relationship 
between comorbid vascular and lung disease have predominantly focused on either 
cardiovascular disease or COPD patients who have a long-standing diagnosis of either 
condition.  Therefore, while it has been established that a relationship between lung 
function decline and cardiovascular disease exists, little is known about the pre- or 
subclinical origins of this comorbid relationship.  Furthermore, few studies have 
exploited pulmonary structural and functional imaging with MRI and CT to characterize 
whether a particular COPD phenotype is associated with cardiovascular disease 
complications.  Hence, the aim of Chapter 2 was to evaluate 
3
He MRI, CT and carotid 
ultrasound data from ex- and never-smokers without airflow limitation or diagnosis of 
cardiovascular disease to provide a better understanding of the pathophysiological link 
between subclinical COPD and vascular disease.  We hypothesized that ex- and never-
smokers without airflow limitation would show pulmonary imaging evidence of airways 
disease that would be related to subclinical atherosclerosis independently of smoking 
history. 
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Findings in Chapter 2 showed that ex-smokers without spirometry evidence of airflow 
limitation showed evidence of pre- or subclinical lung disease on 
3
He MR images.  In that 
study, ex-smokers without airflow limitation had significantly higher 
3
He VDP than 
never-smokers but were not different with regards to pulmonary function test 
measurements.  This suggested that ex-smokers without airflow limitation have pre- or 
subclinical airways disease and/or emphysema that is apparent on 
3
He MRI but not with 
spirometry or other breathing tests.  In Chapter 3 our objective was to improve our 
understanding of the underlying lung disease phenotype that cause 
3
He ventilation defects 
in ex-smokers without airflow limitation by using regional 
3
He MRI ventilation and 
diffusion-weighted measurements and regional CT airway and emphysema 
measurements.  Owing to research that suggested airway obstruction and obliteration is 
the dominant COPD phenotype in mild disease, we hypothesized that 
3
He ventilation 
defects in ex-smokers without airflow limitation would be spatially and quantitatively 
related to airway remodeling but not emphysema. 
The study in Chapter 3 showed that hyperpolarized 
3
He ventilation heterogeneity is 
present in ex-smokers without airflow limitation and the underlying etiology of 
ventilation defects in such subjects could be phenotyped using regional MRI and CT 
measurements.  We therefore wanted to use regional MRI and CT measurements to 
phenotype ex-smokers with a COPD diagnosis.  It is widely known that ex-smokers with 
COPD exhibit ventilation defects and emphysema throughout the lung, however the 
clinical relevance of the spatial location of ventilation heterogeneity and emphysema 
within the lung is not completely understood.  Our objective in Chapter 4 was to 
phenotype ex-smokers with COPD based on the apical-to-basal distribution of ventilation 
abnormalities and emphysema to better understand how regional phenotypes change as 
COPD progresses.  Data presented in Chapter 4 show that with increasing disease 
severity there is a basal-to-apical progression of ventilation abnormalities and an apical-
to-basal progression of emphysema, suggestive of distinct apical-basal lung COPD 
phenotypes. 
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Lastly, Chapter 5 will provide an overview and summary of the findings and conclusions 
from Chapters 2-4, address study specific and general limitations of the imaging studies 
presented in this thesis and provide motivation for future imaging studies in COPD. 
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CHAPTER 2 
To provide a better understanding of the mechanistic links between pre- or sub-clinical 
atherosclerosis and chronic obstructive pulmonary disease we acquired three-
dimensional carotid ultrasound and pulmonary hyperpolarized 
3
He magnetic resonance 
imaging measurements in ex- and never-smokers without clinical evidence of vascular or 
pulmonary disease. 
The contents of this chapter have been previously published in COPD:  Journal of 
Chronic Obstructive Pulmonary Disease (JCOPD) and permission to reproduce the 
article was granted by Taylor and Francis Publishing Group on behalf of JCOPD and is 
provided in Appendix D. 
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and G Parraga.  
Pulmonary Abnormalities and Carotid Atherosclerosis in Ex-smokers without Airflow 
Limitation.  Journal of Chronic Obstructive Pulmonary Disease; DOI: 10.3109: 1-0, 
2014 
2 Pulmonary Abnormalities and Carotid Atherosclerosis in 
Ex-Smokers Without Airflow Limitation 
2.1 Introduction 
Cardiovascular disease is the single largest cause of hospitalization in patients with mild 
and moderate chronic obstructive pulmonary disease (COPD), and after lung cancer, the 
leading cause of death (1, 2).   In addition, in COPD patients, there is a dose-response 
relationship for pulmonary structure-function abnormalities with carotid atherosclerosis 
(3-8), coronary artery calcification (9-12) and vascular dysfunction (13-16).  While these 
studies have shown the presence of cardiovascular disease in patients with COPD that 
cannot be explained by smoking history alone (3, 4, 6-8, 17), the mechanisms by which 
cardiovascular disease may be accelerated in COPD are not clear, nor is our 
understanding of these relationships in early or milder subclinical stages.   
While the diagnosis and monitoring of COPD is mainly based on spirometry 
measurements of airflow obstruction (18, 19), such measurements cannot fully 
characterize the pathophysiological changes that occur in obstructive lung disease (20).  
These include regional small-airways disease and microstructural changes in the terminal 
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bronchi and parenchyma.  In this regard, regional imaging measurements provided by 
hyperpolarized 
3
He magnetic resonance imaging (MRI) are highly sensitive to pulmonary 
abnormalities in asymptomatic ex-smokers (21, 22) and never-smokers with second-hand 
smoke exposure (23).  Similarly, airway morphology and parenchyma density x-ray 
computed tomography (CT) measurements from the ECLIPSE (24) and COPDGene (25) 
studies showed the utility of CT phenotypes (26) for stratifying COPD patients (27-29).  
Cardiovascular disease, predominated by large vessel atherosclerosis, is associated with 
obstructive lung disease (30, 31) that can be regionally and quantitatively evaluated using 
carotid ultrasound (US).  The burden of atherosclerosis can be quantified (32) using 
carotid intima-media thickness (IMT) measurements and this is believed to reflect medial 
hypertrophy and intima abnormalities, and importantly, IMT correlates with 
cardiovascular outcomes (32, 33).  In a similar manner, three-dimensional ultrasound 
(3DUS) carotid atherosclerosis measurements (34) of carotid wall and plaque 
abnormalities are sensitive predictors of cardiovascular risk (35-37) and in some patients, 
these provide a better estimate of plaque burden and risk (37).   
There is a paucity of direct evidence relating subclinical lung disease and atherosclerosis 
in otherwise healthy ex-smokers.  To provide a better understanding of the relationship 
between carotid atherosclerosis and pulmonary abnormalities common to ex-smokers 
with obstructive lung disease, our objective was to acquire highly sensitive pulmonary 
and carotid 3D imaging measurements in never- and ex-smokers with normal pulmonary 
function.  We hypothesized that quantitative 3D imaging phenotypes would provide a 
way to tease out potential relationships for early or mild sub-clinical emphysema or 
airways disease with atherosclerosis in subjects at risk.   
2.2 Materials and Methods 
2.2.1 Study subjects 
Ex-smokers (≥10 pack-year smoking history) without symptoms or a physician-diagnosis 
of COPD and normal spirometry (FEV1/FVC ≥ 70%) as well as never-smokers (<1 pack-
year smoking history) with no history of chronic respiratory or significant or uncontrolled 
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cardiovascular disease between 50-90 years of age were recruited.  These subjects 
enrolled in response to advertisements placed within the community and at local healthy 
aging exercise and atherosclerosis prevention clinics.  All subjects provided written 
informed consent to a protocol approved by a local research ethics board and Health 
Canada. 
2.2.2 Spirometry and plethysmography 
Spirometry, plethysmography and diffusing capacity of carbon monoxide (DLCO) 
measurements were performed according to the American Thoracic Society guidelines 
(19).  An ndd EasyOne spirometer (ndd Medizintchnik AG, Zurich, Switzerland) was 
used to measure FEV1 and FVC.  Whole body plethysmography was performed for lung 
volumes and DLCO measurements were recorded using a gas analyzer (MedGraphics 
Corporation, St. Paul, Minnesota, USA). 
2.2.3 Imaging 
High-resolution B-mode ultrasound (US) images were acquired (ATL HDI 5000; Philips, 
Bothel, Washington, USA) as previously described (38) using a 50 mm L12-5 MHz 
transducer (frequency=8.5 MHz, Philips).  Gain, focal points and time-depth 
compensation were optimized by the sonographer taking into consideration neck size, 
carotid anatomy and tissue depth.  Two dimensional images were reconstructed into a 3D 
volume as previously described (39, 40).  MRI was performed on a whole body 3.0 Tesla 
Discovery 750MR (General Electric Health Care, Milwaukee, Wisconsin, USA) MRI 
system.  
1
H and 
3
He MRI were performed as previously described (41) with the subject in 
an inspiration breath-hold (FRC+1L).  For ex-smokers only, computed tomography (CT) 
was acquired within 10 minutes of MRI and at the same lung volume (FRC+1L) to 
ensure similar parenchymal distension in a method previously described (41). 
2.2.4 Image analysis 
Carotid IMT was measured from the longitudinal plane of the 3DUS volume using 
Prowin 24.0 software (Medical Technologies International Inc., Palm Desert, California, 
54 
 
 
 
USA) as previously described (42).  Carotid total plaque volume (TPV) and vessel wall 
volume (VWV) were measured as previously described (43). 
3
He MRI ventilation defect percent (VDP) and apparent diffusion coefficients (ADC) 
were measured using semi-automated segmentation generated using custom-built 
software in MATLAB R2007b (The Math-works Inc., Natick, Massachusetts, USA) as 
previously described (44, 45).  CT volumes were analyzed using Pulmonary Workstation 
2.0 (PW2, VIDA Diagnostics Inc., Coralville, Iowa, USA).  Pulmonary CT images were 
analyzed for airway dimensions including wall area percent (WA%), lumen area (LA) 
and standardized wall thickness of airways with an inner perimeter of 10 mm (Pi10) (46). 
In addition, the relative area of the lung with CT attenuation values less than -950HU 
(RA950) and total airway count were also measured using PW2. 
2.2.5 Statistics 
Normality of data was tested using the Shapiro-Wilk test and when significant, the Mann-
Whitney U test for nonparametric data was performed using SPSS Statistics V20.0 (SPSS 
Inc., Chicago, Illinois, USA).  Unpaired two tailed t-test comparisons were performed 
using GraphPad Prism V4.0 (GraphPad Software Inc., California, USA) and Welch’s 
correction used when the F test for equal variances was significant.  The Holm-
Bonferroni correction (47) was performed for multiple unpaired t-test comparisons.  
Multiple regression analyses were performed in SPSS to determine the relationship 
between carotid US measurements with 
3
He MRI VDP and pulmonary function 
parameters.    Partial correlations were computed using SPSS.  Multiple regression and 
correlation models were adjusted for age, BMI and DLCO since these parameters are 
established risk factors for cardiovascular and pulmonary diseases (8, 48).  Results were 
considered significant when the probability of two-tailed type I error was less than 5% 
(p<0.05) and summary data are presented as mean ± SD unless otherwise indicated. 
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2.3 Results 
As shown in Table 2-1, 61 subjects including 27 ex-smokers (73±9yr, 18 male) and 34 
never-smokers (72±6yr, 18 male) were evaluated.  Except for BMI, (p=0.001) there were 
no significant differences between subject groups for demographic characteristics.  
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Table 2-1.  Demographic, pulmonary function, thoracic CT and carotid 
ultrasound data for all study subjects 
  Ex-smokers 
n=27 
Never-smokers 
n=34 
Significance of 
Difference p* 
Age yrs (±SD) 73 (9) 72 (6) 1.0 
Male n 18 18 - 
BMI kg·m
-2  
(±SD) 30 (3) 27 (3) 0.001 
Pack years (±SD) 27 (18) - - 
Years quit (±SD) 26 (6) - - 
FEV1%pred (±SD) 106 (16) 106 (18) 0.89 
FVC %pred (±SD) 97 (13) 101 (17) 1.0
 
FEV1/FVC (±SD) 81 (7) 77 (5) 0.36 
TLC %pred (±SD) 102 (14) 106 (15) 1.0 
IC %pred (±SD) 107 (14) 107 (22) 1.0
 
RV %pred (±SD) 110 (26) 109 (29) 1.0 
RV/TLC (±SD) 42 (7) 39 (13) 0.96 
Raw%pred (±SD)  115 (72) 76 (34) 0.11 
DLCO%pred (±SD) 83 (17) 87 (20) 1.0
 
ADC cm
2
/s (±SD) 0.29 (0.04)
1 
0.26 (0.03)
2 
 0.20 
VDP % (±SD) 7 (3)
1 
3 (2)
2 
 0.001 
IMT mm (±SD) 0.84 (0.10) 0.77 (0.09) 0.11 
TPV mm
3
 (±SD) 250 (200) 60 (90)  0.002 
VWV mm
3
 (±SD) 910 (190)
3
 890 (170)
4
 1.0 
5
th
 gen. WA% (±SD) 61 (2) - - 
5
th
 gen. LA mm
2 
(±SD) 17 (11) - - 
Pi10 mm (±SD) 4.1 (0.17) - - 
RA950 % (±SD) 1.5 (1.4) - - 
Airway Count n (±SD) 127 (35)   
BMI: Body mass index, FEV1: Forced expiratory volume in one second, FVC: Forced 
vital capacity, TLC: Total lung capacity, IC: Inspiratory capacity, RV: Residual 
volume, Raw: Airways resistance, DLCO: Diffusing capacity for carbon monoxide, 
ADC: Apparent diffusion coefficient, VDP: Ventilation defect percentage, IMT: 
Intima-media thickness, TPV: Total plaque volume, VWV: Vessel wall volume, 5
th
 
gen.: Fifth generation airway, WA%: Airway wall area percentage, LA: Airway lumen 
area,   Pi10: Standardized wall thickness of airways with an inner perimeter of 10mm, 
RA950: Relative area of the lung with attenuation values below -950HU, SD: Standard 
deviation, %pred: Percent of predicted value 
*Data are Holm-Bonferroni corrected p-values for unpaired t-test comparisons  
1
n=26, 
2
n=29, 
3
n=22, 
4
n=30 
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Figure 2-1.  Representative 
3
He MRI and 3DUS images for two never-smokers (S1 
and S2) and two ex-smokers (S3 and S4).  Never-smoker S1 is a 67-year old female 
with FEV1=120%, FEV1/FVC=0.77, 
3
He MRI VDP=3%, TPV=20mm
3
 and 
IMT=0.79mm.  Never-smoker S2 is a 68-year old male with FEV1=93%, 
FEV1/FVC=0.79, 
3
He MRI VDP=2%, TPV=30mm
3
 and IMT=0.73mm.  Ex-smoker S3 is 
a 79-year old female with FEV1=88%, FEV1/FVC=0.71, VDP=8%, TPV=500mm
3
 and 
IMT=0.94mm.  Ex-smoker S4 is a 85-year old male with FEV1=139%, FEV1/FVC=0.79, 
VDP=8%, TPV=340mm
3
 and IMT=0.96mm.  The axial 3DUS image of the common 
carotid artery shows the intima-lumen boundary in green and carotid plaque-lumen 
boundary in yellow.  The longitudinal 3DUS carotid image shows IMT segmentation of 
the common carotid artery. 
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Figure 2-1 shows 
3
He MRI centre coronal slices and 3DUS axial and longitudinal images 
for representative ex- and never-smokers.  
3
He MRI ventilation images show 
homogeneous ventilation in never-smokers, whereas there is heterogeneous signal 
intensity with visually obvious ventilation defects in ex-smokers.  3DUS axial images 
show carotid plaque that is qualitatively greater in the two ex-smokers.   
Quantitative results are provided in Figure 2-2 and Table 2-1 that show that the ex-
smokers subgroup had significantly greater TPV, (250±200mm
3
, p=0.002) and 
3
He MRI 
VDP, (7±3%, p=0.001) than never-smokers.  No significant differences were observed 
for VWV (p=1.0), IMT (p=0.11), ADC (p=0.20) or FEV1 (p=0.89).  For ex-smokers, CT 
mean RA950 (1.5±1.4%), airway wall thickness at an internal perimeter of 10mm (Pi10, 
4.1±0.17mm), WA% (61±2%), and LA (17±11mm
2
) were within normal range as 
previously published (49, 50). 
 
Figure 2-2.  Imaging phenotypes in asymptomatic ex-smokers and never-smokers.  
Ex-smokers have significantly greater: A) TPV (p=0.002) and D) VDP (p=0.001) than 
never-smokers.  No significant differences were observed for: B) IMT (p=0.11), C) VWV 
(p=1.0), E) ADC (p=0.20).  Holm-Bonferroni corrected p-values are shown. 
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Using previously established age-normalized values for IMT (51), 28 subjects (15 ex-
smokers and 13 never-smokers, 28/61=46%) exceeded the upper limit of normal for IMT 
and 33 subjects (12 ex-smokers and 21 never-smokers, 33/61=54%) had normal IMT.  As 
shown in Figure 2-3, subjects with abnormally elevated IMT had significantly greater 
VDP (p=0.04) than subjects with normal IMT, but the two subgroups were not 
significantly different with respect to ADC (p=0.06), FEV1%pred (p=1.0) or DLCO%pred 
(p=0.85).  CT measurements for the 15 ex-smokers with abnormal IMT were not 
significantly different than ex-smokers with normal IMT for RA950 (p=0.96), WA% 
(p=0.66) or LA (p=0.63). 
 
Figure 2-3.  Never- and ex-smokers with IMT ≥ age-related upper limit of normal 
(IMT >97.5% confidence interval (CI)) and subjects with IMT < age-related normal 
limit (IMT ≤97.5 CI).  A) Subjects with abnormally elevated IMT have statistically 
significantly different 
3
He MRI VDP (p=0.04) than subjects with normal IMT.  No 
significant differences were observed for: B) ADC (p=0.06), C) FEV1 (p=1.0) or D) 
DLCO (p=0.85).  Comparisons displayed are Holm-Bonferroni corrected p-values. 
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As shown in Figure 2-4, univariate Pearson correlations between 
3
He MRI VDP and 
carotid ultrasound measurements revealed a moderate significant relationship for VDP 
with carotid IMT (r=0.42, p=0.004), TPV (r=0.41, p=0.006) and VWV (r=0.40, p=0.007).  
Multivariate regression models for IMT, VWV and TPV are provided in Table 2-2.  VDP 
was a significant determinant of IMT (β=0.41, p=0.001), VWV (β=0.45, p=0.003) and 
TPV (β=0.38, p=0.005).   For the ex-smokers alone, CT-derived measurements including 
RA950 and airway count, WA%, LA and Pi10 did not correlate with carotid US 
measurements of IMT, TPV and VWV. 
 
Table 2-2.  Multiple regression models for IMT, VWV and TPV  
 IMT
 
 VWV  TPV 
 β  p   β  p   β  p  
Age 0.005 0.02  -0.08 0.63  0.18 0.20 
BMI 0.20 0.11  -0.11 0.44  0.09 0.47 
FEV1 -0.03 0.81  0.21 0.18  0.10 0.48 
DLCO 0.15 0.22  -0.08 0.59  -0.10 0.46 
VDP 0.41 0.001  0.45 0.003  0.38 0.005 
Dependent Variables:  IMT, r
2
=0.27, p=0.001; VWV, r
2
=0.21, p=0.08; TPV, r
2
=0.16, 
p=0.02 
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Figure 2-4.  Relationships for carotid atherosclerosis and pulmonary VDP.  
Significant relationships between 
3
He MRI VDP and: A) carotid IMT (r=0.42, p=0.004), 
B) VWV (r=0.40, p=0.007) and C) TPV (r=0.41, p=0.006). 
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2.4 Discussion 
We tested the hypothesis that atherosclerosis and pulmonary structure-function 
measurements were significantly different in ex-smokers without airflow limitation or 
symptoms consistent with COPD than in never-smokers.  We observed: 1) ex-smokers 
had significantly greater carotid TPV and worse 
3
He VDP than never-smokers, but were 
not significantly different with respect to pulmonary function test measurements, 2) 28 
subjects  including 15 ex- and 13 never-smokers with abnormally elevated IMT had 
significantly worse VDP but ADC, FEV1, DLCO and CT measurements were not different 
compared to subjects with normal IMT, 3) 
3
He VDP was significantly related to carotid 
atherosclerosis measurements (IMT, VWV and TPV) but pulmonary function tests were 
not, and 4), multivariate regression models showed that VDP, a measurement of small 
airway function, was the only significant determinant of carotid artery IMT, VWV and 
TPV. 
In these older subjects without COPD, we observed, as expected, that spirometry and 
plethysmography measurements were not different in ex- and never-smokers, but 
importantly 
3
He VDP was significantly worse for ex-smokers.  This finding is concordant 
with previous findings in asymptomatic ex-smokers that showed significant differences in 
3
He MRI ventilation defects compared to never-smokers (22).  Although we did not 
observe differences between subgroups for 
3
He MRI ADC, abnormally elevated 
3
He 
ADC has been previously reported in asymptomatic smokers (21) and never-smokers 
with second-hand smoke exposure (23).  Our finding of abnormal 
3
He ventilation in the 
absence of abnormal DLCO, ADC or CT RA950  in ex-smokers is in agreement with the 
notion that “silent” airway disease (20) and small airway remodeling (52) may be the 
source of ventilation defects in these subjects.  We think that the significant differences 
observed for VDP in the absence of differences in DLCO, ADC or RA950 suggests mild, 
sub-clinical airway abnormalities, although we must point out that a definitive structure-
function etiology for 
3
He ventilation defects (46, 53, 54) is yet to be determined.  It is 
also worth noting that for the healthy ex-smokers evaluated here, there was no CT 
evidence of emphysema or airways disease and such values were in agreement with those 
reported in healthy non-smokers in the COPDGene study (49, 50).  This finding 
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underscores the sensitivity of 
3
He MRI ventilation measurements for detecting functional 
abnormalities that may not be apparent using CT or spirometry.  
Previous work in COPD patients (3, 4, 6, 7, 17, 55, 56) reported a relationship for IMT 
with FEV1 and emphysema measurements, but this was not observed here in ex-smokers 
without COPD.  We were likely underpowered to detect differences in IMT between 
subgroups as these previous studies investigating IMT in COPD and healthy older 
subjects used sample sizes ranging from 305 to 14,480 subjects.  On the other hand, 
significantly elevated 3DUS TPV in ex-smoker subgroup was consistent with previous 
work (35, 36) that showed smaller sample sizes can be used when employing 3D 
measurements of plaque as compared to IMT.  Although no difference was observed for 
IMT between ex- and never-smokers, when age-normalized IMT values were used to 
stratify subjects (51), subjects with abnormal IMT had significantly worse VDP.  This 
finding suggests that in both never- and ex-smokers with elevated IMT, there is evidence 
of mild, subclinical airways disease that may be related to factors other than cigarette 
smoking.  
We also observed significant univariate relationships for 
3
He VDP with carotid artery 
IMT, TPV and VWV, consistent with previous studies that showed relationships between 
spirometry measurements and carotid IMT (3, 4, 6, 17, 55, 56), although this is the first 
report of such relationships in subjects with normal pulmonary function.  Similarly, 
multivariate regression models that controlled for cardiovascular and pulmonary disease 
risk factors showed that VDP was the only significant determinant of carotid artery IMT, 
VWV and TPV.  It is also important to note that carotid TPV and VWV provide 
measurements of intima echogenic (TPV and VWV) and echolucent (VWV) plaque (38, 
57, 58).  Hence, these relationships between VDP and IMT, VWV and TPV suggest that 
in this relatively small group of never- and ex-smokers, mild, subclinical airways disease 
may be related to carotid plaque burden and wall thickening. While it was recently shown 
that COPD patients may have atherosclerotic plaque characteristics that make them more 
vulnerable to rupture (6), we did not evaluate carotid plaque composition here.  The 
significant carotid plaque burden quantified in some of the ex-smokers investigated here 
may be amenable to more complex image methods (59) to develop a better understanding 
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of plaque composition/texture and outcomes.  We acknowledge that the main limitation 
of this study was the relatively small sample size of never- and ex-smokers, and that this 
may have limited our power to detect any potential differences in IMT and FEV1 between 
subgroups.  Certainly, one of the strengths of 3D imaging is that significantly different 
measurements can be detected in small groups of subjects, because of the high dynamic 
range and sensitivity of 3D measurements to structure-function abnormalities.  This is an 
important consideration when powering studies to detect differences in small groups of 
subjects.  Finally, we cannot infer the temporal or causal nature of carotid and pulmonary 
abnormalities in this cross-sectional evaluation.  Questions related to “which came first” 
still need to be answered in longitudinal natural disease and intervention studies (60).  
In conclusion, we acquired sensitive 3D imaging measurements of atherosclerosis and 
pulmonary structure-function in order to illuminate potential relationships between early 
or mild sub-clinical pulmonary disease with atherosclerosis in otherwise healthy ex-
smokers.  Although a number of studies have provided evidence that pulmonary and 
carotid abnormalities are both present and related in COPD patients, here, this important 
relationship was shown in never- and ex-smokers smokers with normal pulmonary 
function.  Whilst the clinical relevance of these observations is not yet clear, these data 
suggest that lung abnormalities and carotid atherosclerosis in never- and ex-smokers 
without airflow limitation may be directly related.  As our knowledge of comorbid lung 
and vascular disease increases, such findings may potentially have implications for 
patient management decision strategies in preclinical stages. 
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CHAPTER 3 
The study in Chapter 2 showed how hyperpolarized 
3
He MRI reveals clinically relevant 
ventilation defects in the lungs of ex-smokers without airflow limitation.  This suggests 
that ex-smokers without spirometry evidence of COPD may suffer from a form of pre- or 
sub-clinical obstructive lung disease attributable to airway and/or parenchymal 
abnormalities which are not detected using conventional spirometry or plethysmography.  
Here, we aimed to provide a better understanding of the underlying pathophysiology of 
ventilation defects in ex-smokers without airflow limitation by collecting regional 
3
He 
ventilation and diffusion-weighted imaging data, as well as regional thoracic computed 
tomography airway and emphysema measurements in ex-smokers without airflow 
limitation. 
The contents of this chapter have been previously published in Academic Radiology and 
permission to reproduce the article was granted by Elsevier Publishing and is provided 
in Appendix D. 
D Pike, M Kirby, F Guo, DG McCormack and G Parraga.  Ventilation Heterogeneity in 
Ex-smokers without Airflow Limitation.  Academic Radiology; DOI:  
10.1017/j.acra.2015.04.006 
3 Ventilation Heterogeneity in Ex-smokers without Airflow 
Limitation 
3.1 Introduction 
Chronic obstructive pulmonary disease (COPD) is characterized by irreversible airflow 
limitation caused by small airway remodeling, airway obliteration (1) and 
emphysematous tissue destruction (2).  COPD is typically diagnosed after respiratory 
symptoms become obvious and intolerable (3), and this usually occurs when spirometry 
measurements of lung function reflect airflow limitation and obstruction.  However it is 
well-understood that ex- and current-smokers may report normal lung function (3) and 
mild symptoms and this may represent an early or ‘subclinical’ phase.  A deep 
understanding of the underlying morphological changes that accompany this ‘subclinical’ 
phase is lacking, mainly because methods for evaluating pulmonary function cannot 
detect very mild or early structure-function abnormalities.   
Hyperpolarized 
3
He magnetic resonance imaging (MRI) ventilation heterogeneity has 
been shown in healthy older subjects (4) and patients with COPD (5) and asthma (6).  To 
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evaluate the underlying anatomical and structural determinants of ventilation 
heterogeneity, thoracic x-ray computed tomography (CT) has been used to help 
determine the spatial relationship of airways disease and emphysema with ventilation 
abnormalities.  For example, recent work (7) provided evidence that in COPD, 
3
He 
ventilation defects represent regions of emphysema and airways disease and that this 
relationship depends on disease severity.  In asthma (6), 
3
He ventilation heterogeneity 
was also shown to be spatially related to abnormally remodeled airways.  Whilst previous 
work reported the presence of ventilation heterogeneity in ex-smokers with normal 
spirometry (8), the underlying etiology and clinical relevance of these findings is not 
well-understood.  
In order to better understand the pathophysiological features of ventilation heterogeneity 
in the ‘subclinical phase’ of obstructive lung disease in otherwise normal healthy ex-
smokers, we evaluated a group of well-characterized ex-smokers without airflow 
limitation using both MRI and CT.  Based on previous work using micro-CT that 
suggested that airway obstruction and obliteration may provide the dominant contribution 
to airflow limitation in COPD (1), we hypothesized that in normal ex-smokers, 
3
He 
ventilation abnormalities would be spatially and quantitatively related to airway 
remodeling and not emphysema. 
3.2 Materials and Methods 
3.2.1 Study Subjects 
Study participants provided written informed consent to a protocol approved by a local 
research ethics board and Health Canada and was compliant with the Personal 
Information Protection and Electronic Documents Act (PIPEDA, Canada) and Health 
Insurance Portability and Accountability Act (HIPAA, USA).  Research volunteers were 
recruited from a tertiary health care practice.  Each visit was completed in approximately 
two hours when spirometry, plethysmography, the six-minute walk test (6MWT), St. 
George’s Respiratory Questionnaire (SGRQ), 3He MRI and CT were completed.   
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3.2.2 Spirometry and Plethysmography 
Spirometry was performed according to the American Thoracic Society guidelines (9).  
Whole-body plethysmography was used to measure lung volumes (MedGraphics 
Corporation, St. Paul, Minnesota, USA) and the attached gas analyzer was used to 
measure diffusing capacity of the lung for carbon monoxide (DLCO).   
3.2.3 Imaging 
MRI was performed on a 3T Discovery MR750 (General Electric Health Care, 
Milwaukee, Wisconsin, USA) system with subjects in inspiratory breath hold at 
functional residual capacity (FRC)+1L.  
1
H MRI was acquired prior to 
3
He MRI after 
inhalation of 1L high purity, medical grade nitrogen (N2) from FRC using the whole-
body radiofrequency coil and a fast spoiled gradient-recalled-echo sequence (10).  
3
He 
MRI was acquired with subjects in inspiratory breath-hold after inhalation from FRC of a 
1L mixture of hyperpolarized 
3
He (5ml/kg body weight) diluted with N2.  
3
He static-
ventilation and diffusion-weighted MRI was performed as previously described (10, 11). 
CT was acquired within 30 minutes of MRI using a 64 slice Lightspeed VCT system 
(General Electric Health Care, Milwaukee, Wisconsin, USA) and a single spiral 
acquisition from apex to base with the subjects in the supine position.  Subjects were 
transported to the CT suite by wheelchair to prevent the potential for exercise-induced 
changes between MRI and CT image acquisitions.  CT was acquired during inspiratory 
breath-hold of FRC+1L of N2 as previously described (12).  The total effective dose was 
1.8 mSv as calculated using manufacturer settings and the ImPACT CT dosimetry 
calculator based on Health Protection Agency (UK) NRPB-SR250. 
3.2.4 Image analysis 
Ventilation heterogeneity or regions of “signal void” were quantified as 3He ventilation 
defect percent (VDP) using semi-automated software generated in MATLAB 
(Mathworks, Natick, Massachusetts, USA) as previously described (13).  Lobar VDP was 
generated by registering the segmented thoracic CT lobe mask from VIDA Pulmonary 
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Workstation 2.0 (VIDA Diagnostics Inc., Coralville, Iowa, USA) to 
3
He MRI ventilation 
images using deformable registration, and generating VDP for each lobe (right upper lobe 
(RUL), right middle lobe (RML), right lower lobe (RLL), left upper lobe (LUL), left 
lower lobe (LLL)) using hierarchical k-means clustering (13).  All ex-smokers were 
classified on the basis of the 95% confidence interval for VDP in healthy elderly never-
smokers of 4.3% as previously described (4). Therefore, ex-smokers with VDP<4.3% 
were classified as normal whereas ex-smokers with VDP≥4.3% were classified as having 
abnormally-elevated VDP.  
3
He MRI apparent diffusion coefficients (ADC) were 
generated as previously described (11).   
CT volumes were evaluated using Pulmonary Workstation 2.0 to generate airway wall 
area percent (WA%), lumen area (LA) and airway count.  It was previously shown that 
airway lumen area is related to body surface area (BSA) (14, 15) and therefore LA was 
normalized to BSA (LA/BSA).  CT WA%, LA and LA/BSA were measured for 
subsegmental bronchi including RB1, RB5, RB8, LB1 and LB8 airways because each of 
these feed individual lobes (RB1-RUL, RB5-RML, RB8-RLL, LB1-LUL and LB8-LLL) 
and they were measureable for each subject.  Emphysema was also measured using 
Pulmonary Workstation 2.0 including the relative area of the lung with attenuation ≤ -950 
Hounsfield units (HU) (RA950) for whole-lung and each individual lung lobe.   
3.2.5 Statistics 
All tests were performed in IBM SPSS V22 (SPSS Inc., Chicago, Illinois, USA).  
Normality was tested using the Shapiro-Wilk test.  A one-way analysis of variance 
(ANOVA) was used to compare multiple parameters and univariate comparisons were 
investigated using unpaired two-tailed t-tests (parametric data) or Mann-Whitney U tests 
(non-parametric data).  Spearman correlations were performed for non-parametric data.   
3.3 Results 
A summary of demographic, pulmonary function test and imaging measurements is 
provided in Table 3-1 for all 60 subjects, while Supplemental Table 3I-1 (online) 
provides a subject listing of data.  All participants reported normal spirometry 
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measurements (FEV1=104±13%, FEV1/FVC=80±6%) and no subjects reported Global 
initiative for Chronic Obstructive Lung Disease (GOLD) unclassified COPD (16).  
Eighteen subjects (18/60=30%) reported normal VDP and 42 (42/60=70%) subjects 
reported abnormally-elevated VDP.  As shown in Figure 3-1 for four representative 
subjects, volunteers with normal VDP showed small or no ventilation defects along the 
periphery of the lung, whereas participants with abnormally-elevated VDP showed 
evidence of patchy ventilation throughout the lung and on the periphery.  The qualitative 
spatial relationship for patchy ventilation and subsegmental airway morphology 
reconstructed from CT is also shown in Figure 3-1.   
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Figure 3-1.  
3
He MRI Ventilation and CT airway trees in representative ex-smokers 
with normal (S1–S3) and abnormally-elevated VDP (S4–S6).  S1=70y female, 12 pack 
years, FEV1=93% and VDP=2%.  S2=59y female, 18 pack years, FEV1=97% and 
VDP=2%.  S3=51y female, 20 pack years, FEV1=103% and VDP=4%.   S4=74y male, 
50 pack years, FEV1=89% and VDP=6%.  S5=79y male, 10 pack years, FEV1=88% and 
VDP=8%.  S6=74y male, 60 pack years, FEV1=95% and VDP=11%. 
 
As shown in Table 3-1, subjects with abnormally-elevated VDP were not significantly 
different (p>0.05) with respect to pulmonary function test or CT measurements but they 
did report significantly greater (p=0.02) 
3
He ADC than subjects with normal VDP.  
 
Table 3-1.  Demographic, pulmonary function and imaging data 
Parameter (±SD) All  
(n=60) 
Normal VDP 
(n=18) 
Elevated VDP 
(n=42) 
Age yr  69 (9) 67 (10) 70 (9) 
Male n (%) 38 (63) 9 (50) 29 (69) 
Pack years  28 (16) 27 (14) 28 (17) 
BMI kg/m
2
  29 (4) 29 (5) 30 (4) 
FVC%pred  97 (13) 100 (10) 95 (14) 
FEV1%pred  104 (13) 106 (12) 102 (14) 
FEV1/FVC % 80 (6) 80 (6) 80 (6) 
RV/TLC%pred 103 (15) 104 (12) 103 (16) 
DLCO %pred  80 (20) 87 (16) 77 (22) 
6MWD m 404 (95) 433 (81) 392 (98) 
SGRQ total 36 (26) 22 (20) 23 (22) 
WA %  65 (2) 65 (2) 65 (2) 
LA mm
2
  14 (3) 13 (2) 14 (4) 
LA/BSA mm
2
/m
2
 7 (2) 7 (1) 7 (2) 
Airway count 115 (37) 106 (28) 119 (40) 
RA950 %  1.2 (1.0) 0.8 (0.5) 1.4 (1.1) 
VDP %  6 (3) 3 (1) 7 (3)
†
 
ADC cm
2
/s 0.28 (0.04) 0.26 (0.03) 0.29 (0.03)
†
 
BMI: Body mass index, FVC: Forced vital capacity, FEV1: Forced expiratory volume in 
one second, RV: Residual volume, TLC: Total lung capacity, DLCO: Diffusing capacity 
for carbon monoxide,  SGRQ:  St. Georges Respiratory Questionnaire,  6MWD:  Six 
minute walk distance,  WA%:  Mean fifth generation airway wall area percent, LA:  
Mean fifth generation airway lumen area, BSA:  Body surface area, RA950:  Relative area 
of the lung parenchyma with attenuation ≤ -950HU, VDP:  3He MRI ventilation defect 
percent, ADC:  
3
He MRI apparent diffusion coefficient, SD:  standard deviation 
†
Significantly different p<0.05 
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Table 3-2 shows quantitative airway morphology and emphysema measurements for 
subjects with normal and abnormally-elevated VDP.  No significant differences were 
observed for whole-lung airway (mean of fifth generation airways) WA% (p=0.88), LA 
(p=0.50) or LA/BSA (p=0.57) and this was consistent in all lung lobes.  Table 3-2 and 
Figure 3-2 show that only 
3
He MRI ADC was significantly greater in the apical lung 
(RUL: p=0.02, RML: p=0.04 and LUL: p=0.009) in subjects with elevated VDP.   
Table 3-3 shows the relationships for VDP with airway morphology and emphysema 
measurements.  Whole lung VDP was significantly correlated with whole lung ADC 
(r=0.40, p=0.001) and whole lung RA950 (r=0.34, p=0.008).  As shown in Table 3-3 and 
in more detail in Figure 3-3, regional VDP correlated with regional ADC in each of the 
lung lobes (RUL: r=0.32, p=0.01, RML: r=0.46, p=0.002, RLL:  r=0.38, p=0.003, LUL:  
r=0.35, p=0.006 and LLL:  r=0.37, p=0.004).  As shown in Table 3, whole lung VDP did 
not correlate with whole lung (mean of fifth generation airways) WA%, LA or LA/BSA.  
There were no significant correlations for regional VDP and airway morphological 
measurements in the RML (RB5 morphology), LUL (LB1 morphology) or LLL (LB8 
morphology).  However, as shown Figure 3-4 in more detail, RUL VDP significantly 
correlated RB1 morphological measurements (LA: r=-0.37, p=0.004, LA/BSA: r=-0.42, 
p=0.0008) and RLL VDP significantly correlated with RB8 morphological measurements 
(WA%: r=0.28, p=0.03, LA: r=-0.28, p=0.03, LA/BSA: r=-0.37, p=0.004).   
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Table 3-2. Whole lung and regional measurements for ex-smokers with normal 
and elevated VDP 
Parameter (±SD) Normal  
VDP (n=18) 
Elevated  
VDP (n=42) 
p-value 
Whole Lung    
**WA% 65 (2) 65 (2) 0.88 
**LA mm
2
 13 (2) 14 (4) 0.50 
**LA/BSA mm
2
/m
2
 7 (1) 7 (2) 0.57 
VDP % 3 (1) 7 (3) <0.0001 
ADC cm
2
/s 0.26 (0.03) 0.29 (0.03) 0.02 
RA950 % 0.8 (0.5) 1.4 (1.1) 0.08 
Right upper lobe    
RB1 WA% 62 (2) 61 (4) 0.29 
RB1 LA mm
2 
25 (5) 25 (11) 0.64 
RB1 LA/BSA mm
2
/m
2 
13 (3) 13 (6) 0.39 
VDP % 3 (2) 5 (4) 0.02 
ADC cm
2
/s 0.24 (0.03) 0.27 (0.03) 0.02 
RA950 % 0.7 (0.6) 1.2 (1.2) 0.08 
Right middle Lobe     
RB5 WA% 63 (4) 62 (4) 0.25 
RB5 LA mm
2
 22 (13) 21 (8) 0.80 
RB5 LA/BSA mm
2
/m
2
 12 (7) 11 (4) 0.99 
VDP % 6 (9) 9 (10) 0.04 
ADC cm
2
/s 0.24 (0.03) 0.27 (0.04) 0.04 
RA950 % 1.6 (1.0)  2.0 (1.8) 0.79 
Right lower lobe    
RB8 WA% 62 (3) 62 (3) 0.43 
RB8 LA mm
2
 21 (8) 21 (7) 0.99 
RB8 LA/BSA mm
2
/m
2
 11 (5) 11 (4) 0.67 
VDP % 5 (3) 8 (6) 0.02 
ADC cm
2
/s 0.25 (0.03) 0.27 (0.03) 0.07 
RA950 % 0.6 (0.4) 1.0 (1.0) 0.42 
Left Upper Lobe     
LB1 WA% 63 (3) 63 (3) 0.52 
LB1 LA mm
2
 15 (4) 18 (6) 0.19 
LB1 LA/BSA mm
2
/m
2 
8 (2) 9 (3) 0.34 
VDP % 4 (4) (3) 8 (8) 0.02 
ADC cm
2
/s 0.25 (0.03) 0.28 (0.04) 0.009 
RA950 % 1.0 (0.6) 1.8 (1.7) 0.22 
Left Lower Lobe     
LB8 WA% 59 (4) 60 (4) 0.68 
LB8 LA mm
2
 30 (11) 28 (12) 0.27 
LB8 LA/BSA mm
2
/m
2 
17 (8) 14 (6) 0.13 
VDP % 3 (1) 7 (3) <0.0001 
ADC cm
2
/s 0.25 (0.03) 0.27 (0.04) 0.07 
RA950 % 0.7 (0.4) 1.1 (1.1) 0.42 
WA%: Wall area percent, LA: Lumen area, BSA: Body surface area, RB1: Right upper 
lobe apical bronchus, RB5: Right middle lobe lateral bronchus, RB8: Right lower lobe 
subsegmental bronchus, LB1: Left upper lobe apical bronchus, LB8: Left lower lobe 
subsegmental bronchus, RA950: Relative area of the lung parenchyma with attenuation ≤ -
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950HU, VDP:  
3
He MRI ventilation defect percent, ADC:  
3
He MRI apparent diffusion 
coefficient, **Mean of fifth generation airway 
 
 
Figure 3-2. Whole lung and regional emphysema measurements in ex-smokers with 
normal (n=18) and abnormally-elevated VDP (n=42).  ADC was significantly greater 
in apical lung in subjects with elevated VDP.  A) Whole lung ADC (p=0.02), B) Right 
upper lobe ADC (p=0.02), C) Left upper lobe ADC (p=0.009), D) Right middle lobe 
ADC (p=0.04), E) Left lower lobe ADC (p=0.07), F) Right lower lobe ADC (p=0.07).   
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Table 3-3.  Relationship of 
3
He MRI VDP with airways disease and emphysema 
measurements 
  Spearman r  p 
Whole Lung VDP  
**WA% 0.002 0.99 
**LA  0.04 0.76 
**LA/BSA  -0.04 0.75 
ADC 0.40 0.001 
RA950 0.34 0.008 
Right Upper Lobe VDP   
RB1 WA% 0.24 0.06 
RB1 LA -0.37 0.004 
RB1 LA/BSA -0.42 0.0008 
ADC 0.32 0.01 
RA950 0.15 0.27 
Right Middle Lobe VDP   
RB5 WA% -0.11 0.40 
RB5 LA -0.003 0.98 
RB5 LA/BSA -0.02 0.91 
ADC 0.46 0.002 
RA950 0.24 0.07 
Right Lower Lobe VDP   
RB8 WA% 0.28 0.03 
RB8 LA -0.28 0.03 
RB8 LA/BSA -0.37 0.004 
ADC 0.38 0.003 
RA950 0.21 0.11 
Left Upper Lobe VDP   
LB1 WA% 0.07 0.62 
LB1 LA 0.13 0.33 
LB1 LA/BSA -0.01 0.94 
ADC 0.35 0.006 
RA950 0.23 0.08 
Left Lower Lobe VDP  
LB8 WA% 0.04 0.73 
LB8 LA 0.05 0.68 
LB8 LA/BSA -0.02 0.86 
ADC 0.37 0.004 
RA950 0.26 0.05 
WA%:  Wall area percent, LA:  Lumen area, BSA:  Body surface area WL; Whole lung, 
RB1:  Right upper lobe apical bronchus, RB5:  Right middle lobe lateral bronchus, RB8:  
Right lower lobe subsegmental bronchus, LB1:  Left upper lobe apical bronchus, LB8:  
Left lower lobe subsegmental bronchus, RA950: Relative area of the lung parenchyma 
with attenuation ≤ -950HU, VDP:  3He MRI ventilation defect percent, ADC:  3He MRI 
apparent diffusion coefficient, **Mean of fifth generation airways 
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Figure 3-3.  Relationships for whole lung and regional VDP with 
3
He MRI 
emphysema measurements.  A) Whole lung (WL) VDP correlated with WL ADC 
(r=0.40, p=0.001), B) RUL VDP correlated with RUL ADC (r=0.32, p=0.01), C) RLL 
VDP correlated with RLL ADC (r=0.38, p=0.003), D) RML VDP correlated with RML 
ADC (r=0.46, p=0.002), E) LUL VDP correlated with LUL ADC (r=0.35, p=0.006), F) 
LLL VDP correlated with LLL ADC (r=0.37, p=0.004). 
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Figure 3-4.  Relationships for regional VDP with CT airways disease measurements. 
Right upper lobe (RUL) VDP correlated with A) RB1 LA (r=-0.37, p=0.004), B) RB1 
LA/BSA (r=-0.42, p=0.0008) but not C) RB1 WA% (r=0.24, p=0.06).  Right lower lobe 
(RLL) VDP correlated with D) RB8 LA (r=-0.28, p=0.03), E) RB8 LA/BSA (r=-0.37, 
p=0.004) and F) RB8 WA% (r=0.28, p=0.03). 
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3.4 Discussion 
We acquired 
3
He MRI and CT in 60 ex-smokers without airflow limitation and made the 
following observations: 1) 42 of 60 volunteers reported abnormally-elevated 
3
He VDP 
and these subjects reported normal airflow and lung volume measurements that were not 
significantly different from 18 ex-smokers with normal VDP, 2) there was significantly 
greater (worse) apical lung 
3
He ADC in the 42 ex-smokers with abnormally-elevated 
VDP as compared to ex-smokers with normal VDP, but there were no other imaging 
differences between the subgroups, 3) 
3
He VDP was significantly correlated with whole 
lung and regional ADC, and, 4) whole lung 
3
He VDP was not correlated with whole lung 
airway morphological measurements, although RUL and RLL VDP was associated with 
thicker airway walls (WA%) and narrowed airway lumen (LA) in those regions of 
interest. 
We observed that 42 ex-smokers reported VDP ≥ 95% confidence interval for VDP in 
never-smokers (4).  Although all participants had a significant smoking history (mean 
pack years=28), spirometry, plethysmography and CT showed no evidence of lung 
function decline or lung destruction and these same measurements showed no significant 
differences in subjects with elevated VDP compared to subjects with normal VDP.  
Previous work (8) in ‘healthy’ smokers showed significantly different MRI ventilation 
measurements as compared to never-smokers and COPD smokers and our findings build 
on this previous work by showing that ex-smokers with abnormally-elevated VDP also 
showed significantly greater whole-lung and apical lung 
3
He ADC. These MRI findings 
were not observed using CT measurements of emphysema.  In this regard, it is important 
to note that 
3
He ADC provides a surrogate measure of microstructural emphysema (17) 
and was previously shown to be sensitive to very mild emphysematous changes by 
detecting differences in subjects exposed only to second-hand smoke (18).  We observed 
that subjects with elevated VDP reported greater whole-lung and apical lung 
3
He ADC.  
Previous work (19) evaluated the anatomical ADC distribution in more severe COPD and 
established the presence of elevated ADC in the apical lung regions and this is in 
agreement with predominant centrilobular emphysema in such patients.  However to our 
knowledge the spatial distribution of ADC in ex-smokers without COPD has not yet been 
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evaluated.  We did not observe differences in CT emphysema (RA950) measurements.  
However, previous research (20) showed that CT-derived emphysema measurements may 
underestimate the extent of emphysema in very mild disease.  The mean RA950 in the ex-
smokers in our study was very low (mean RA950 = 1.2%) and this may reflect why CT 
RA950 was not significantly different between subgroups.  Nevertheless, these results 
suggest that ex-smokers with a significant smoking history and abnormal 
3
He VDP but 
without airflow limitation may also have a mild or subclinical form of centrilobular 
emphysema that is not detected using CT or conventional pulmonary function tests.   
Whole lung and regional VDP were correlated with ADC which suggests that ventilation 
abnormalities and very mildly abnormal parenchyma co-existed in these otherwise 
normal ex-smokers.  We evaluated regional (lobar) correlations for 
3
He VDP and ADC 
because a direct spatial comparison previously described in COPD patients (7) was not 
feasible here.  This previous approach (7) evaluated the direct spatial relationship 
between 
3
He ventilation defects and emphysema by evaluating the overlap of RA950 
(emphysema) regions and 
3
He ventilation defects.  As compared with COPD patients 
with severe emphysema (RA950>15%), the ex-smokers here reported very low or normal 
RA950 and therefore the spatial overlap of 
3
He ventilation defects and RA950 could not be 
evaluated. We wonder about the long-term consequences of these very mild 
abnormalities in ventilation and emphysema measurements and whether these are 
predictors of a transition to COPD.  Future longitudinal evaluations in these subjects are 
warranted and will be undertaken.  
It was not expected that whole-lung airway measurements would show differences 
between subgroups since it is widely appreciated that obstructive disease is regionally 
(and not uniformly) distributed in the lung (21).  However it was surprising that we did 
not detect or measure abnormal or different regional airway morphologies in the ex-
smokers with abnormally elevated VDP, especially since whole-lung and lobar VDP was 
significantly greater in these participants.  We think one explanation for this may be 
related to the airways we measured and the fact that they may not have been distal 
enough to reflect such mild disease.  We did observe that RUL and RLL VDP were 
significantly correlated with RB1 and RB8 airway morphological abnormalities, but these 
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relationships were not significant in the other lung lobes.  Nonetheless, the finding that 
airway walls thicken and airway lumens narrow with increasing ventilation heterogeneity 
in the RUL and RLL suggests a relationship between airway morphology and ventilation 
in these ex-smokers without COPD.  These findings also highlight some of the limitations 
of CT and advantages of MRI for pulmonary imaging and characterization of very mild 
lung disease.  As described elsewhere (22, 23), CT measurements are limited because of 
the inherent spatial resolution limit achievable on thoracic CT scans.  On the other hand, 
MRI ADC provides a way to reveal subtle parenchymal changes to the alveolar 
microstructure and the subjects in our study certainly exemplify a patient group in whom 
MRI is highly advantageous. 
We must acknowledge several limitations to our study.  First, we measured five 
individual subsegmental airways (RB1, RB5, RB8, LB1 and LB8) and not all 
subsegmental airways.  We chose these five airways in particular because they were most 
easily visible and measureable on thoracic CT and because they lead to the individual 
lung lobes of interest.  While it is possible to quantitatively evaluate more distal 
subsegmental airways, the reproducibility of this in all subjects would be difficult to 
determine.  Second, our findings were derived on a VDP threshold determined in never-
smokers from a previous 
3
He MRI study (4).  The range of VDP for all subjects in our 
study was 2% - 18% and the VDP data distribution was not normally distributed, but 
reflected a Poisson distribution centered at 5-6%.  This partially explains why 42 of 60 
subjects reported abnormal VDP.  If this threshold was greater, for example 5%, 33 of 60 
subjects would have reported abnormally-elevated VDP.  Nevertheless, the results of our 
analysis point to very mild emphysema and airways disease in ex-smokers without 
airflow limitation.  We must also acknowledge that 
3
He MRI may only be employed at a 
limited number of research centres worldwide due to the limited supply of 
3
He gas and 
need for specialized equipment and software.  However, pulmonary functional MRI using 
hyperpolarized 
129
Xe is emerging as an attractive alternative with the potential for 
implementation and translation. In this regard, longitudinal measurements in these 60 ex-
smokers will be undertaken using 
129
Xe and more conventional 
1
H MRI methods.  We 
also recognize that although this study evaluated 60 ex-smokers – a relatively large study 
by MRI standards, the sample size may have limited our ability to detect significant 
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relationships for CT airway morphology and emphysema measurements between 
subgroups.  Finally, while this study did not evaluate current smokers (with or without 
airflow limitation), future work investigating MRI ventilation measurements in current-
smokers would also provide an understanding of acute effects of cigarette smoke on 
pulmonary ventilation. 
In conclusion, in ex-smokers without airflow limitation, 
3
He MRI identified a subgroup 
with abnormally elevated ventilation defect percent – a measure of ventilation 
heterogeneity.  While there were no other pulmonary function or CT differences in ex-
smokers with normal or abnormal VDP, there was significantly different MRI ADC and 
there was a relationship for whole-lung and regional VDP with ADC and for regional 
VDP with regional CT airway morphological abnormalities.  Taken together, these data 
suggest that ex-smokers with normal airflow and lung volumes may represent a 
subclinical COPD phenotype that warrants further longitudinal investigation. 
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CHAPTER 4 
In Chapter 3 we observed that hyperpolarized 
3
He MRI ventilation abnormalities in ex-
smokers without chronic obstructive pulmonary disease (COPD) were spatially related to 
airways disease and microstructural emphysema.  Results from Chapters 2 and 3 and 
previous research from our group and others established that individuals with COPD 
exhibit ventilation abnormalities and emphysema throughout the lung.  Therefore we 
were interested in how individuals could be grouped into clinically meaningful 
phenotypes based on the location of pulmonary abnormalities within the lung and 
furthermore, how these regional phenotypes might change with disease progression.  
Therefore, here we used 
3
He MRI and CT to phenotype COPD ex-smokers based on the 
apical – basal distribution of ventilation abnormalities and emphysema and evaluate the 
change in phenotype with disease progression. 
The contents of this chapter have been published in COPD:  Journal of Chronic 
Obstructive Pulmonary Disease (JCOPD) and permission to reproduce the article was 
granted by Taylor and Francis Publishing Group on behalf of JCOPD and is provided in 
Appendix D. 
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4 Regional Heterogeneity of Chronic Obstructive 
Pulmonary Disease Phenotypes:  Pulmonary 
3
He 
Magnetic Resonance Imaging and Computed 
Tomography 
4.1 Introduction 
Chronic obstructive pulmonary disease (COPD) is characterized by irreversible airflow 
obstruction, mainly due to airways disease, emphysema, or a combination of airway and 
parenchymal abnormalities (1).  While both airways disease and emphysema influence 
the clinical course of COPD, the emphysema phenotype is associated with more rapid 
disease progression, more frequent exacerbation episodes and significantly worse 
mortality than the airways disease phenotype (2-4).  In this regard, high-resolution 
computed tomography (CT) has emerged as a robust method for quantifying and spatially 
mapping emphysema and its progression (5-7).  At the same time, heterogeneity in the 
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clinical presentation of patients (8, 9) with the same lung function and emphysema 
measurements, has prompted several CT studies (10-19) to provide a better understanding 
of the clinical relevance of the spatial distribution of emphysema.  While these previous 
studies have yielded important results, the clinical relevance and physiological outcomes 
associated with different emphysema (10, 14, 17, 20) and airways disease (21, 22) 
distribution is not well-understood.  
Hyperpolarized 
3
He magnetic resonance imaging (MRI) has emerged as another imaging 
approach for quantifying airways disease and emphysema phenotypes in COPD (23-25).  
3
He and 
129
Xe MRI ventilation imaging readily identifies regions of signal void (26) that 
are believed to reflect poorly ventilated regions of the parenchyma (27).  In COPD 
patients,  
3
He ventilation defects are highly reproducible over long periods of time in 
stable patients (28), predict COPD exacerbations (29), and diminish in response to short-
acting bronchodilator therapy (30) and bronchoscopic lung volume reduction using stents 
(31).   Previous work (32) showed that 
3
He ventilation defects in asthma are spatially 
related to abnormal airway morphology and it has been suggested (29) that in COPD, 
ventilation defects may be related to airways disease,  emphysema or a combination of 
both.  However, the relationship of the distribution of 
3
He ventilation defects and 
progression of COPD has not yet been investigated.  Therefore, our objective here was to 
investigate the relationship between COPD severity and the spatial distribution of 
ventilation defects measured using MRI and emphysema measured using CT in a 
relatively large group of COPD ex-smokers.   
4.2 Methods 
4.2.1 Study Subjects 
This study was registered as NCT02279329 (ClinicalTrials.gov, National Institute of 
Health, Maryland, USA). Study subjects with a clinical diagnosis of COPD provided 
written informed consent to a protocol that was compliant with the Personal Information 
Protection and Electronic Documents Act (PIPEDA, Canada) and Health Insurance 
Portability and Accountability Act (HIPAA, USA) and approved by a local research 
ethics board and Health Canada.  Each two-hour visit consisted of spirometry, 
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plethysmography, the six-minute-walk-test (6MWT) for the six-minute walk distance 
(6MWD), St. George’s Respiratory Questionnaire (SGRQ), 3He MRI and inspiratory CT.  
Subjects were clinically diagnosed and classified according to the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) criteria (33) and/or clinical symptoms over a 
3 month period in addition to a smoking history of >10 pack years. 
4.2.2 Spirometry and Plethysmography 
Spirometry measurements, including the forced expiratory volume in one second (FEV1) 
and forced vital capacity (FVC), were acquired according to the American Thoracic 
Society guidelines (34).  Whole-body plethysmography was used to measure lung 
volumes (residual volume (RV) and total lung capacity (TLC)) (MedGraphics 
Corporation, St. Paul, Minnesota, USA) and a stand-alone gas analyzer (attached to 
plethysmograph) was used to measure diffusing capacity of the lung for carbon monoxide 
(DLCO). 
4.2.3 Imaging 
Subjects were randomized to first receive either MRI or CT and image acquisition was 
performed within 15 minutes of each other. For both MRI and CT, image acquisition was 
completed within 5-7 minutes of patients being made comfortable in a supine position. 
MRI was performed using a 3.0 Tesla Discovery MR750 (General Electric Health Care, 
Milwaukee, Wisconsin, USA) system, as previously described (35), using a whole-body 
gradient set with a maximum gradient amplitude of 1.94G/cm and a single-channel, rigid 
elliptical transmit/receive chest coil (Rapid Biomedical GmbH, Rimpar, Germany) with 
patients in inspiratory breath-hold at functional residual capacity (FRC) + 1L.  
Anatomical 
1
H MRI was acquired prior to 
3
He MRI after inhalation of 1L medical grade 
nitrogen (N2) from FRC using the whole-body radiofrequency coil and a 
1
H fast-spoiled, 
gradient-recalled-echo sequence using a partial echo [16s total data acquisition, posterior 
to anterior repetition time (TR)/echo times (TE)/flip angle=4.7ms/1.2ms/30
○
, field of 
view (FOV)=40x40cm, bandwidth 24.4 kHz, matrix=128x80, 15-17 slices, 15mm slice 
thickness, zero gap] as previously described (35).  
3
He static-ventilation MR images were 
acquired with a mixture of hyperpolarized 
3
He (5ml/kg body weight) diluted to 1L with 
92 
 
 
 
N2 and using a fast-gradient echo method using a partial echo [14s total data acquisition, 
posterior to anterior, TR/TE/flip angle=4.3ms/1.4ms/7
○
, FOV=40x40cm, 
bandwidth=48.8kHz, matrix=128x80, 15-17 slices, 15mm slice thickness, zero gap].  
3
He 
diffusion-weighted MRI was also performed as previously described (27), however we 
did not evaluate apparent diffusion coefficients (ADCs) as estimates of emphysema 
because these values only report from regions of normal ventilation which would have 
biased the ADC-based emphysema estimates. 
CT was acquired using a 64 slice Lightspeed VCT system (General Electric Health Care, 
Milwaukee, Wisconsin, USA) using a single spiral acquisition from apex to base 
(64×0.625mm collimation, 120kVp, 100mA, tube rotation time=500ms, pitch=1.25, 
standard reconstruction kernel and 1.25mm slice thickness).  All subjects were 
transported from the MRI suite to the CT suite by wheelchair to prevent the potential of 
any exercise-induced dilatation of the airways or lung parenchyma.  CT was acquired 
during inspiratory breath-hold of high-purity, medical grade N2 at the same volume as 
MRI (FRC+1L) as previously described (36) to enable direct comparison to MR images.  
The total effective dose for each CT scan was 1.8 mSv as calculated using manufacturer 
settings and the ImPACT CT dosimetry calculator based on Health Protection Agency 
(UK) NRPB-SR250. 
4.2.4 Image Analysis 
Hyperpolarized 
3
He MR static-ventilation images were used to generate whole-lung 
3
He 
ventilation defect percent (VDP) using semi-automated software generated using 
MATLAB (Mathworks, Natick, Massachusetts, USA) (37). 
Inspiratory CT images were evaluated using VIDA Pulmonary Workstation 2.0 (VIDA 
Diagnostics, Coralville, Iowa, USA).  Emphysema was measured for whole-lung and 
individual lung lobes using the relative area of the lung parenchyma with attenuation ≤ -
950 Hounsfield units (HU) (RA950).  Airway wall area percent for the 5th generation 
airways (WA%) and airway wall thickness for airways with an internal perimeter of 
10mm (Pi10) were estimated as previously described (38). 
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Ventilation defect percent for each lung lobe (right upper lobe (RUL), right lower lobe 
(RLL), left upper lobe (LUL), left lower lobe (LLL)) was generated by registering the 
thoracic CT segmentation of the lung lobes (VIDA Pulmonary Workstation 2.0) to 
3
He 
MRI ventilation images using deformable registration as previously described (39).  
4.2.5 Distribution of Emphysema and Ventilation Defects 
Apical-lung (AL) and basal-lung (BL) predominant emphysema phenotypes were defined 
using a method adapted from a previously described technique (10) whereby RA950 in the 
BL (RA950BL = RA950RLL + RA950LLL) and RA950 in the AL (RA950AL = RA950RUL + 
RA950LUL) were used to generate the difference between AL and BL RA950 (∆RA950).  A 
positive ∆RA950 was indicative of AL-predominant distribution, and a negative ∆RA950 
indicated BL-predominant emphysema distribution such that:  
AL-predominant emphysema:  RA950AL  - RA950BL  = + ∆RA950   (1) 
BL-predominant emphysema:  RA950AL  - RA950BL  = - ∆RA950  (2) 
In a similar manner, regional 
3
He VDP was used to identify AL- and BL-predominant 
3
He ventilation defect phenotypes.  The ventilation defect percent in BL (VDPBL = 
VDPRLL + VDPLLL) was subtracted from the ventilation defect percent in the AL (VDPAL 
= VDPRUL + VDPLUL) to generate the difference between AL- and BL-VDP (∆VDP), 
whereby a positive ∆VDP indicated an AL-predominant distribution of ventilation 
defects and a negative ∆VDP indicated a BL-predominant distribution of ventilation 
defects such that: 
AL-predominant ventilation defects:  VDPAL  - VDPBL  = + ∆VDP  (3) 
BL-predominant ventilation defects:  VDPAL  - VDPBL  = - ∆VDP  (4) 
All participants were classified in AL- and BL-predominant subgroups using both CT and 
3
He MRI measurements for all lobes except the right middle lobe (RML) because recent 
research (40) has shown that the RML contributes disproportionately to imaging 
measurements of emphysema.  
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4.2.6 Statistics 
All statistical tests were performed in IBM SPSS V22 (SPSS Inc., Chicago, Illinois, 
USA).  A one-way analysis of variance (ANOVA) was used to compare parameters 
between COPD grades of severity.  Comparisons between imaging measurements of AL 
and BL subgroups were performed using unpaired t-tests with Holm-Bonferroni 
corrections to adjust for family-wise error.  Pearson correlations were used for univariate 
analyses and p-values were adjusted for family-wise error.  All statistical figures were 
created in GraphPad Prism V6 (GraphPad Software Inc., La Jolla, California, USA). 
 
4.3 Results 
We evaluated 100 COPD ex-smokers (n=22 GOLD I, n=46 GOLD II and n=32 GOLD 
III/IV).  Table 4-1 shows the demographic and pulmonary function measurements for all 
subjects and stratified by GOLD grade severity.  Measurements of pulmonary function 
and volumes including FEV1, FVC, FEV1/FVC, RV, RV/TLC and DLCO worsened with 
increasing GOLD grade severity (all p<0.0001).  Similarly, SGRQ total score increased 
(p<0.0001) and 6MWD decreased (p=0.001) with increasing disease severity. 
 
Table 4-1.  Demographic and pulmonary function test measurements  
Parameter  
(±SD) 
All 
(n=100) 
GOLD I 
(n=22) 
GOLD II 
(n=46) 
GOLD III/IV 
(n=32) 
p* 
Age yr  71 (8) 75 (7) 70 (8) 70 (8) 0.03 
Male n (%) 65 (65) 19 (86) 27 (59) 19 (59) 0.06 
Pack years  50 (30) 48 (36) 48 (27) 54 (31) 0.6 
BMI kg/m
2
  27 (4) 28 (4) 27 (4) 26 (5) 0.3 
6MWD m 377 (91)
1
 419 (47)
2 388 (90)
3 323 (98)
4 
0.001 
FEV1%pred  62 (23) 95 (12) 64 (9) 36 (7) <0.0001 
FVC%pred  90 (20) 109 (12) 92 (14) 73 (16) <0.0001 
FEV1/FVC % 50 (12) 63 (5) 52 (8) 37 (8) <0.0001 
RV%pred 160 (48) 123 (30) 148 (34) 202 (45) <0.0001 
RV/TLC %pred 133 (27) 107 (18) 127 (17) 159 (22) <0.0001 
DLCO%pred 55 (20) 69 (19) 57 (16) 42 (18) <0.0001 
SGRQ Total Score 40 (19) 23 (16) 37 (14) 56 (12) <0.0001 
BMI: Body mass index, FEV1: Forced expiratory volume in one second, FVC:  Forced 
vital capacity, RV:  Residual volume, TLC: Total lung capacity, DLCO: Diffusing 
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capacity for carbon monoxide, SGRQ:  St. George’s Respiratory Questionnaire, 
6MWD:  Six-minute walk distance,
 1
n=91, 
2
n=21, 
3
n=44, 
4
n=26, *ANOVA corrected p-
value 
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Figure 4-1 shows 
3
He MR static-ventilation and CT images for COPD ex-smokers 
stratified by GOLD grade with ventilation defects and corresponding emphysema.  
3
He 
ventilation is shown in cyan and emphysema is shown using an RA950 mask (voxels ≤-
950HU in yellow).  It was visibly obvious that ex-smokers (S1, S2, S3, S4 and S5) with 
BL-predominant 
3
He ventilation defects showed ventilation heterogeneity in the lower 
lung lobes while ex-smokers (S6, S7, S8, S9 and S10) with AL-predominant 
3
He 
ventilation defects had ventilation abnormalities localized to the upper lung lobes.  At the 
same time, corresponding CT emphysema masks were not spatially concordant with the 
BL and AL ventilation defect phenotypes in milder COPD (as shown in subjects S1 and 
S2 as well as in S6 and S7).  However in moderate-severe grade ex-smokers (such as S3, 
S4 and S5 and also S8, S9 and S10) the spatial relationship between ventilation defects 
and CT RA950 was more obvious.  
Table 4-2 provides a summary of whole-lung and regional RA950 and VDP as well as 
airway measurements for all study subjects and stratified by GOLD grade.  Whole-lung 
and regional RA950 (RUL, RLL, LUL, LLL, RA950AL, RA950BL) were significantly worse 
(all p<0.05) with increasing GOLD grade.  Similarly, whole-lung and regional VDP 
(RUL, RLL, LUL, LLL, VDPAL, VDPBL) was significantly worse (all p<0.05 except LLL 
VDP p=0.05) with increasing disease severity.  No significant differences were observed 
for ∆RA950 (p=0.7) or ∆VDP (p=0.9) between GOLD grades and there were no 
differences for airway Pi10 (p=0.6) or mean fifth generation WA% (p=0.5) or LA (p=1.0) 
between GOLD grades.  Women had significantly decreased VDP in the RLL and LLL 
and significantly different VDPBL and ΔVDP compared to men for GOLD II and GOLD 
III/IV while no significant differences were observed for the 3 women in the GOLD I 
subgroup (data not shown). 
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Figure 4-1. Thoracic 
3
He MRI and CT of COPD ex-smokers with representative 
apical- and basal-lung predominant 
3
He ventilation defects and corresponding 
emphysema.  Ex-smokers with basal-lung predominant 
3
He ventilation defects (S1, S2, 
S3, S4 and S5) show ventilation heterogeneity localized to the basal-lung while subjects 
with apical-lung predominant ventilation defects (S6, S7, S8, S9 and S10) show 
abnormalities localized in the apical lung.  Emphysema is shown using a yellow RA950 
mask.  Note that the trachea was excluded from VDP and RA950 measurements. 
 
Table 4-3 reports whole-lung and regional imaging measurements for MRI and CT AL- 
and BL-predominant phenotypes.  Based on 
3
He MRI VDP, 72 subjects reported BL-
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predominant VDP while 28 reported AL-predominant VDP.  Subjects with AL-
predominant VDP reported significantly greater whole-lung (p=0.03) and upper lobe 
(RUL p=0.002, LUL p=0.01, RA950AL p=0.003) emphysema measured using RA950.  
Based on CT RA950 measurements, 71 subjects reported AL-predominant RA950 while 29 
subjects reported BL-predominant RA950.  Subjects with AL-predominant RA950 had 
significantly diminished VDP in the RLL (p=0.002) and basal-lung (VDPBL p=0.003).   
Figure 4-2 shows the distribution (in percent) for subjects with AL- and BL-predominant 
MRI and CT phenotypes by GOLD grade.  BL-predominant ventilation defects 
dominated the mild-moderate grades (AL/BL: GOLD I=18%/82%, GOLD II=24%/76%) 
while there was a more uniform distribution for severe GOLD grades (AL/BL: GOLD 
III=40%/60%, GOLD IV=43%/57%).  The opposite trend was observed for CT 
emphysema phenotypes whereby the AL-predominant RA950 phenotype was more typical 
in the mild-moderate grade COPD (AL/BL:  GOLD I=84%/16%, GOLD II=72%/28%) 
and in severe grade COPD, the distribution was more equivalent (AL/BL:  GOLD 
III=64%/36%, GOLD IV=43%/57%). 
Table 4-4 shows the spatial relationships for whole-lung and regional RA950 with VDP.  
The strongest correlations were observed for VDP and RA950 in the apical lobes (RUL: 
r=0.77, p<0.0001, LUL: r=0.65, p<0.0001) with moderate to weak correlations in the 
basal lobes (RLL:  r=0.48, p<0.0001, LLL:  r=0.37, p=0.0001).  
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Table 4-2.  Imaging measurements  
Parameter 
(±SD) 
All 
(n=100) 
GOLD I 
(n=22) 
GOLD II 
(n=46) 
GOLD III/IV 
(n=32) 
p* 
RA950 %      
   Whole lung 11 (10) 5 (4) 9 (9) 18 (12) <0.0001 
   RUL 12 (14) 6 (8) 10 (13) 19 (15) <0.0001 
   RLL 9 (11) 2 (2) 7 (8) 17 (13) <0.0001 
   LUL 12 (14) 5 (4) 11 (16) 19 (14) 0.001 
   LLL 8 (9) 3 (2) 6 (5) 15 (12) <0.0001 
   RA950AL 24 (27) 11 (10) 21 (28) 38 (28) <0.0001 
   RA950BL 17 (19) 5 (3) 12 (12) 32 (24) <0.0001 
   ∆RA950 7 (19) 6 (9) 9 (21) 6 (20) 0.7 
Airways      
   Pi10 mm 4.2 (0.5) 4.2 (0.2) 4.2 (0.7) 4.3 (0.2) 0.6 
   WA% 65 (2) 65 (2) 65 (2) 65 (2) 0.5 
   LA mm
2
 13 (5) 13 (3) 13 (6) 13 (3) 1.0 
VDP %      
   Whole lung 18 (10) 9 (5) 17 (8) 26 (7) <0.0001 
   RUL 20 (18) 11 (11) 18 (17) 30 (19) <0.0001 
   RLL 29 (20) 17 (10) 28 (20) 38 (22) 0.001 
   LUL 19 (15) 11 (6) 19 (14) 25 (17) 0.002 
   LLL 24 (17) 17 (8) 25 (19) 28 (16) 0.05 
   VDPAL 40 (31) 22 (15) 37 (29) 55 (33) <0.0001 
   VDPBL 53 (35) 34 (17) 52 (37) 66 (35) 0.003 
   ∆VDP -13 (40) -12 (15) -16 (40) -11 (50) 0.9 
RA950:  Relative area of the lung with attenuation values ≤ -950HU, HU:  Hounsfield 
unit, RA950AL=RA950RUL+RA950LUL, RA950BL=RA950RLL+RA950LLL, ∆RA950=RA950AL-
RA950BL, Pi10:  Airway wall thickness of airways with an internal perimeter of 10mm, 
WA%:  Mean fifth generation airway wall area percent, LA:  Mean fifth generation 
airway lumen area, VDP:  Ventilation defect percent, VDPAL=VDPRUL+VDPLUL, 
VDPBL=VDPRLL+VDPLLL, ∆VDP=VDPAL-VDPBL, RUL:  Right upper lobe, RLL:  Right 
lower lobe, LUL:  Left upper lobe, LLL:  Left lower lobe, *ANOVA corrected p-value
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Table 4-3. 
3
He MRI and CT apical-lung (AL) and basal-lung (BL) phenotype 
measurements 
 3He MRI CT 
Parameter 
(±SD) 
BL VDP 
(n=72) 
AL VDP 
(n=28) 
p* BL RA950 
(n=29) 
AL RA950 
(n=71) 
p* 
RA950 %       
   Whole lung 9 (8) 16 (13) 0.03 11 (9) 11 (11) 1.0 
   RUL 9 (11) 20 (17) 0.002 8 (8) 14 (15) 0.3 
   RLL 8 (10) 11 (11) 1.0 13 (12) 7 (10) 0.3 
   LUL 9 (12) 20 (16) 0.01 9 (8) 14 (16) 1.0 
   LLL 7 (9) 9 (11) 0.9 12 (11) 6 (8) 0.07 
   RA950AL 18 (22) 40 (32) 0.003 17 (15) 28 (30) 0.6 
   RA950BL 15 (18) 21 (22) 1.0 25 (22) 14 (17) 0.1 
   ∆RA950 3 (17) 19 (17) 0.001 -8 (8) 14 (18) <0.0001 
Airways       
   Pi10 mm 4.3 (0.5) 4.2 (0.2) 0.8 4.1 (0.8) 4.2 (0.2) 0.9 
   WA% 65 (2) 65 (2) 1.0 66 (2) 65 (2) 1.0 
   LA mm
2
 13 (5) 14 (3) 1.0 13 (4) 13 (5) 2.0 
VDP %       
   Whole lung 17 (10) 21 (9) 0.4 20 (10) 17 (9) 1.0 
   RUL 14 (12) 36 (22) <0.0001 15 (11) 22 (20) 0.8 
   RLL 32 (21) 21 (14) 0.07 41 (23) 24 (17) 0.002 
   LUL 15 (11) 31 (17) <0.0001 16 (12) 21 (15) 1.0 
   LLL 27 (18) 17 (9) 0.06 32 (22) 21 (13) 0.03 
   VDPAL 29 (21) 66 (34) <0.0001 32 (22) 43 (33) 0.8 
   VDPBL 59 (37) 37 (22) 0.049 73 (42) 45 (28) 0.003 
   ∆VDP -30 (28) 29 (34) <0.0001 -41 (35) -2 (36) <0.0001 
RA950:  Relative area of the lung with attenuation values ≤ -950HU, HU:  Hounsfield 
unit, RA950AL=  RA950RUL+RA950LUL, RA950BL=RA950RLL+RA950LLL, ∆RA950= RA950AL-
RA950BL, Pi10:  Airway wall thickness of airways with an internal perimeter of 10mm, 
WA%:  Mean fifth generation airway wall area percent, LA:  Mean fifth generation 
airway lumen area, VDP:  Ventilation defect percent, VDPAL=VDPRUL+VDPLUL, 
VDPBL=VDPRLL+VDPLLL, ∆VDP=VDPAL-VDPBL, RUL:  Right upper lobe, RLL:  Right 
lower lobe, LUL:  Left upper lobe, LLL:  Left lower lobe, *ANOVA corrected p-value
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Figure 4-2.  GOLD Grade distribution of AL- and BL-predominant VDP and RA950 
phenotypes. A) Basal-lung ventilation defects predominated in mild-moderate COPD 
subjects. AL/BL: GOLD I=18%/82%, GOLD II=24%/76%, GOLD III=40%/60% and 
GOLD IV=43%/57%. B) Apical-lung emphysema predominated in mild-moderate COPD 
subjects.  AL/BL:  GOLD I=84%/16%, GOLD II=72%/28%, GOLD III=64%/36% and 
GOLD IV=43%/57%. 
 
 
Table 4-4.  Regional relationships for ventilation defects (VDP) and emphysema 
(RA950) for all subjects and by GOLD Grade 
 Pearson Correlation coefficient for VDP and RA950 (p*) 
 All GOLD I GOLD II GOLD III/IV 
Whole lung  0.61 (<0.0001) 0.73 (0.0006) 0.47 (0.003) 0.42 (0.06) 
RUL  0.77 (<0.0001) 0.72 (0.001) 0.70 (<0.0001) 0.77 (<0.0001) 
LUL  0.65 (<0.0001) 0.44 (0.1) 0.62 (<0.0001) 0.59 (0.001) 
RLL  0.48 (<0.0001) 0.34 (0.3) 0.34 (0.02) 0.39 (0.05) 
LLL  0.37 (0.0001) 0.28 (0.2) 0.38 (0.02) 0.36 (0.04) 
RUL:  Right upper lobe, LUL:  Left upper lobe, RLL:  Right lower lobe, LLL:  Left 
lower lobe, GOLD:  Global initiative for chronic obstructive lung disease, *p-value 
corrected for family-wise error 
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4.4 Discussion 
To provide a better understanding of the apical and basal lung regional distribution of 
emphysema and airways disease phenotypes in COPD, we stratified patients based on 
functional MRI and parenchymal CT measurements.  We observed: 1) patients with mild-
moderate COPD reported BL-predominant ventilation defects and AL-predominant 
emphysema, and, 2) patients with severe COPD reported ventilation defects and 
emphysema that was homogeneously (or evenly) distributed in the apical and basal lung 
regions.  
Numerous studies have investigated CT measurements of emphysema, their 
spatial/regional distribution and their relationship with clinical findings.  However, there 
is no consensus about the clinical meaning or physiological outcomes that can be directly 
related to the distribution of emphysema (10, 14, 17, 20, 41) or airways disease (21, 22).  
For example, some studies (12, 14, 16) reported that apical-predominant emphysema was 
associated with diminished pulmonary function, while other studies (13, 17, 20, 41, 42) 
showed that homogeneous or basal-lung emphysema was related to poorer lung function 
in patients.  Others have reported that (10) the regional location of emphysema may not 
be clinically important.  Unlike CT-based measurements of emphysema, MRI ventilation 
defects are resultant from both airways disease and emphysema in COPD patients (29).  
Similar to previous studies (11, 42-44), we observed that smoking-related emphysema 
was more severe in apical lung regions, especially in the milder grade subgroups.  
However, we also observed that ventilation abnormalities were predominantly present in 
the lung bases in the mild COPD stages.  For both emphysema and ventilation 
abnormalities, the apical-basal gradients lessen in more severe disease.  The fact that 
VDP and RA950 were quantitatively and strongly correlated appears paradoxical, given 
their regional differences.  However, this may be related to the fact that in COPD 
patients, the temporal onset of ventilation abnormalities and emphysema is similar, but 
this study showed that their presence and site of initiation are likely regionally different.  
Previous MRI studies have shown that in more severe COPD, ventilation defects may 
reflect both emphysema and airways disease or collapse (45), and this may explain some 
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of the differences in the regional distribution of ventilation abnormalities in severe 
COPD. 
Patients with mild-moderate and severe disease also showed different distributions of 
AL- and BL-predominant phenotypes.  Similar to a previous report (12), we observed 
that the relationship between basal-lung emphysema and impaired airflow was stronger 
than the relationship with apical-lung emphysema.  Since ventilation is greater at the lung 
bases it would follow that increased emphysema at the bases would have a greater impact 
on FEV1 than emphysema at the apices.  To our knowledge, the spatial relationship 
between ventilation defects and FEV1 has not yet been reported.  This finding will be 
investigated further in the future as phenotyping COPD patients based on the distribution 
of ventilation abnormalities may help explain symptoms or disease progression. 
We also wanted to better understand how ventilation abnormalities and emphysema 
might be related to one another in the apical and basal lung regions.  VDP and RA950 
were significantly correlated in all lung regions but showed the strongest correlations in 
the apical-lung.  Basal-lung ventilation defects predominated in mild-moderate GOLD 
grades, and a more homogeneous distribution of ventilation defects was observed in more 
advanced grade COPD; these differences suggest that over time, regional ventilation 
abnormalities become more homogeneously distributed during disease progression.  This 
is in agreement with previous micro-CT analyses (1) that showed that in early stages, 
there was evidence of mainly terminal airway obliteration and not emphysematous 
destruction.  In the future, longitudinal studies of ex- and current-smokers who are at risk 
of developing COPD may provide a deeper understanding of the regional initiation and 
progression of airways disease and emphysema. 
Finally, we must also acknowledge a number of study limitations.  First, hyperpolarized 
3
He MRI is not widely used and likely never will be, because of the high cost and limited 
global supply of 
3
He gas, and this limits the applicability of the results presented here.  
However, our team and others (46, 47) are transitioning to pulmonary MRI using 
129
Xe 
gas which is much more readily available (24, 48), less expensive and poised on the 
threshold of regulatory approval and clinical translation.  We should also note that the 
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phenotyping approach used here was adapted from previous work (10) and was based on 
the binary classification of AL- and BL-predominant phenotypes.  Binary classification 
methods based on a threshold do not stratify subjects based on ∆VDP and ∆RA950 so all 
subjects with a positive ∆VDP and ∆RA950 were classified as AL-predominant and those 
with a negative ∆VDP and ∆RA950 were classified as BL-predominant.  This 
straightforward method can certainly be improved by using three- or multi-dimensional 
indices and thresholds.  In addition, we did not take into account emphysema or 
ventilation heterogeneity distributions between the lung core and rind regions as 
previously described (12-14, 49).  CT images were acquired at the same inhalation 
volume as MRI (FRC+1L) rather than full inspiration in order to enable the direct 
comparison of MRI and CT phenotypes at the same lung volume.  For this reason, the 
estimates of emphysema generated here based on CT cannot be directly compared with 
other quantitative CT emphysema estimates acquired at full inspiration.  We note, 
however that in gas-trapped COPD patients, the differences between full inspiration and 
FRC+1L is approximately 1L and that the whole-lung RA950 values reported here derived 
at a smaller lung volume are similar to those reported in the COPDGene study (18, 50).  
Expiratory CT scans were not performed and in future studies, paired inspiratory-
expiratory CT scans and phenotyping ex-smokers using novel parametric response 
mapping (PRM) techniques (21) might provide a better understanding of apical- and 
basal-predominant phenotypes.  Furthermore, although acquired, ADC-based measures of 
emphysema from 
3
He MRI were not used to quantify emphysema here because of the 
bias that results from the fact that only well-ventilation regions report ADC.  Future 
studies comparing regional ADCs with CT RA90 may be useful to further verify the 
apical to basal pattern observed here.  We must also point out that some of the patients 
classified with GOLD I COPD (ie. Subject 1 in Figure 4-1: 69 year-old female, 
FEV1=84%pred, FVC=94%pred, FEV1/FVC=69%) were within the lower limit of normal 
(LLN) spirometry values for the mean age of this subgroup (75±7 years).  The mean 
values of 95±12%pred and 109±12%pred for FEV1 and FVC respectively for the GOLD I 
subgroup (as show in Table 4-1) were also greater than the LLN as previously described 
(51).  It is worth noting, however, that for this study, the diagnosis and classification of 
COPD included clinical symptoms over a 3 month period, a smoking history of >10 pack 
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years as well as the GOLD thresholds.  We also acknowledge that this study focused on 
COPD patients with mainly mild-moderate disease (grade I COPD=22 subjects and grade 
II COPD=46 subjects) and that there was a small number of GOLD III (n=25) and GOLD 
IV (n=7) subjects and therefore our findings must be interpreted in this context. 
In conclusion, we phenotyped ex-smokers with COPD based on the apical-basal 
distribution of emphysema and ventilation defects.  We observed that a BL-predominant 
distribution of ventilation defects and AL-predominant distribution of emphysema was 
present in subjects with mild–moderate airflow obstruction.  With increasing disease 
severity, there may be a basal-to-apical progression of ventilation abnormalities and an 
apical-to-basal progression of emphysema.   
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CHAPTER 5 
5 Conclusions and Future Directions 
This last chapter will provide a summary of the research findings in Chapters 2 – 4 and 
address important research questions that remain unanswered.  I will also discuss 
limitations to the research work presented throughout the thesis and outline future 
directions that have been motivated by the work presented in Chapters 2 – 4. 
5.1 Overview and Research Questions 
COPD is the only one of the leading causes of morbidity and mortality that has a steadily 
increasing mortality rate (1).  This increasing mortality rate is suspected to be attributable 
to poor performance of conventional pulmonary function tests to: 1) characterize early or 
subclinical lung disease, 2) to identify susceptible individuals and 3) to diagnose 
individuals in the mild stages.  It has become clear over the last few decades that 
spirometry alone is unable to fully characterize the extreme heterogeneity of the disease 
(2, 3).  In this regard, advances in pulmonary imaging with CT and MRI have become 
more sophisticated, now able to provide whole-lung and regional quantitative measures 
of emphysema and airways disease in vivo.  The major goal of this thesis was to exploit 
regional and direct measurements of pulmonary ventilation from hyperpolarized 
3
He MRI 
to tease out clinically relevant pre- and subclinical lung disease phenotypes in ex-smokers 
with and without airflow limitation.  The specific research questions addressed here were: 
1) is there a mechanistic link between pre- or subclinical airflow limitation and vascular 
disease (Chapter 2)?  2) What is the underlying, pathophysiological phenotype of 
disease causing 
3
He ventilation abnormalities in ex-smokers without airflow limitation 
(Chapter 3)? 3) Can the apical-to-basal distribution of MRI ventilation abnormalities and 
CT emphysema be used to identify clinically relevant COPD phenotypes (Chapter 4)?  
Does the apical – basal phenotype change with COPD progression (Chapter 4)? 
 
5.2 Summary and Conclusions 
In Chapter 2 we collected carotid three-dimensional ultrasound and hyperpolarized 
3
He 
MRI from ex- and never-smokers without airflow limitation or a diagnosis of 
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cardiovascular disease to better understand the mechanistic link between pre- or 
subclinical lung and vascular disease.  First, we observed that ex-smokers showed 
significantly more carotid plaque, indicative of carotid atherosclerosis, and more 
3
He 
ventilation heterogeneity, a sign of subclinical lung disease, compared to never-smokers.  
Second, carotid ultrasound measurements of plaque, wall thickness and vessel wall 
volume correlated with 
3
He ventilation heterogeneity for all subjects.  Together these 
results suggest that there is a subclinical phenotype in ex-smokers without airflow 
limitation characterized by mild carotid atherosclerosis and airflow limitation that is not 
obvious on spirometry. 
In Chapter 3 we aimed to better characterize the underlying pathophysiology of 
3
He 
ventilation defects in ex-smokers without airflow limitation using regional 
3
He MRI and 
CT measurements of emphysema and airways disease.  In 60 ex-smokers without airflow 
limitation, 42 subjects had abnormal 
3
He ventilation heterogeneity while 18 had normal 
ventilation.  Those ex-smokers with abnormal 
3
He ventilation exhibited worse whole-
lung and apical-lung 
3
He ADC and we also observed that ventilation defects were 
spatially related to abnormal airway morphology and microstructural emphysema (ADC) 
in all subjects.  These results suggested that there is a phenotype of ex-smokers with 
airflow limitation characterized by abnormal 
3
He ventilation, abnormal airway 
morphology and very mild emphysema. 
In Chapter 4 our objectives were: 1) to phenotype COPD ex-smokers based on the 
apical-to-basal distribution of 
3
He ventilation defects and CT emphysema and 2) to 
evaluate how apical-basal disease phenotypes change with COPD progression.  Out of 
100 COPD patients, seventy-two reported basal-lung (BL) -predominant MRI ventilation 
defects and 71 reported apical-lung (AL) -predominant CT emphysema.  BL-predominant 
ventilation defects and AL-predominant emphysema were the major phenotypes in mild-
moderate COPD.  In severe COPD there was a more uniform distribution for ventilation 
defects and emphysema.  Together these results suggest that with increasing disease 
severity (worse airflow obstruction) there is a basal-to-apical progression of ventilation 
abnormalities and an apical-to-basal progression of emphysema. 
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5.3 Limitations 
This section will provide an overview of the major limitations of each study presented in 
this thesis and how they can be overcome in future work. 
5.3.1 Study Specific Limitations 
The study in Chapter 2 was dependent on the collection of carotid three-dimensional 
ultrasound scans from every subject.  The quality of carotid ultrasound scans is highly 
dependent on; 1) the anatomy of the patient being imaged and 2) having a highly trained 
technician perform the ultrasound scan (4).  In our study, all ultrasound data acquired was 
sufficient quality for analysis but the scans had to be repeated several times for many 
individuals.  This increased the overall time for ultrasound acquisition and time of each 
patient visit at our centre.  This led us to believe that such a study might not be feasible in 
large cohorts of subjects, especially in patients with disease who are not as mobile and 
require careful monitoring even for short study visits.  This is an issue because the 
relatively small sample size in our study may have limited our power to detect clinically 
meaningful differences in pulmonary function or ultrasound measurements of 
atherosclerosis.  A large-scale cohort study exploiting pulmonary imaging and carotid 
ultrasound may provide more useful information on the comorbidity between 
atherosclerosis and airflow limitation, however a challenge would be collecting high-
quality ultrasound data in a feasible timeframe.  A second limitation to this study was the 
vessel-wall-volume (VWV) measurement (5) that was used to measure carotid 
atherosclerosis in the study subjects.  We were not surprised that the one-dimensional 
measurement of carotid intima-media thickness (IMT) was not significantly different 
between ex- and never-smokers as the dynamic range for this parameter is extremely 
small which is known to reduce its sensitivity to small changes (6).  However, the three-
dimensional measurement of total plaque volume (TPV) revealed that ex-smokers had 
more carotid plaque than never-smokers while VWV, the second three-dimensional 
measurement, showed no difference between the two subgroups.  This was an unexpected 
result because the VWV is the sum of plaque and carotid wall volume and we observed 
quantitatively more plaque in the ex-smokers.  However, several carotid ultrasound 
studies (7, 8) have established that the VWV measurement is truly dependent on the 
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anatomy of the carotid artery and two subjects with a different amount of carotid plaque 
may have the same vessel-wall-volume.  With this in mind, the refined vessel-wall 
measurement, termed the ‘vessel-wall-plus-plaque thickness’ (VWT) (9) which 
overcomes the size dependence of vessel wall volume, might provide clinically 
meaningful three-dimensional ultrasound findings in these ex- and never-smokers.   
In Chapter 3 we endeavored to provide a better understanding of the underlying etiology 
of 
3
He ventilation defects in ex-smokers without airflow limitation using regional MRI 
and CT measurements.  One major limitation to this study was that for regional airway 
measurements we measured only one individual subsegmental airway that feeds into each 
lung lobe and not all airways associated with each lobe.  We observed significant spatial 
relationships between ventilation defects in the right lung lobes and subsegmental airway 
morphology feeding into those lobes but did not observe these significant relationships in 
the left lung.  The lobes of the left lung are larger than those in the right lung (10) and 
therefore lobar ventilation in the left lung is spread across more airways.  By measuring 
only one subsegmental airway in each lobe we may have potentially missed abnormal 
airway morphology of other airways in each lobe.  Furthermore, the subsegmental 
airways we measured were 3
rd
 – 6th generation airways which are cartilaginous airways of 
the conducting zone.  We chose to measure these airways in particular because they were 
consistently measurable in cross-section and clearly visible on thoracic CT for each and 
every subject, whereas higher generation airways were not always visible and 
measureable in every subject.  Previous work (11) suggested that subsegmental airway 
morphology measured on CT reflects that of the small airways, however there is also 
evidence (12) that this may not always be the case.  We must also acknowledge that the 
ability to measure up to a maximum airway generation is an inherent limitation of CT due 
to the achievable resolution on these scans (13).  A second major limitation to this study 
was that we used a threshold cut off to subdivide ex-smokers into abnormally elevated 
ventilation defect percent (VDP) and those within the normal range for VDP and 
therefore our results are dependent on this threshold value.  This threshold was based on 
the upper-limit of normal (95% confidence interval) of VDP in a well characterized 
group of never-smokers from a previous study (14).  We are unsure how our findings 
would have changed if a different threshold value (ie. 90% confidence interval) was used.  
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Although it is likely we would have observed slightly different results with a more 
conservative VDP threshold. 
In Chapter 4 our goal was to phenotype COPD ex-smokers based on the apical-to-basal 
distribution of ventilation abnormalities and emphysema and to determine if apical-basal 
phenotype changes with disease progression.  We divided subjects into apical- and basal-
lung predominant phenotypes based on a method previously described by Gietema (15).  
In our study phenotypes were defined as follows (where RA950 is the relative area with 
attenuation ≤ -950HU):  RA950 in the basal-lung (RA950BL = RA950RLL + RA950LLL) and 
RA950 in the apical-lung (RA950AL = RA950RUL + RA950LUL) were used to generate the 
difference between apical- and basal-lung RA950 (∆RA950) where ∆RA950 = RA950AL - 
RA950BL.  A positive ∆RA950 was indicative of apical-lung-predominant emphysema, and 
a negative ∆RA950 indicated basal-lung-predominant emphysema.  Similarly, regional 
3
He 
VDP was used to specify apical-lung- and basal-lung-predominant 
3
He ventilation defect 
phenotypes where the ventilation defect percent in the basal-lung (VDPBL = VDPRLL + 
VDPLLL) was subtracted from the ventilation defect percent in the apical-lung (VDPAL = 
VDPRUL + VDPLUL) to generate the VDP difference between the apical- and basal-lung- 
(∆VDP).  A positive ∆VDP indicated an apical-lung-predominant ventilation defects and 
a negative ∆VDP indicated basal-lung predominant ventilation defects.  Therefore the 
method we used to phenotype COPD subjects was very specific and it is entirely possible 
that our findings may have been different if we chose to use a different apical- basal-
phenotyping strategy/equation as several others have been described (16-19).  At the 
same time, the binary classification method we used to phenotype subjects might be 
oversimplistic for characterizing such a heterogeneous and multi-component disease such 
as COPD.  Other strategies that phenotype COPD subjects based on the spatial location 
of disease using three- or multi-dimensional thresholds may offer more information on 
how the spatial location of disease impacts lung function.  In addition, we did not explore 
the distribution of ventilation abnormalities and emphysema between the lung core and 
rind regions to phenotype COPD subjects as previous studies have done (16-18, 20).  
Phenotyping based on lung core – rind distribution may offer another useful method to 
identify clinically meaningful COPD subgroups. 
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5.3.2 General Limitations 
The studies present in Chapters 2 – 4 all focus on using 3He MRI to phenotype ex-
smokers.  
3
He MRI is an extremely costly research technique and is only used in a 
handful of research centres worldwide.  It requires expensive spin-exchange optical 
pumping polarization equipment, specialized transmit – receive radiofrequency coils and 
highly trained physicists and technicians to operate polarization equipment and the MRI 
scanner.  Therefore, just being able to construct and operate a hyperpolarized noble gas 
research centre alone is a large endeavor (21).  At the same time, while we predominantly 
focused on the use of 
3
He noble gas, the global supply of this gas is declining and its 
price is increasing quickly.  Currently, 1 litre of 
3
He costs in excess of $1K.  Therefore 
given the limited supply of 
3
He along with the expense and resources required to operate 
a hyperpolarized noble gas MRI research centre, the transition of this imaging method 
into clinical setting does not seem likely.  Concomitantly, the expense of 
3
He MRI ties in 
with the general limitation common in each study presented in this thesis of small sample 
sizes.  While we believe our results are clinically relevant, we acknowledge that the 
number of subjects used in each study was much smaller than those in other large-scale 
lung imaging studies that used CT such as ECLIPSE (22), COPDGene (23) and MESA 
(24).  Future hyperpolarized noble gas studies may benefit from multi-centre trials where 
more subjects can be recruited for imaging as was previously done in the Polarized 
Helium to Image the Lung (PHIL) trial (25). 
Despite the limitations imposed by the declining levels of 
3
He, it is important to note that 
noble has MR images of ventilation were first proposed (26) with 
129
Xe gas which is 
substantially more abundant and cost effective than 
3
He.  Furthermore, recent 
improvements in commercialization of 
129
Xe polarization equipment and software have 
made global exploitation of 
129
Xe MRI a possibility. 
Along with general limitations imposed by 
3
He MRI in our studies, there may also be 
inherent limitations in our CT measurements.  We aimed to provide an understanding on 
the structure-function relationships of 
3
He ventilation abnormalities and airway and 
parenchymal disease but it is established that CT is not sensitive to very mild or 
subclinical changes to the airways and parenchyma (27).  First, due to CT resolution 
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limits, even among the most compliant subjects and highest quality scans, airways can 
only be counted and measured with confidence up to about the 10
th
 generation (13).  And 
often there will be extreme heterogeneity among the airway generations that can be 
measured in COPD cohorts making the most commonly reported measurements from the 
large and central airways of the conducting zone.  The highest generation airways we 
reported were from the 6
th
 generation airways in Chapter 3 and these were ex-smokers 
with normal spirometry and without severe disease.  Therefore the resolution limits 
imposed by CT may have limited our power to find significant results using these airway 
measurements, since the airways being measured were more central than the small 
airways < 2mm which are the origin of airflow limitation in smoking related COPD.  At 
the same time, it has also been shown (27) that CT measurements of emphysema cannot 
detect small emphysematous lesions, such as those that may occur in early or mild forms 
of COPD.  Therefore another limitation inherent in the studies in Chapters 2 – 4 is related 
to the ability of CT to measure mild or microstructural emphysema.  In this regard, we 
found that 
3
He MRI ADC measurements showed much higher sensitivity to early and 
mild emphysema as these measurements predominantly measure microstructural 
emphysema. 
 
5.4 Future Directions 
5.4.1 Longitudinal Hyperpolarized 
3
He MRI of Ex-smokers With 
and Without Airflow Limitation 
Longitudinal imaging studies monitoring pulmonary pathophysiology in susceptible 
groups of ex- and current smokers are essential to improve our understanding of COPD 
progression and treatment outcomes.  The Thoracic Imaging Network of Canada 
(TINCan) is a three-year follow-up pulmonary imaging study of 
3
He MRI and CT in ex-
smokers with and without airflow limitation (28).  Previous research has established that 
that 
3
He MRI ventilation measurements are reproducible (29), reflect response to therapy 
(30) and predict COPD exacerbation episodes (31) and therefore we believe it is valuable 
to investigate  how and if pulmonary MRI ventilation measurements change over time.   
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Thus far, 82 ex-smokers (33 ex-smokers without airflow limitation, 48 ex-smokers with 
COPD (FEV1/FVC<70%)) have undergone 
3
He MRI, inspiratory CT, pulmonary 
function testing and the six-minute walk test and completed the St. George’s Respiratory 
Questionnaire at baseline and follow-up at approximately three-years.  Figure 5-1 shows 
3
He ventilation images at baseline and follow-up and the unventilated lung regions at 
follow-up for representative subjects (The change in ventilation heterogeneity, or change 
in ventilation defect percent (∆VDP) is calculated as ∆VDP=VDPFollow-up – VDPBaseline). 
 
Figure 5-1.  
3
He ventilation images in ex-smokers at baseline and follow-up (3yr).  
Visually and quantitatively ex-smokers with COPD had a greater change and annual rate 
of change (ROC) in 
3
He ventilation over the three-years.  S1 is a 65yr male ex-smoker 
without COPD ∆VDP = +3% (ROC=+1%/yr), S2 is a 76yr male ex-smoker with 
moderate COPD ∆VDP = +6% (ROC=+2%/yr) and S3 is a 72yr female ex-smoker with 
severe COPD ∆VDP = +10% (ROC=3%/yr). 
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This longitudinal pulmonary study will address several compelling questions including: 
1) Are there regional and/or whole-lung changes in 3He ventilation 
heterogeneity from baseline to follow-up in ex-smokers with and without 
airflow limitation? 
 
2) Are there differences in ∆VDP and annual rate of change (ROC) in VDP 
between ex-smokers with mild, moderate and severe COPD?  
 
3) How do longitudinal pulmonary imaging measurements compare to 
longitudinal conventional pulmonary function test and exercise capacity 
measurements? 
 
4) How do CT measurements of emphysema and airways disease relate to 
longitudinal pulmonary MRI measurements? 
 
5) Do baseline and follow-up MRI measurements predict mortality in ex-smokers 
with and without airflow limitation? 
 
 
5.4.2 Hyperpolarized 
3
He MRI Apparent Diffusion Coefficients:  A 
Potential Tool to Evaluate Alpha-1 Antitrypsin Augmentation Therapy 
Alpha-1 antitrypsin deficiency (AATD) results in an imbalance of neutrophil elastase and 
alpha-1 antitrypsin (AAT) causing panlobular emphysema and airflow limitation.  AAT 
augmentation therapy is approved for the treatment of AATD-related lung disease and 
influences lung function decline in some AATD patients (32).  Since 
3
He MRI ADC 
measurements are highly reproducible measurements of alveolar microstructure that are 
sensitive to emphysematous changes in the lungs, we believe that acquiring longitudinal 
3
He MRI ADC measurements in AATD patients might serve as a sensitive and direct 
method to evaluate disease progression and response to AAT augmentation therapy.  
Figure 5-2 shows 
3
He ADC maps in three AATD patients and three ex-smokers with 
centrilobular emphysema at baseline and 3-year follow-up.  AATD patients reported 
elevated 
3
He ADC in the basal-lung while COPD ex-smokers reported elevated ADC in 
the apical-lung.  At the same time, AATD patients reported increased whole-lung ADC at 
3 year follow-up compared to COPD ex-smokers who reported the same ADC at baseline 
and follow-up.  The AATD subject receiving weekly augmentation therapy had a smaller 
increase in whole-lung ADC (+0.01 cm
2
/s) compared to subjects not receiving 
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augmentation therapy (S2 and S3, +0.02 cm
2
/s).  Similarly, the basal-lung ADC did not 
change in the AATD subject on augmentation therapy but increased in both AATD 
subjects not receiving therapy. 
 
 
Figure 5-2.  
3
He ADC in alpha-1 antitrypsin patients & ex-smokers with emphysema 
at baseline and three-year follow-up.  S1, 66yr male never-smoker undergoing 
augmentation therapy once/week.  S2, 62yr female ex-smoker (44pck yr) and S3, 52yr 
male never-smoker not receiving augmentation therapy.  S4, S5 and S6 are ex-smokers 
(>20 pack yr) with moderate (GOLD II) and severe (GOLD III) COPD. 
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Future work on this proof-of-concept longitudinal study of 
3
He MRI ADC measurements 
in AATD will provide answers to the following questions: 
1) Do 3He MRI ADC measurements change regionally and throughout the whole 
lung in AATD patients over time? 
2) Are changes in ADC measurements different between AATD patients and COPD 
patients with centrilobular emphysema? 
3) How do ADC measurements change longitudinally in AATD patients receiving 
augmentation therapy compared to those who are not? 
 
5.4.3 Second-Order Texture Analysis of Hyperpolarized 
3
He MR 
Images:  Beyond the Ventilation Defect 
Current image processing methods for evaluating ventilation heterogeneity on 
3
He MR 
images focus on quantifying the volume of ventilation defects throughout the lung as the 
ventilation defect percent (VDP).  Unfortunately, these measurements do not exploit the 
valuable information inherent in the ventilation signal itself.  We and other groups have 
observed that patients with the same VDP can have different local and regional 
ventilation patterns as depicted on MRI and different respiratory diseases, suggesting that 
there are measureable differences in ventilation heterogeneity that are not reflected by the 
VDP measurement alone.  Figure 5-3 shows an example of this where the 
3
He ventilation 
images from an ex-smoker without COPD, a COPD ex-smoker and an asthmatic subject 
have the same VDP but each subject has different regions of ventilation heterogeneity 
and second-order texture measurements of ventilation signal.  Therefore we believe that a 
texture analysis approach of analyzing the 
3
He ventilation signal may provide 
physiologically-relevant information on underlying disease processes. 
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Figure 5-3.  
3
He static-ventilation and 
3
He texture maps and measurements for a 
representative ex-smoker without airflow limitation, COPD subject and asthmatic 
subject.   
The Ex-smoker is a 79 year-old female with FEV1=88%, VDP=10%, f3=0.96, f12=-0.34 
and f13=0.98, the COPD subject is a 57 year-old female with FEV1=93%, VDP=10%, 
f3=0.97, f12=-0.35 and f13=0.98 and the Asthmatic is a 49 year-old female with 
FEV1=69%, VDP=10%, f3=0.97, f12=-0.35 and f13=0.97. 
 
The preliminary work for this research was focused on 1) developing a second-order 
texture analysis algorithm that measures sixteen (f1 – f16) texture features through 
statistical evaluation of a grey level co-occurrence matrix (GLCM) (33), 2) using the 
algorithm to collect texture measurements from ex-smokers without COPD, ex-smokers 
with COPD and asthmatics with similar VDP and 3) performing statistical analyses on 
texture measurements to investigate any differences between lung disease phenotypes and 
testing the sensitivity and specificity of texture measurements for predicting lung disease 
phenotype.  A semi-automated second-order texture analysis algorithm was created in 
MATLAB and is shown in Figure 5-4.   
123 
 
 
 
 
Figure 5-4.  Second-order texture analysis algorithm for hyperpolarized 
3
He MR 
images 
Texture information was only of interest in the 
3
He ventilation signal and not from the 
regions surrounding it.  Therefore we constructed an algorithm that could semi-
automatically extract the 
3
He ventilation signal without the surrounding signal void and 
then calculate texture parameters of the signal.  1, is the raw data 
3
He static-ventilation 
MR image coronal centre slice.  2 is the 
3
He static-ventilation MR image coronal centre 
slice with the trachea is removed.  3 is the filtered 
3
He image (filtered with a 10×10 
median filter) which is used to extract 4, the maximum entropy threshold mask.  4 is then 
multiplied by 1 to generate 5 which is the 
3
He ventilation signal with no surrounding 
noise.  Four gray-level co-occurrence matrices (6, one for each direction of interest; (-
1,0), (-1,-1), (0,-1) and (1,-1)) are generated from 5 and are subsequently used to extract 
the sixteen texture features used in this study (f1-f16). 
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The sixteen second-order texture parameters measured by the semi-automated algorithm 
from are listed in Table 5-1 (33).   
 
Table 5-1.  Second-order texture measurements  
f1 : Angular Second Moment  
f2 : Contrast  
f3 : Correlation 
f4 : Variance 
f5 : Homogeneity 
f6 : Sum Average 
f7 : Sum Variance 
f8 : Sum Entropy 
f9 : Entropy 
f10 : Difference Variance 
f11 : Difference Entropy 
f12 : Information Measures of Correlation 1 
f13 : Information Measures of Correlation 2 
f14 : Cluster Shade 
f15 : Cluster Prominence 
f16 : Autocorrelation 
  
 
Sixty subjects consisting of 20 ex-smokers without COPD, 20 ex-smokers with COPD 
and 20 asthmatics with VDP < 20% were included in a preliminary analysis which found 
that f3, f12 and f13 were significantly different on one-way analysis of variance (ANOVA) 
analysis (Table 5-2). 
This early work with second-order texture analysis in 
3
He MRI provided compelling data 
and motivated subsequent research from our group using texture analysis in asthmatics. 
 
 
 
 
 
125 
 
 
 
Table 5-2.  Second-order texture measurements for all study subjects 
 Ex-smokers 
(n=20) 
Mild COPD 
(n=20) 
Asthma 
(n=20) 
ANOVA 
p-value* 
f1 (×10
-4
) 100 (10) 80 (80) 100 (8) 0.70 
f2 70 (62) 63 (44) 63 (48) 0.88 
f3 0.95 (0.01) 0.96 (0.01) 0.96 (0.01) 0.003 
f4  4610 (3420) 5080 (3210) 6350 (4830) 0.36 
f5  0.29 (0.07) 0.29 (0.06) 0.30 (0.07) 0.84 
f6  120 (42) 120 (39) 140 (60) 0.47 
f7 (×10
3
) 17 (13) 19 (12) 23 (19) 0.35 
f8  5 (0.4) 5 (0.4) 5 (0.4) 0.44 
f9  8 (0.7) 8 (0.6) 8 (0.7) 0.76 
f10  70 (62) 63 (44) 63 (48) 0.88 
f11  2.7 (0.4) 2.7 (0.3) 2.6 (0.4) 0.89 
f12  -0.31 (0.03) -0.34 (0.03) -0.34 (0.03) 0.009 
f13  0.97 (0.01) 0.98 (0.01) 0.98 (0.01) 0.02 
f14 (×10
3
) 38 (159) 118 (160) 41 (154) 0.21 
f15  (×10
4
) 3630 (6070) 5080 (5760) 4950 (6180) 0.71 
f16  4570 (3390) 5050 (3190) 6310 (4810) 0.35 
f1:  Angular second moment, f2 :  Contrast,  f3:  Correlation,  f4 :  Variance,  f5 :  
Homogeneity,  f6 :  Sum Average,  f7 :  Sum Variance,  f8 :  Sum Entropy,  f9 :  
Entropy,  f10 :  Difference Variance,  f11 :  Difference Entropy,  f12 :  
Information Measures of Correlation 1,  f13 :  Information Measures of 
Correlation 2,  f14 :  Cluster Shade,  f15 :  Cluster Prominence,  f16 :  
Autocorrelation  
 
 
The Future of Texture Analysis in Pulmonary MRI:  Applications in 
129
Xe and 
19
F 
MRI 
 
The theory and data presented in this subsection laid the groundwork for the manuscript 
titled ‘Second-Order Texture Measurements of 3He Ventilation MRI:  Proof-of-Concept 
Evaluation of Asthma Bronchodilator Response’ published in Academic Radiology 
(DOI:  10.1016/j.acra.2015.10.010).  The manuscript was co-authored by Nanxi Zha, 
Damien Pike, Sarah Svenningsen, Dante PI Capaldi, David G McCormack and Grace 
Parraga.   
This manuscript confirmed that texture analysis methods can be applied to 
3
He 
ventilation MR images and used to extract measurements that quantify ventilation 
heterogeneity and change in response to therapy (34, 35).  However, in the future it is 
likely that pulmonary MRI studies using inhaled gases may transition from the use of 
3
He 
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to 
129
Xe and fluorinated (
19
F) gases.  Therefore, owing to this previous research that has 
revealed clinically meaningful results in 
3
He, scientists and clinicians should start 
investigating and implementing texture analysis algorithms (first, second, third and/or 
higher order) in 
129
Xe and 
19
F MR images.  Texture analysis algorithms and texture 
measurements, unlike quantitative measurements of ventilation defects, take advantage of 
ventilation signal present within the lung.  Early work with 
129
Xe has shown that 
ventilation defects are larger in 
129
Xe MR images compared to 
3
He MR images (36).  
This means that 
129
Xe MR images have less ventilation signal from which to extract 
texture measurements from compared to 
3
He MR images.  This may cause the texture 
measurements to be different between 
129
Xe to 
3
He MR images and importantly, the 
clinically important change in response to therapy previously observed in 
3
He MR images 
may also change or not be detected using texture measurements from 
129
Xe or 
19
F images.  
Future work using 
129
Xe and 
19
F MRI should focus on providing a better understanding of 
how/if texture measurements show clinically relevant changes in response to therapy in 
these images analogous to those observed with 
3
He MRI.  Since most previous work with 
pulmonary MRI and pulmonary ventilation has focused on ventilation defects (regions of 
signal void), a deeper understanding of pulmonary ventilation signal present in the lung 
through texture measurements could provide scientists and clinicians with novel findings 
related to ventilation heterogeneity and lung disease phenotypes. 
 
5.5 Significance and Impact 
Spirometry measurements are continuously used as the gold-standard for assessing 
pulmonary function and airflow limitation in COPD patients.  Although expiratory 
airflow measurements are globally used as diagnostic criteria for COPD, it is now widely 
known that these measurements alone do not adequately characterize the heterogeneity of 
COPD with regards to lung function and structure.  In light of this, imaging phenotypes 
of COPD have emerged as a solution to identify and characterize clinically relevant 
components of pulmonary structure and function in patients beyond conventional 
pulmonary function testing.  In this thesis we demonstrated that 
3
He MRI measurements 
of pulmonary structure and function provide a way to phenotype ex-smokers without 
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airflow limitation and COPD patients.  In this regard, in ex-smokers with normal 
spirometry there was 
3
He MRI evidence of pulmonary structural and functional 
abnormalities that were concordant with carotid atherosclerosis and mild microstructural 
emphysematous destruction or gas trapping.  In COPD patients, 
3
He MRI provided a way 
to identify distinct apical- and basal-lung predominant disease phenotypes and we 
observed that these phenotypes were different according to disease severity.   
Taken together, these results show how hyperpolarized noble gas MRI can be used as a 
tool to identify and characterize clinically relevant structural and functional changes that 
occur in COPD.  As advances in pulmonary imaging continue, and novel quantitative 
measurements emerge to evaluate lung disease, the important findings from this thesis 
will serve as a foundation for knowledge for understanding COPD phenotypes. 
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APPENDIX 
 
APPENDIX A – Imaging Evidence of the Relationship Between 
Carotid Atherosclerosis and Chronic Obstructive Pulmonary 
Disease 
As the focus of this thesis is on pulmonary imaging phenotypes of COPD, and given that 
the study in Chapter 1 provides an overview and understanding on the relationships 
between MR imaging measurements of airflow limitation and 3DUS measurements of 
carotid atherosclerosis, In Appendix A we have provided the review article titled 
‘Imaging Evidence of the Relationship between Atherosclerosis and Chronic Obstructive 
Pulmonary Disease’ which is published in Imaging in Medicine (DOI: 10.2217/iim. 
13.70, 2013).  Permission to reproduce the chosen section(s) of this article was granted 
by Future Medicine® and is provided in Appendix D. 
D Pike, TJ Lindenmaier, DD Sin and G Parraga.  Imaging Evidence of the Relationship 
between Atherosclerosis and Chronic Obstructive Pulmonary Disease.  Imaging in 
Medicine; DOI: 10.2217/iim. 13.70, 2013 
 
REVIEW ARTICLE: 
Imaging Evidence of the Relationship between Atherosclerosis 
and Chronic Obstructive Pulmonary Disease  
D Pike, TJ Lindenmaier, DD Sin and G Parraga 
 
ABSTRACT 
Tobacco smoking is a risk factor for both pulmonary disease and atherosclerosis and a 
number of studies have provided experimental and epidemiological evidence about the 
potential links between chronic obstructive pulmonary disease (COPD) and 
atherosclerosis that is not explained by tobacco smoking alone.   While this evidence is 
very compelling, the direct mechanisms that potentially accelerate atherosclerosis 
development in patients with COPD have not been established.  At the same time, major 
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advances in quantitative pulmonary and vascular non-invasive imaging tools have 
advanced the development and validation of surrogate or intermediate endpoints of these 
chronic disorders. This article provides a review of emerging and established imaging 
methods that have the potential to quantify pulmonary disease and atherosclerosis non-
invasively and robustly, in the same patients over time; we summarize studies that 
endeavored to evaluate lung structure-function and atherosclerosis in order to provide 
novel insights on disease pathogenesis and progression. 
 
INTRODUCTION AND OVERVIEW: Is there a relationship between chronic lung 
and vascular disease that is not explained by smoking history? 
There is increasing evidence that chronic obstructive pulmonary disease (COPD) and 
atherosclerosis may be directly and mechanistically related beyond shared risk factors of 
cigarette smoking and exposure to environmental pollutants.  Large scale investigations 
such as the Lung Health Study (1), the Multi-ethnic Study of Atherosclerosis (MESA) 
Lung Study (2) and the Atherosclerosis Risk in Communities (ARIC) study (3), along 
with population based studies on COPD mortality and morbidity (4-6) have established 
that impaired lung function is a risk factor for vascular disease, independent of cigarette 
smoking.   While atherosclerosis and chronic pulmonary disease share common risk 
factors such as cigarette smoke, air pollution, biomass exposure, poor nutrition and in 
much of the developed world, low socio-economic status (7), the relationship between 
COPD and atherosclerosis-related morbidities such as ischemic heart disease and stroke 
extend beyond these shared risk factors.  However, the exact mechanisms underlying this 
relationship are not well understood (8). 
As shown in Figure 1, recently, van Eeden and others have proposed the “lung 
permeability” theory as an important mechanism behind the relationship between COPD 
and atherosclerosis (8).  These authors and others suggest that inhalation of the 
environmental irritant (e.g. cigarette smoke, air pollution particles, respiratory viral or 
bacterial microbes) is the inciting event.  In response, the host mounts a robust 
inflammatory reaction to control and eliminate these environmental irritants, preventing 
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the direct translocation of toxic chemicals, respiratory pathogens and air pollution 
particles into the systemic circulation and enabling the host defenses to remove these 
unwanted visitors.  To promote this process, airway epithelial cells, alveolar macrophages 
and various circulating hematopoietic cells (eg. neutrophils) synthesize cytokines, 
chemokines and reactive oxygen and nitrogen species in the lungs.  Because the lungs are 
highly vascularized, it is possible although not proven, that during periods of 
inflammatory and oxidant stress, the alveolar-capillary interface may become highly 
permeable and allow inflammatory mediators to migrate into the systemic circulation.  
Some of these inflammatory mediators (e.g. interleukin-6 (IL-6) and interleukin 1-beta) 
can coax the liver to increase production of secondary mediators of inflammation such as 
C-reactive protein, fibrinogen, serum amyloid protein and pro-coagulant factors, and the 
bone marrow to increase the synthesis and release of leukocytes into the systemic 
circulation, causing an amplification of the inflammatory signal.  With chronic lung insult 
(as in the case of cigarette smoking or living in highly polluted areas), the alveolar-
capillary interface may “re-model” and become persistently “leaky”, leading to a state of 
chronic (low-grade) systemic inflammation even after the environmental exposure is 
removed (as in the case of smoking cessation).  The constantly elevated level of 
inflammatory markers may contribute to the genesis and progression of atherosclerosis.  
However recent work in this area (9, 10) has shown that systemic inflammation is not the 
only factor contributing to atherogenesis in COPD.  In fact, systemic inflammation is 
common to several COPD comorbidities (9) and it was recently shown that COPD 
patients with cardiovascular disease differ only in levels of IL-6 (10).  This suggests there 
must be other drivers of cardiovascular disease in COPD.  Potential mediators such as 
nutrition, inactivity, genetic factors or medication may promote vascular dysfunction in 
COPD patients.   
To date, the large majority of studies evaluating links between pulmonary and vascular 
disease have focused on pulmonary function tests to assess lung function and mainly 
carotid atherosclerosis intermediate endpoints such as intima media thickness.   One 
major limitation of “global” pulmonary function tests is that they provide no anatomical 
or regional information of the lungs (11).  This limitation has been surmounted by the 
advent of non-invasive pulmonary imaging techniques that can directly quantify 
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pulmonary structure-function correlates and enable accurate phenotyping of disease (12-
14).  
The risk of atherosclerosis can be monitored with or without vascular imaging 
techniques.  Commonly, blood level measurements of lipids such as low density 
lipoprotein (LDL), high density lipoprotein (HDL) and triglycerides and less frequently, 
inflammatory mediators such as C-reactive protein and myeloperoxidase are used to 
provide surrogate measures of lipid profile and systemic inflammation which may play a 
role in atherogenesis.  In addition to blood sampling, the ankle brachial index (ABI) -the 
ratio of the systolic pressure of the ankle to the arm, is also widely used as another “non-
imaging” surrogate measure of atherosclerosis (15, 16).  Although these non-imaging 
methods have been used in pulmonary-vascular disease studies, they are limited in the 
fact that they provide measurements of “generalized” atherosclerosis or vascular disease 
(15).  From a direct imaging perspective, carotid ultrasound (US) measurements have 
emerged as reliable tools for evaluating atherosclerosis burden because they correlate 
well with future cardiovascular events (17, 18) and importantly, the method is relatively 
rapid, inexpensive and uncomplicated to acquire and quantify.  Although there is still 
some controversy as to which ultrasound measurement best estimates risk of outcomes 
such as stroke (19), there is no disagreement that extensive development of non-invasive 
imaging methods to directly quantify atherosclerosis (20-24) has stimulated the 
development of improved medical treatment options and improved outcomes (25). 
As several excellent reviews are available on chronic respiratory disease (26) and 
cardiovascular risk (7, 27-29), and owing to the limited use of angiography (30-33)  and 
intravascular ultrasound (IVUS) (34, 35) for research purposes outside of coronary artery 
disease, here we focus on emerging pulmonary and atherosclerosis imaging techniques.  
There are few studies published that use imaging to interrogate pulmonary and vascular 
disease in the same patients.  As summarized in Table 1, a number of key studies have 
primarily used imaging to investigate the relationship between carotid atherosclerosis and 
pulmonary function in COPD.  Collectively, these studies provide a strong foundation for 
future studies that may incorporate novel imaging methods of both pulmonary and 
vascular disease in smokers and ex-smokers.  
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attenuation area, CSA: Cross sectional area 
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Figure 1:  Schematic for proposed mechanism explaining atherosclerosis burden in 
patients with chronic lung disease related to smoking or environmental toxins. 
Chronic exposure to toxins, mainly cigarette smoke and/or air pollution triggers an 
inflammatory response within the lung airspaces that is dominated by alveolar 
macrophages.  The inflammatory markers within the alveoli spill [8] into the vascular 
system where they stimulate the liver and bone marrow to release various inflammatory 
and coagulation mediators such as; C-reactive protein (CRP), fibrinogen, platelets and 
leukocytes.  The systemic inflammatory response that follows promotes atherogenesis in 
combination with high levels of circulating cholesterol, coagulation factors and 
inflammatory mediators. 
  
139 
 
 
 
IMAGING ATHEROSCLEROSIS: 
Carotid Arteries 
Carotid atherosclerosis is the main cause of transient ischemic attack and ischemic stroke, 
and is believed to be closely linked to atherosclerosis in the coronary and peripheral 
vascular beds that cause  myocardial infarction, and leg claudication, respectively (36).  
As shown in Figure 1 and in more detail in Figure 2, the carotid artery bifurcates within 
the neck and in most subjects, this allows for direct and non-invasive imaging through the 
neck tissues using ultrasound methods.  In the longitudinal or transverse view, 
atherosclerotic plaque is typically observed near the bifurcation and in the internal carotid 
artery and in the axial view, wall thickening and lumen stenosis can be visualized.  
Several imaging techniques have evolved to better understand the morphology of 
atherosclerosis and monitor its progression over time.  B-mode carotid ultrasound is a 
non-invasive, relatively inexpensive imaging technique that provides direct 
morphological measurements at the site of future cardiovascular events (18, 37).  Doppler 
ultrasound is commonly used for evaluating carotid stenosis (38).  For research purposes, 
three-dimensional US (3DUS) and carotid magnetic resonance imaging (MRI) are unique 
among carotid imaging methods in their ability to readily distinguish between different 
atherosclerotic tissue components and plaque.  This provides a way to potentially assess 
carotid plaque vulnerability (20).  Distinct from carotid atherosclerosis imaging, imaging 
the heart using thoracic computed tomography (CT) for the detection and quantification 
of coronary artery calcifications has also emerged as a means to non-invasively evaluate 
atherosclerosis risk (33). 
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Figure 2:  Schematic for Carotid Artery Atherosclerosis. 
Axial or Cross-sectional view: The common carotid artery (CCA) is shown with 
atherosclerotic plaque in yellow under a thin fibrous cap within the intima layer and 
modest lumen narrowing or arterial stenosis.   
Longitudinal or Transverse view: The CCA bifurcates approximately at the jaw line 
into the internal carotid artery (ICA) and the external carotid artery (ECA), at the 
bifurcation (BF) point. The lumen-intima, and media-adventitia boundaries and calcified 
atherosclerotic plaque are readily visible in both the axial and longitudinal views of the 
artery.  
 
B-mode ultrasound 
Brightness-mode (B-mode) ultrasound (US) is typically used to image carotid arteries for 
atherosclerotic burden principally because it is non-invasive, it is relatively inexpensive 
and it is widely available in most clinical facilities.  To obtain a two-dimensional (2D) 
grey-scale image, high frequency ultrasound pulses are transmitted to internal tissues and 
their reflections (which themselves are dependent on the different acoustic impedances of 
the tissues) are converted to different pixel intensities (39, 40).  A good example of this is 
provided in Figure 3 and shows the IMT measurement that is now recognized as robust 
and reliable for evaluating atherosclerotic burden (41).  It provides a 1D measurement of 
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the mean distance between the lumen-intima and media-adventitia boundaries of the 
common carotid artery (CCA) (40).  To standardize IMT measurements, guidelines were 
established by the Mannheim Intima-Media Thickness Consensus (42, 43).  The 2D 
ultrasound images used to segment IMT are either generated by navigating a 
reconstructed 3D volume to visualize the desired plane (44), or by directly acquiring a 2D 
image using the ultrasound probe (23).  Importantly, IMT measurements do not 
incorporate a measure of carotid plaque, as users are encouraged to perform IMT 
segmentation only in regions of the CCA that are void of plaque to ensure they capture an 
accurate representation of the intima-media layer(42, 43). 
Doppler ultrasound 
Carotid Doppler ultrasound incorporates B-mode and Doppler ultrasound imaging (45).  
The recorded B-mode 2D image provides structural and anatomical information about the 
vessel and surrounding tissues, while the Doppler component provides useful information 
about the blood flow in the vessel (46).  This offers a way to determine the velocity of 
blood in a vessel and provides information regarding the degree of stenosis in the artery 
(46).  Atherosclerotic stenosis and blood flow velocity are directly proportional; therefore 
arteries with larger plaques present with a greater blood velocity (46).  Even though 
carotid disease is still diagnosed using conventional angiography, carotid Doppler US is 
suggested to be the most accurate non-invasive imaging modality in screening individuals 
for carotid artery stenosis (38, 46).  
Three-dimensional ultrasound 
Figure 4 shows a schematic for the methodology of three dimensional (3D) ultrasound 
(US) volume acquisition.  These scans differ slightly from 2D acquisition because the US 
probe is translated along the neck of the individual.  This “linear translation” (21) along 
the neck acquires a series of 2D images that are co-registered spatially into a 3D volume 
(40).  As shown in Figure 3, several measurements have been developed to date that 
utilize reconstructed 3DUS volumes in order to monitor atherosclerotic disease 
progression.  These measurements include 2D total plaque area (TPA) measurement, and 
the 3D total plaque volume (TPV) and vessel wall volume (VWV) measurement (47-50).  
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The TPA ultrasound measurement provides a 2D measurement that quantifies the area of 
a plaque along the longitudinal view of the artery.  The user is required to outline the 
plaque as it appears in its largest dimension which can be somewhat subjective.  The 
segmentation can be performed on the US scanner by finding the plane of interest and 
freezing and magnifying the image (47) and the cursor is used to trace around the 
selected plaque (47).  The reconstructed 3D volume can also be used to isolate the 
longitudinal view of interest and perform the measurement by tracing the perimeter of the 
plaque using computer software.  Previous research (47, 51) has demonstrated that TPA 
is associated with serum cholesterol levels, hypertension myocardial infarction, risk of 
stroke and risk of death. 
Three-dimensional TPV and VWV measurements have been developed to monitor 
atherosclerotic disease progression, while providing useful information about the 
development of atherosclerotic plaques.  The first technical development of TPV (48) 
used a manual segmentation approach where the volume of the plaque was generated 
from the area of a series of axial slices.  However, more recently, TPV has been 
generated using a semi-automated approach (52) and this has helped to improve speed 
and reproducibility of the measurements. 
 A 3D IMT measurement that includes plaque can be generated from 3DUS – the 3DUS 
vessel wall volume (VWV) (41).  3DUS VWV provides a circumferential wall thickness 
measurement, including plaque (41, 53) and can be used to track changes over short time 
scales (54) and recent research has shown that these measurements correlate well with 
age and sex (40).  Ultrasound imaging measurements have been widely used to 
understand cardiovascular disease and patient outcomes (47, 55), although it is difficult to 
distinguish between atherosclerotic plaque components.   
 
  
143 
 
 
 
 
Figure 3: B-mode and 3DUS of the Common Carotid Artery. 
Top panel:  Conventional B-mode ultrasound common carotid artery image in the 
transverse plane and the generation of intima-media thickness (IMT) measurement.  
Bottom panel: 3DUS common carotid artery in the axial or cross-sectional plane with the 
generation of total plaque volume (TPV), and vessel wall volume (VWV) ultrasound 
measurements. 
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Figure 4:  Three-Dimensional Ultrasound Image Acquisition. 
Left panel: Typical 3DUS scanning procedure.  The subject is supine with head turned to 
enable access to R or L carotid artery.  The mechanical mover shown in the left panel 
holds the transducer in place and translates it up the neck.  Middle panel: Schematic for 
transducer acquiring a series of two-dimensional images that are co-registered to generate 
a three-dimensional (3D) volume. Right panel: 3D volume for the common carotid artery 
in the axial or transverse plane. 
 
Carotid magnetic resonance imaging  
Magnetic resonance imaging (MRI) provides a way to distinguish between soft tissues, 
allowing for the evaluation of plaque composition and potentially, plaque vulnerability to 
rupture and thrombosis (56).  Plaque vulnerability is typically assessed by examining 
different characteristics such as the fibrous cap, lipid core and localized calcifications in 
the carotid arteries (20, 57).  In particular, the thickness of the fibrous cap is of great 
interest, since rupturing of this component would expose the necrotic lipid core to the 
blood flow which is believed to cause thromboembolic events;  recent studies (58) have 
shown that carotid MRI findings correlate with histology and are sensitive in detecting 
thin and ruptured fibrous layers (59).  Other studies (60, 61) have reported the use of a 
gadolinium-based contrast agent to obtain a higher contrast between atherosclerotic 
plaque characteristics and have found that the contrast between plaque structures can be 
enhanced even more. 
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Thoracic computed tomography 
As shown in Figure 5, thoracic CT can be used to reveal and quantify calcifications 
within the coronary arteries as a surrogate measurement of advanced coronary artery 
disease and atherosclerosis (33).  Such calcified lesions within the arterial wall are much 
denser than surrounding cardiovascular tissue and are visualized as regions of greater x-
ray attenuation on thoracic CT scans.  Commonly, a threshold of ≥130HU is used to 
identify calcified lesions on thoracic CT based on the scoring method previously 
described by Agatston (62).  This approach has been the most widely-used quantification 
method for coronary calcifications and studies have shown that Agatston scores correlate 
with future cardiovascular events (63, 64).  The use of coronary artery calcifications has 
not been widely-used however to evaluate the relationship between vascular and 
pulmonary disease.   
 
 
Figure 5:  Axial CT view of Chronic Obstructive Pulmonary Disease Patients with 
Coronary Calcifications. 
Yellow arrows point to coronary calcifications which are easily visible by increased x-ray 
attenuation within cardiovascular tissues. 
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IMAGING CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
COPD is characterized by chronic airflow limitation and systemic inflammation and is 
currently the fourth leading cause of death worldwide, affecting approximately 10% of 
the population over 40 years of age (65).  COPD is a heterogeneous disease comprised of 
airway inflammation, alveolar destruction (emphysema), mucociliary dysfunction, 
pulmonary hypertension, and small airway remodeling (11, 66).  Traditionally, COPD is 
diagnosed using the spirometry thresh-hold of the forced expiratory volume in one 
second (FEV1) <70% of the forced vital capacity (FVC).  However, it has been suggested 
that FEV1 and FVC are relatively insensitive to the pathophysiological changes that occur 
well before lung function declines (66).  Consequently, FEV1 and FVC alone do not 
sufficiently characterize lung disease onset, progression or response to treatment, 
especially early in the disease (67, 68).  Moreover, spirometry provides only a global 
measurement of overall lung disease with no regional structural or functional information 
to identify the diseased area or the underlying pathology.  These drawbacks have 
provided the major motivation behind the development and optimization of sensitive and 
non-invasive pulmonary imaging modalities that can locate, characterize and quantify 
pathophysiological changes that cause lung function decline. 
Pulmonary imaging offers several advantages for characterization of COPD: 1) it is 
sensitive to early structural and functional changes in the lungs (69-73), 2) it allows 
visualization of the pathophysiological processes contributing to airflow limitation (14, 
74), 3) it provides regional information of which anatomical locations of the lung are 
affected by disease (14, 75), and, 4) patients can potentially be stratified for treatment 
based on lung disease phenotype identified using pulmonary imaging (74, 76-78). 
Thoracic X-ray computed tomography of COPD 
The development of quantitative tools to measure airway dimensions and parenchyma 
structure using high-resolution computed tomography (CT) have made it the pulmonary 
imaging modality of choice (13, 14, 78, 79).  As previously mentioned, pulmonary 
function tests do not correlate well with morphological changes in the lung (11, 67, 68).  
CT however, is well suited to distinguish whether lung function decline is attributable to 
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emphysema or airways disease.  Thoracic CT images of pulmonary structure are based on 
tissue attenuation of x-rays in the lung parenchyma and surrounding vasculature.  
Therefore, high-resolution images of pulmonary structure can be acquired without the use 
of contrast agents. 
Smoking-related emphysema is characterized by alveolar destruction which leads to 
increased lung volume, decreased surface area for gas exchange and either localized or 
uniform emphysematous lesions to the lung parenchyma (66).  The emphysematous 
lesions have markedly reduced density which can be identified by regions of lower x-ray 
attenuation values in Hounsfield units from the density frequency histogram taken from 
CT images (78).  One approach for quantifying the extent of emphysema has employed a 
threshold cutoff for voxels with attenuation values below a predetermined Hounsfield 
unit as emphysematous tissue (78).  CT attenuation thresholds have been used to identify 
emphysema at -910HU (80), -950HU (81), -960HU and -970HU (82).  However, -950HU 
has emerged as the most common cutoff to distinguish between emphysematous and 
healthy lung tissue (81).  Another widely-used method for determining emphysema 
severity is with a “percentile cutoff” (eg. the lowest 15th percentile) that identified the 
percent of emphysematous tissue based on the frequency distribution of attenuation 
values across a group of subjects (78, 82, 83).  Both techniques are considered acceptable 
for cross-sectional COPD studies.  However, the Alpha-1 Foundation workshop 
committee recommended (84) that only the percentile cutoff approach be used for 
longitudinal studies since technical variations have less influence on these measurements 
(84).  Another technique for quantifying emphysema also incorporated attenuation cutoff 
values, but used a statistical approach to identify low attenuation clusters (LAC) (85, 86).  
Briefly, the size of an emphysematous lesion (connected voxels below a certain 
attenuation value) is plotted against the total number of “clusters” of connected voxels on 
a log-log plot (cluster size on x axis, number of clusters on y-axis).  The slope of this 
relationship, which follows a power law, represents the size of the emphysematous lesion 
(87).  Typically flatter curves with lower slope values represent larger emphysematous 
lesions. 
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Airways disease can be assessed using CT-derived measurements of airways dimensions.  
Airway remodeling in COPD is prominently caused by inflammation within the airway 
wall epithelium and mucous plugs in the airway lumen (66).  Therefore, CT 
measurements of airway wall area (WA) and lumen area (LA) are of interest for 
evaluating the severity of airways disease.  The primary limitation of CT airway analysis 
lies within the limits of x-ray resolution and dose (78).  Previous work (88) has 
established that the major site of airflow limitation in COPD is in airways <2 mm in 
diameter.  These airways, however, are difficult to visualize on CT (89).  Many different 
computational algorithms have been used to measure airways (90-93) however, it remains 
unknown which algorithm provides the most useful airway data (84).  Figure 6 shows 
representative coronal CT images and CT-derived airway trees and LAC maps for two 
healthy (FEV1/FVC≥.70) and two COPD subjects (FEV1/FVC<.70).  Compared to the 
healthy subjects, the COPD patients have larger and greater heterogeneity of attenuation 
values which are reflected in the large LAC clusters corresponding to these low 
attenuation regions.  These images are a good representation of how CT along with 
quantification software can be used to evaluate disease severity. 
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Figure 6: Thoracic x-ray Computed tomography (CT) in Healthy older subjects and 
patients with Chronic Obstructive Pulmonary Disease. 
Left panels: CT coronal and axial centre slice scans Right panels: Corresponding CT-
derived volume rendered airway tree next to co-registered airway tree with low 
attenuation cluster (LAC) map for two healthy subjects (S1 and S2) and two COPD 
subjects (S3 and S4).  
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Magnetic Resonance Imaging of COPD  
Until recently, pulmonary magnetic resonance imaging (MRI) has been challenging 
owing to the low proton (
1
H) density (and in contrast high air density) within the lungs.  
Conventional MRI generates signal and tissue contrast based on the perturbation of 
1
H 
which is bound to both water and fat in most tissues of the body.  Distinct from other 
organs, the lungs have very low proton density which results in low contrast and little to 
no morphological information on pulmonary 
1
H MR images (25).  This has motivated the 
development and optimization of MRI techniques that are able to visualize lung structure 
and function.  Namely, hyperpolarized noble gas MRI and ultra-short echo time (UTE) 
1
H MRI have emerged as promising methods to non-invasively image the lungs and have 
been used to study COPD. 
Hyperpolarized noble-gas MRI provides a way to visualize lung function by imaging 
ventilation within the lung.  As shown in Figure 7, this breath-hold technique can be 
performed using hyperpolarized 
3
He or 
129
Xe gases (94) to generate images of ventilation 
within the lungs.  These “static-ventilation” (SV) images provide functional information 
by visualizing gas distribution, and as shown in Figure 8, ventilation distribution in 
healthy subjects is homogeneous, with gas filling all regions within the lung (95).  In 
contrast, COPD patients have regions of signal void, or ventilation defects, which 
represent areas of the lung that do not participate in ventilation (25).  To quantify 
hyperpolarized 
3
He and 
129
Xe MRI data the volume of gas visualized in the images can 
be normalized to patient’s thoracic cavity volume to generate a ventilation defect volume 
(VDV) (96), a ventilation defect percent (VDP) (97) and percent ventilation volume 
(PVV) (71).  Although it is likely that ventilation defects represent disease, the exact 
etiology underlying them is not entirely clear.  In COPD, these ventilation abnormalities 
may be due to airway disease, emphysema or a combination of both diseases.  Another 
possibility is that these areas may be slow filling and are not ventilated during the breath-
hold scan.  In the future, uncovering the pathophysiology of noble gas ventilation defects 
in COPD will require the accurate registration of structural CT images with functional 
MR images, integrating other lung structural modalities such as optical coherence 
tomography (98) and comparing MRI data with histology (99).  Beyond functional 
151 
 
 
 
imaging, noble gas MRI can also be used to probe lung microstructure by using 
diffusion-weighted MRI which can characterize the dimensions of acinar ducts and 
alveoli, the main structures involved in gas exchange (12, 100, 101).  By sensitizing the 
MRI system to diffusion of the noble gas atoms, apparent diffusion coefficient (ADC) 
maps can be generated and quantified to assess lung microstructure (100).  In COPD, 
emphysema is associated with acinar duct enlargement and alveolar destruction (66).  
These larger alveolar spaces in diseased subjects will generate higher ADC values on 
diffusion-weighted MRI scans compared to small, intact alveoli of a healthy volunteer 
(75, 99) because the gas atoms have a larger distance per unit time to travel.  This is 
represented in Figure 8 where the ADC maps display brighter colors as 
COPD/emphysema severity increases, representing an increase in ADC values and larger 
airspaces in these subjects.  A limitation to diffusion-weighted MRI in noble gas imaging 
of the lungs is related to the ventilation patterns mentioned previously.  ADC values can 
be extracted only for regions of the lung that participate in ventilation, therefore in 
patients with high VDP the structure of the VDV cannot be probed. 
Independent of MRI methods that employ tracer gases to visualize lung structure and 
function, conventional 
1
H MRI using short echo times can be used to visualize pulmonary 
structure (12).  Such methods have been employed to try to reduce air-tissue interface 
artifacts (102) which are typically abundant on pulmonary MRI, allowing acquisition of 
images that can provide structural information by differentiating between regions of low 
and high proton density (103).  This has potentially useful applications to COPD because 
low proton-density regions may represent emphysematous lesions whereas regions of 
high proton density could represent areas of other diseases or lung injuries such as edema 
(25, 103).   
Imaging Relationships Between Lung Disease and Atherosclerosis 
While cardiovascular and respiratory diseases are the first and third leading causes of 
death in the United States (104), both diseases are typically evaluated as separate 
conditions.   However, the last two decades have seen numerous studies providing 
imaging evidence that both diseases are related (1, 2, 5, 6, 57, 105-115).  These studies, 
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summarized in Table 1, have established two important clinical findings: 1) COPD 
patients have an increased burden of atherosclerosis in the form of carotid atherosclerosis 
and coronary artery plaque, and, 2) the relationship linking lung and heart diseases is 
complex and involves both structural and functional abnormalities to the lungs and 
vascular system. 
 
 
Figure 7: Conventional anatomical 
1
H MR and functional 
3
He and 
129
Xe MR 
images. 
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Top panel: Anatomical 
1
H MRI, and, Bottom panels: corresponding 
3
He (aqua-blue) and 
129
Xe (purple) MRI co-registered to anatomical MRI (grey-scale) for a healthy and COPD 
subject.   
 
Application of Carotid Ultrasound to Lung and Atherosclerosis Studies 
Carotid ultrasound semi-automated measurements of IMT make it well-suited to be used 
in large-scale studies investigating atherosclerosis and lung disease.  Studies using carotid 
ultrasound to investigate a relationship between atherosclerosis and lung disease started 
to emerge over a decade ago (55, 116, 117).  In one study (55), subjects from the British 
Regional Heart Study were evaluated and the investigators observed a cross-sectional 
relationship between carotid IMT and spirometry.  Shortly after, a significant association 
between spirometry and Doppler ultrasound measurements of stenosis in an elderly 
population of Swedish men was reported (117).  Another study (116) used carotid 
ultrasound to examine carotid IMT and the development of carotid plaques in relation to 
peak expiratory flow (PEF) in an elderly cohort from France.  Consistent with the two 
other studies, they found that reduced lung function (reduced PEF) was associated with 
increased atherosclerotic burden through elevated IMT and increased carotid plaque 
occurrence.  Four years later this area of research was revisited (3) in a large cohort 
recruited from the Atherosclerosis Risk in Communities (ARIC) study.  Using carotid 
ultrasound IMT and the ankle-brachial index (ABI) or the ratio of ankle to arm systolic 
blood pressure in tandem with spirometry measurements, a cross-sectional association 
was observed between spirometry and IMT and ABI.  This study invited future research 
on the coincident findings of lung disease and atherosclerosis using a number of imaging 
techniques.  Subsequent work focused on the relationship of carotid ultrasound 
measurements of atherosclerosis and spirometry measurements of pulmonary function. 
Several years later, a study (105) in 305 Japanese volunteers showed that COPD smokers 
had significantly greater IMT and plaque compared to smokers and non-smokers without 
airflow limitation.  Furthermore it was observed that FEV1 was independently associated 
with IMT after adjustment for age, BMI and blood pressure.  The finding that IMT was 
elevated in patients with airflow limitation was replicated two years later (106) in a 
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Korean study that showed greater IMT in COPD patients compared to non-COPD 
subjects.  This group also observed a significant correlation between IMT and spirometry 
(FEV1, FEV1/FVC and FVC).  There is evidence that this relationship may work in both 
directions, meaning that cardiovascular disease patients may have equally high risk of 
developing respiratory diseases as COPD patients are of developing cardiovascular 
conditions.  Another research team obtained pre-operative spirometry and carotid 
ultrasound measurements in a group of vascular surgery patients undergoing aortic or 
carotid artery surgeries and classified the patients based on severity of COPD (107).  
They observed that subjects with spirometry evidence of airflow limitation had 
significantly greater IMT than non-COPD vascular surgery patients.  In the five-year 
follow-up period nearly 30% of vascular surgery patients died, and after adjusting for 
confounders, elevated IMT was associated with increased total mortality.  This work was 
in agreement with another investigation that evaluated (118) relationships between 
carotid plaque, FEV1 and VC along with total lung capacity (TLC), residual volume (RV) 
and diffusion capacity of the lung for carbon monoxide (DLCO).  The researchers 
observed that subjects with plaque had statistically significantly lower FEV1, VC and 
DLCO and higher RV but no significant difference in TLC.  This was the first study to 
probe pulmonary measurements beyond spirometry and PEF, and showed that these 
relationship were complex, with lung structure-function implications (118). 
Application of Carotid Magnetic Resonance Imaging to Lung and Atherosclerosis 
Studies 
Few studies have utilized carotid MRI to study lung and heart disease that is coincident in 
patients.  One recent study (57) evaluated a subgroup from the Rotterdam cohort (119) 
using carotid MRI, carotid ultrasound and pulmonary function tests.  The results were 
consistent with other studies, showing elevated carotid wall thickening in subjects with 
airflow limitation. However the carotid MRI data added valuable information about 
carotid plaque characteristics in COPD subjects that had not previously been reported.  
They showed that:1) the severity of stenosis measured using carotid MRI was greater in 
COPD patients, 2) subjects without COPD had higher incidence of plaque calcification 
than subjects with COPD, and, 3) carotid plaque in COPD patients were more likely to 
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have a large lipid core, a recognized plaque component that is associated with 
cerebrovascular events (120).  These results were the first to associate carotid plaque 
characteristics with COPD cases and increased awareness that COPD is a risk factor for 
cardiovascular disease and importantly for debilitating ischemic events such as stroke. 
Application of Pulmonary Imaging to Lung and Atherosclerosis Studies 
Thus far, pulmonary imaging has not played a large role in studies focused on the 
relationship between lung and heart disease in smokers.  In Figure 9, we show the direct 
comparison of carotid 3DUS total plaque volume and intima media thickness with 
hyperpolarized 
3
He MRI ventilation defect percent in a never- and 2 ex-smokers with 
normal pulmonary function and without airflow limitation from our own centre.  In a 
similar approach, a study from the Emphysema and Cancer Action Project (EMCAP) 
(121) incorporated the use of thoracic CT to evaluate flow-mediated dilation (FMD) of 
the brachial artery in a group of ex-smokers with early or very mild COPD.  The results 
showed that low FEV1 and greater indices of emphysema was associated with attenuated 
FMD, suggesting that vascular endothelial function is influenced by lung function and 
structure.  Other findings from the Multi-Ethnic Study of Atherosclerosis (MESA) Lung 
Study (2, 122) also used thoracic CT to measure emphysema in subjects without 
cardiovascular disease, and evaluated subclinical atherosclerosis with carotid ultrasound 
and cardiac CT to determine vascular phenotypes.  Inverse associations were observed 
between spirometry and IMT, similar to previously described (3, 55, 105-107), but novel 
insights with respect to the relationship between emphysema and vascular disease were 
also provided.  Although whole lung emphysema percent was not related to IMT, upper-
lobe emphysema was significantly related with internal carotid IMT.  Other studies (123, 
124), have furthered our understanding of this relationship between emphysema and 
vascular disease by showing that emphysema percentage is related not only to carotid 
atherosclerosis, but also to calcification scores in the aorta, coronary arteries, as well as 
aortic and mitral annuli.  Collectively, these studies provide strong evidence of a 
relationship between atherosclerosis and emphysema and support the notion of complex, 
heterogeneous vascular and lung disease in ex-smokers. 
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Figure 8: 
3
He MRI ventilation and ADC maps. 
Top Row: Healthy older never-smoker.  Bottom Rows: Four representative COPD 
subjects with GOLD stages I– IV.  Greyscale 1H anatomical MRI is co-registered to 
aqua-blue ventilation pattern from 
3
He MRI.  Corresponding apparent diffusion 
coefficient (ADC) maps generated from diffusion-weighted MRI using b=1.6 s/cm
2
. 
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Application of Thoracic and Vascular Imaging to Evaluate Pulmonary and 
Cardiovascular Disease 
The development of cardiovascular imaging modalities that can provide surrogate 
measurements of vascular disease has played an important role in characterizing lung-
vascular disease phenotypes.  In 2003, real-time MRI of aortic flow (125) was used to 
quantify left ventricle stroke volume and cardiac performance in healthy control and 
COPD subjects (114).  The investigators observed that the COPD subjects had decreased 
cardiac performance compared to healthy volunteers and that the non-uniform breathing 
patterns in the COPD patients resulted in decreased stroke-volume.  Taken together these 
results provided evidence that the abnormal breathing patterns and shallow respiration 
that may accompany COPD may be related to cardiovascular complications.  Thoracic 
CT has also been used to provide a way to measure vascular changes and coronary artery 
calcification in patients with lung disease.  Three studies in particular (111-113), have 
used thoracic CT to investigate the relationship between aortic calcification and 
pulmonary physiology using pulmonary function tests.  Importantly, associations 
between the severity of aortic calcification were reported with lung function and 
morphologic parameters.  Interestingly, (112) this work showed that pulmonary vascular 
alterations were correlated with aortic calcification, whereas other studies (111, 113) 
showed associations between aortic calcifications and FEV1.  A number of studies (126-
128) have also investigated vascular dysfunction and arterial stiffness in COPD patients 
using pulse wave velocity (PWV), a functional measurement of vascular tone.  These 
findings showed that COPD patients exhibit increased arterial stiffness (126) and 
furthermore, that the degree of arterial stiffness was related to the severity of airflow 
limitation (127, 128). 
 
FUTURE PERSPECTIVE 
A number of recent studies have demonstrated the value of emerging and well-
established vascular and pulmonary imaging approaches for furthering our understanding 
on the direct relationship between advanced lung and vascular disease in smokers and ex-
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smokers that cannot be explained on the basis of tobacco-smoking alone.  In particular, 
carotid ultrasound measurements are valuable tools for the evaluation of cardio- and 
cerebrovascular risk. 
Beyond the evaluation and screening for inflammatory markers, the incorporation of 
carotid ultrasound and perhaps other atherosclerosis imaging methods into the clinical 
workflow and treatment plan for COPD may help identify significant peripheral, 
cardiovascular or cerebrovascular atherosclerosis.  Similarly, the acquisition of 
spirometry and other pulmonary function measurements in ex-smokers with 
cardiovascular disease or vascular risk factors would help detect airflow limitation that 
might otherwise go undiagnosed (8, 106).  In mild COPD especially, cardiovascular 
events are a major source of morbidity and mortality (8), so it is possible that advanced 
imaging of both diseases may help treatment decisions that improve outcomes overall and 
cardiovascular events in particular.  Regardless, it is important to keep in mind that the 
underlying mechanisms linking COPD and atherosclerosis are still not clear, and as 
recently described (9, 10) systemic inflammation may only provide a partial explanation 
for the links between COPD and advanced progressive atherosclerosis.   
The incorporation of pulmonary functional imaging into vascular disease studies will 
provide new insight on the role of pulmonary morphological changes in the 
pathophysiology of vascular disease.  Such studies will build on previous findings of 
emphysema in subjects with subclinical atherosclerosis (2, 123, 124).  In addition, the 
notion of different vascular and lung disease phenotypes (74, 76, 77, 129-132) also holds 
promise for this area of research.  In the future, a large-scale prospective study should be 
executed to monitor longitudinal changes in vascular and pulmonary conditions using 
sophisticated imaging techniques.  Longitudinal monitoring of vascular and pulmonary 
disease in ex-smokers will provide more insight onto the genesis and progression of 
vascular disease changes in COPD patients and using imaging, there is potential to 
monitor treatment effects and phenotype relationships.  At present, there is some 
evidence supporting a mechanistic link between pulmonary and vascular disease that is 
not explained by tobacco smoking alone, however the direct mechanisms that potentially 
accelerate atherosclerosis in ex-smokers with COPD have not been firmly established. 
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At the same time, major advances in quantitative pulmonary and vascular non-invasive 
imaging tools have advanced the development and validation of surrogate or intermediate 
endpoints of these chronic disorders.  Based on this foundation of previous research, 
there is a clear role for novel vascular and pulmonary imaging methods to identify the 
direct potential links in future studies. 
  
160 
 
 
 
REFERENCES 
1.  Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE, et al. 
The effects of a smoking cessation intervention on 14.5-year mortality: a randomized 
clinical trial. Ann Intern Med. 2005;142(4):233-9. 
2.  Barr RG, Ahmed FS, Carr JJ, Hoffman EA, Jiang R, Kawut SM, et al. Subclinical 
atherosclerosis, airflow obstruction and emphysema: the MESA Lung Study. The 
European respiratory journal. 2012;39(4):846-54. 
3.  Schroeder EB, Welch VL, Evans GW, Heiss G. Impaired lung function and 
subclinical atherosclerosis. The ARIC Study. Atherosclerosis. 2005;180(2):367-73. 
4.  Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for 
cardiovascular morbidity and mortality. Proc Am Thorac Soc. 2005;2(1):8-11. 
5.  Hansell AL, Walk JA, Soriano JB. What do chronic obstructive pulmonary disease 
patients die from? A multiple cause coding analysis. The European respiratory journal. 
2003;22(5):809-14. 
6.  Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of 
comorbidities in newly diagnosed COPD and asthma in primary care. Chest. 
2005;128(4):2099-107. 
7.  Ghoorah K, De Soyza A, Kunadian V. Increased cardiovascular risk in patients with 
chronic obstructive pulmonary disease and the potential mechanisms linking the two 
conditions: a review. Cardiol Rev. 2013;21(4):196-202. 
8.  Van Eeden S, Leipsic J, Paul Man SF, Sin DD. The relationship between lung 
inflammation and cardiovascular disease. American journal of respiratory and critical 
care medicine. 2012;186(1):11-6. 
9.  Agusti A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, et al. 
Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a 
novel phenotype. PLoS One. 2012;7(5):e37483. 
10.  Vanfleteren LE, Spruit MA, Groenen M, Gaffron S, van Empel VP, Bruijnzeel PL, et 
al. Clusters of comorbidities based on validated objective measurements and systemic 
inflammation in patients with chronic obstructive pulmonary disease. American journal 
of respiratory and critical care medicine. 2013;187(7):728-35. 
11.  Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, Edwards L, et al. Evaluation 
of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). The 
European respiratory journal. 2008;31(4):869-73. 
12.  Fain S, Schiebler ML, McCormack DG, Parraga G. Imaging of lung function using 
hyperpolarized helium-3 magnetic resonance imaging: Review of current and emerging 
translational methods and applications. J Magn Reson Imaging. 2010;32(6):1398-408. 
161 
 
 
 
13.  Coxson HO, Rogers RM. Quantitative computed tomography of chronic obstructive 
pulmonary disease. Acad Radiol. 2005;12(11):1457-63. 
14.  Mets OM, de Jong PA, van Ginneken B, Gietema HA, Lammers JW. Quantitative 
computed tomography in COPD: possibilities and limitations. Lung. 2012;190(2):133-45. 
15.  Collaboration ABI, Fowkes F, Murray G, Butcher I, Heald C, Lee R, et al. Ankle 
brachial index combined with Framingham risk score to predict cardiovascular events 
and mortality. JAMA: the journal of the American Medical Association. 
2008;300(2):197-208. 
16.  Khan TH, Farooqui FA, Niazi K. Critical review of the ankle brachial index. Curr 
Cardiol Rev. 2008;4(2):101-6. 
17.  Polak JF, Pencina MJ, Pencina KM, O'Donnell CJ, Wolf PA, D'Agostino RB, Sr. 
Carotid-wall intima-media thickness and cardiovascular events. N Engl J Med. 
2011;365(3):213-21. 
18.  Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, et al. Use of 
carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular 
disease risk: a consensus statement from the American Society of Echocardiography 
Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular 
Medicine. J Am Soc Echocardiogr. 2008;21(2):93-111; quiz 89-90. 
19.  Wannarong T, Parraga G, Buchanan D, Fenster A, House AA, Hackam DG, et al. 
Progression of carotid plaque volume predicts cardiovascular events. Stroke. 
2013;44(7):1859-65. 
20.  Toussaint JF, LaMuraglia GM, Southern JF, Fuster V, Kantor HL. Magnetic 
resonance images lipid, fibrous, calcified, hemorrhagic, and thrombotic components of 
human atherosclerosis in vivo. Circulation. 1996;94(5):932-8. 
21.  Fenster A, Parraga G, Bax J. Three-dimensional ultrasound scanning. Interface 
Focus. 2011;1(4):503-19. 
22.  Fenster A, Landry A, Downey DB, Hegele RA, Spence JD. 3D ultrasound imaging 
of the carotid arteries. Curr Drug Targets Cardiovasc Haematol Disord. 2004;4(2):161-
75. 
23.  Mallett C, House AA, Spence JD, Fenster A, Parraga G. Longitudinal ultrasound 
evaluation of carotid atherosclerosis in one, two and three dimensions. Ultrasound Med 
Biol. 2009;35(3):367-75. 
24.  Grant EG, Benson CB, Moneta GL, Alexandrov AV, Baker JD, Bluth EI, et al. 
Carotid artery stenosis: gray-scale and Doppler US diagnosis--Society of Radiologists in 
Ultrasound Consensus Conference. Radiology. 2003;229(2):340-6. 
162 
 
 
 
25.  Simon BA, Kaczka DW, Bankier AA, Parraga G. What can computed tomography 
and magnetic resonance imaging tell us about ventilation? J Appl Physiol. 
2012;113(4):647-57. 
26.  Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: Role of 
comorbidities. The European respiratory journal. 2006;28(6):1245-57. 
27.  Man SF, Van Eeden S, Sin DD. Vascular risk in chronic obstructive pulmonary 
disease: role of inflammation and other mediators. Can J Cardiol. 2012;28(6):653-61. 
28.  Sin DD, Wu L, Man SF. The relationship between reduced lung function and 
cardiovascular mortality: a population-based study and a systematic review of the 
literature. Chest. 2005;127(6):1952-9. 
29.  Maclay JD, McAllister DA, Macnee W. Cardiovascular risk in chronic obstructive 
pulmonary disease. Respirology. 2007;12(5):634-41. 
30.  Hartung MP, Grist TM, Francois CJ. Magnetic resonance angiography: current status 
and future directions. J Cardiovasc Magn Reson. 2011;13:19. 
31.  Miller JM, Rochitte CE, Dewey M, Arbab-Zadeh A, Niinuma H, Gottlieb I, et al. 
Diagnostic performance of coronary angiography by 64-row CT. N Engl J Med. 
2008;359(22):2324-36. 
32.  Schuleri KH, George RT, Lardo AC. Applications of cardiac multidetector CT 
beyond coronary angiography. Nat Rev Cardiol. 2009;6(11):699-710. 
33.  Schoepf UJ, Becker CR, Ohnesorge BM, Yucel EK. CT of coronary artery disease. 
Radiology. 2004;232(1):18-37. 
34.  Berry C, L'Allier PL, Gregoire J, Lesperance J, Levesque S, Ibrahim R, et al. 
Comparison of intravascular ultrasound and quantitative coronary angiography for the 
assessment of coronary artery disease progression. Circulation. 2007;115(14):1851-7. 
35.  Kaneda H, Ako J, Terashima M. Intravascular ultrasound imaging for assessing 
regression and progression in coronary artery disease. Am J Cardiol. 2010;106(12):1735-
46. 
36.  Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 
1993;362(6423):801-9. 
37.  Bots ML, Hoes AW, Hofman A, Witteman JC, Grobbee DE. Cross-sectionally 
assessed carotid intima-media thickness relates to long-term risk of stroke, coronary heart 
disease and death as estimated by available risk functions. J Intern Med. 
1999;245(3):269-76. 
163 
 
 
 
38.  Carpenter JP, Lexa FJ, Davis JT. Determination of sixty percent or greater carotid 
artery stenosis by duplex Doppler ultrasonography. J Vasc Surg. 1995;22(6):697-703; 
discussion -5. 
39.  Chan V, Perlas A. Basics of ultrasound imaging.  Atlas of Ultrasound-Guided 
Procedures in Interventional Pain Management: Springer; 2011. p. 13-9. 
40.  Buchanan DN, Lindenmaier T, McKay S, Bureau Y, Hackam DG, Fenster A, et al. 
The relationship of carotid three-dimensional ultrasound vessel wall volume with age and 
sex: comparison to carotid intima-media thickness. Ultrasound Med Biol. 
2012;38(7):1145-53. 
41.  Egger M, Spence JD, Fenster A, Parraga G. Validation of 3D ultrasound vessel wall 
volume: an imaging phenotype of carotid atherosclerosis. Ultrasound Med Biol. 
2007;33(6):905-14. 
42.  Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Desvarieux M, et al. 
Mannheim intima-media thickness consensus. Cerebrovasc Dis. 2004;18(4):346-9. 
43.  Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, et al. 
Mannheim carotid intima-media thickness consensus (2004-2006). An update on behalf 
of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th 
European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. 
Cerebrovasc Dis. 2007;23(1):75-80. 
44.  Shai I, Spence JD, Schwarzfuchs D, Henkin Y, Parraga G, Rudich A, et al. Dietary 
intervention to reverse carotid atherosclerosis. Circulation. 2010;121(10):1200-8. 
45.  Schäberle W. Ultrasonography in Vascular Diagnosis: A Therapy-Oriented Textbook 
and Atlas: Springer; 2010. 
46.  Byrnes KR, Ross CB. The Current Role of Carotid Duplex Ultrasonography in the 
Management of Carotid Atherosclerosis: Foundations and Advances. International 
journal of vascular medicine. 2012;2012. 
47.  Spence JD, Eliasziw M, DiCicco M, Hackam DG, Galil R, Lohmann T. Carotid 
plaque area: a tool for targeting and evaluating vascular preventive therapy. Stroke. 
2002;33(12):2916-22. 
48.  Landry A, Spence JD, Fenster A. Measurement of carotid plaque volume by 3-
dimensional ultrasound. Stroke. 2004;35(4):864-9. 
49.  Landry A, Spence JD, Fenster A. Quantification of carotid plaque volume 
measurements using 3D ultrasound imaging. Ultrasound Med Biol. 2005;31(6):751-62. 
50.  Landry A, Fenster A. Theoretical and experimental quantification of carotid plaque 
volume measurements made by three-dimensional ultrasound using test phantoms. Med 
Phys. 2002;29(10):2319-27. 
164 
 
 
 
51.  Barnett PA, Spence JD, Manuck SB, Jennings JR. Psychological stress and the 
progression of carotid artery disease. Journal of hypertension. 1997;15(1):49-55. 
52.  Buchanan D, Gyacskov I, Ukwatta E, Lindenmaier T, Fenster A, Parraga G, editors. 
Semi-automated segmentation of carotid artery total plaque volume from three 
dimensional ultrasound carotid imaging2012. 
53.  Ukwatta E, Awad J, Ward A, Buchanan D, Samarabandu J, Parraga G, et al. Three-
dimensional ultrasound of carotid atherosclerosis: Semiautomated segmentation using a 
level set-based method. Medical Physics. 2011;38:2479. 
54.  Krasinski A, Chiu B, Spence JD, Fenster A, Parraga G. Three-dimensional 
ultrasound quantification of intensive statin treatment of carotid atherosclerosis. 
Ultrasound in medicine & biology. 2009;35(11):1763-72. 
55.  Ebrahim S, Papacosta O, Whincup P, Wannamethee G, Walker M, Nicolaides AN, et 
al. Carotid plaque, intima media thickness, cardiovascular risk factors, and prevalent 
cardiovascular disease in men and women: the British Regional Heart Study. Stroke. 
1999;30(4):841-50. 
56.  Yuan C, Oikawa M, Miller Z, Hatsukami T. MRI of carotid atherosclerosis. Journal 
of nuclear cardiology. 2008;15(2):266-75. 
57.  Lahousse L, van den Bouwhuijsen QJ, Loth DW, Joos GF, Hofman A, Witteman JC, 
et al. Chronic obstructive pulmonary disease and lipid core carotid artery plaques in the 
elderly: the Rotterdam Study. American journal of respiratory and critical care medicine. 
2013;187(1):58-64. 
58.  Hatsukami TS, Ross R, Polissar NL, Yuan C. Visualization of fibrous cap thickness 
and rupture in human atherosclerotic carotid plaque in vivo with high-resolution 
magnetic resonance imaging. Circulation. 2000;102(9):959-64. 
59.  Mitsumori LM, Hatsukami TS, Ferguson MS, Kerwin WS, Cai J, Yuan C. In vivo 
accuracy of multisequence MR imaging for identifying unstable fibrous caps in advanced 
human carotid plaques. Journal of magnetic resonance imaging. 2003;17(4):410-20. 
60.  Yuan C, Kerwin WS, Ferguson MS, Polissar N, Zhang S, Cai J, et al. Contrast-
enhanced high resolution MRI for atherosclerotic carotid artery tissue characterization. 
Journal of magnetic resonance imaging : JMRI. 2002;15(1):62-7. 
61.  Wasserman BA, Smith WI, Trout HH, Cannon RO, Balaban RS, Arai AE. Carotid 
Artery Atherosclerosis: In Vivo Morphologic Characterization with Gadolinium-
enhanced Double-oblique MR Imaging—Initial Results1. Radiology. 2002;223(2):566-
73. 
62.  Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Jr., Detrano R. 
Quantification of coronary artery calcium using ultrafast computed tomography. J Am 
Coll Cardiol. 1990;15(4):827-32. 
165 
 
 
 
63.  Folsom AR, Kronmal RA, Detrano RC, O’Leary DH, Bild DE, Bluemke DA, et al. 
Coronary artery calcification compared with carotid intima-media thickness in prediction 
of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA). 
Archives of Internal Medicine. 2008;168(12):1333. 
64.  Becker A, Leber AW, Becker C, von Ziegler F, Tittus J, Schroeder I, et al. Predictive 
value of coronary calcifications for future cardiac events in asymptomatic patients with 
diabetes mellitus: a prospective study in 716 patients over 8 years. BMC Cardiovasc 
Disord. 2008;8:27. 
65.  Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al. 
International variation in the prevalence of COPD (the BOLD Study): a population-based 
prevalence study. Lancet. 2007;370(9589):741-50. 
66.  Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary 
disease. Lancet. 2004;364(9435):709-21. 
67.  Franciosi LG, Page CP, Celli BR, Cazzola M, Walker MJ, Danhof M, et al. Markers 
of disease severity in chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 
2006;19(3):189-99. 
68.  Gelb AF, Hogg JC, Muller NL, Schein MJ, Kuei J, Tashkin DP, et al. Contribution 
of emphysema and small airways in COPD. Chest. 1996;109(2):353-9. 
69.  Wang C MJPI, de Lange E and Altes T A, editor Elevated short-time-scale 
hyperpolarized helium-3 diffusion in secondhand smokers. International Society of 
Magnetic Resonance in Medicine Proceedings 2012; 2012. 
70.  Fain SB, Panth SR, Evans MD, Wentland AL, Holmes JH, Korosec FR, et al. Early 
emphysematous changes in asymptomatic smokers: detection with 3He MR imaging. 
Radiology. 2006;239(3):875-83. 
71.  Woodhouse N, Wild JM, Paley MN, Fichele S, Said Z, Swift AJ, et al. Combined 
helium-3/proton magnetic resonance imaging measurement of ventilated lung volumes in 
smokers compared to never-smokers. J Magn Reson Imaging. 2005;21(4):365-9. 
72.  Swift AJ, Wild JM, Fichele S, Woodhouse N, Fleming S, Waterhouse J, et al. 
Emphysematous changes and normal variation in smokers and COPD patients using 
diffusion 3He MRI. Eur J Radiol. 2005;54(3):352-8. 
73.  Irion KL, Marchiori E, Hochhegger B, Porto Nda S, Moreira Jda S, Anselmi CE, et 
al. CT quantification of emphysema in young subjects with no recognizable chest disease. 
AJR Am J Roentgenol. 2009;192(3):W90-6. 
74.  Galban CJ, Han MK, Boes JL, Chughtai KA, Meyer CR, Johnson TD, et al. 
Computed tomography-based biomarker provides unique signature for diagnosis of 
COPD phenotypes and disease progression. Nat Med. 2012;18(11):1711-5. 
166 
 
 
 
75.  Kirby M, Heydarian M, Wheatley A, McCormack DG, Parraga G. Evaluating 
bronchodilator effects in chronic obstructive pulmonary disease using diffusion-weighted 
hyperpolarized helium-3 magnetic resonance imaging. J Appl Physiol. 2012;112(4):651-
7. 
76.  Tulek B, Kivrak AS, Ozbek S, Kanat F, Suerdem M. Phenotyping of chronic 
obstructive pulmonary disease using the modified Bhalla scoring system for high-
resolution computed tomography. Can Respir J. 2013;20(2):91-6. 
77.  Coxson HO, Eastwood PR, Williamson JP, Sin DD. Phenotyping airway disease with 
optical coherence tomography. Respirology. 2011;16(1):34-43. 
78.  Coxson HO, Mayo J, Lam S, Santyr G, Parraga G, Sin DD. New and current clinical 
imaging techniques to study chronic obstructive pulmonary disease. American journal of 
respiratory and critical care medicine. 2009;180(7):588-97. 
79.  Matsuoka S, Yamashiro T, Washko GR, Kurihara Y, Nakajima Y, Hatabu H. 
Quantitative CT assessment of chronic obstructive pulmonary disease. Radiographics. 
2010;30(1):55-66. 
80.  Muller NL, Staples CA, Miller RR, Abboud RT. "Density mask". An objective 
method to quantitate emphysema using computed tomography. Chest. 1988;94(4):782-7. 
81.  Gevenois PA, De Vuyst P, de Maertelaer V, Zanen J, Jacobovitz D, Cosio MG, et al. 
Comparison of computed density and microscopic morphometry in pulmonary 
emphysema. American journal of respiratory and critical care medicine. 
1996;154(1):187-92. 
82.  Madani A, Zanen J, de Maertelaer V, Gevenois PA. Pulmonary emphysema: 
objective quantification at multi-detector row CT--comparison with macroscopic and 
microscopic morphometry. Radiology. 2006;238(3):1036-43. 
83.  Dirksen A, Piitulainen E, Parr DG, Deng C, Wencker M, Shaker SB, et al. Exploring 
the role of CT densitometry: a randomised study of augmentation therapy in alpha1-
antitrypsin deficiency. The European respiratory journal. 2009;33(6):1345-53. 
84.  Coxson HO. Quantitative chest tomography in COPD research: chairman's summary. 
Proc Am Thorac Soc. 2008;5(9):874-7. 
85.  Mishima M, Hirai T, Itoh H, Nakano Y, Sakai H, Muro S, et al. Complexity of 
terminal airspace geometry assessed by lung computed tomography in normal subjects 
and patients with chronic obstructive pulmonary disease. Proc Natl Acad Sci U S A. 
1999;96(16):8829-34. 
86.  Coxson HO, Whittall KP, Nakano Y, Rogers RM, Sciurba FC, Keenan RJ, et al. 
Selection of patients for lung volume reduction surgery using a power law analysis of the 
computed tomographic scan. Thorax. 2003;58(6):510-4. 
167 
 
 
 
87.  Gietema HA, Muller NL, Fauerbach PV, Sharma S, Edwards LD, Camp PG, et al. 
Quantifying the extent of emphysema: factors associated with radiologists' estimations 
and quantitative indices of emphysema severity using the ECLIPSE cohort. Acad Radiol. 
2011;18(6):661-71. 
88.  Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, et al. The nature of 
small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 
2004;350(26):2645-53. 
89.  Lutey BA, Conradi SH, Atkinson JJ, Zheng J, Schechtman KB, Senior RM, et al. 
Accurate measurement of small airways on low-dose thoracic CT scans in smokers. 
Chest. 2013;143(5):1321-9. 
90.  Nakano Y, Muro S, Sakai H, Hirai T, Chin K, Tsukino M, et al. Computed 
tomographic measurements of airway dimensions and emphysema in smokers. 
Correlation with lung function. American journal of respiratory and critical care 
medicine. 2000;162(3 Pt 1):1102-8. 
91.  King GG, Muller NL, Whittall KP, Xiang QS, Pare PD. An analysis algorithm for 
measuring airway lumen and wall areas from high-resolution computed tomographic 
data. American journal of respiratory and critical care medicine. 2000;161(2 Pt 1):574-
80. 
92.  Reinhardt JM, D'Souza ND, Hoffman EA. Accurate measurement of intrathoracic 
airways. IEEE Trans Med Imaging. 1997;16(6):820-7. 
93.  Saba OI, Hoffman EA, Reinhardt JM. Maximizing quantitative accuracy of lung 
airway lumen and wall measures obtained from X-ray CT imaging. J Appl Physiol. 
2003;95(3):1063-75. 
94.  Albert MS, Cates GD, Driehuys B, Happer W, Saam B, Springer CS, Jr., et al. 
Biological magnetic resonance imaging using laser-polarized 129Xe. Nature. 
1994;370(6486):199-201. 
95.  Kirby M, Svenningsen S, Owrangi A, Wheatley A, Farag A, Ouriadov A, et al. 
Hyperpolarized 3He and 129Xe MR imaging in healthy volunteers and patients with 
chronic obstructive pulmonary disease. Radiology. 2012;265(2):600-10. 
96.  Parraga G, Mathew L, Etemad-Rezai R, McCormack DG, Santyr GE. 
Hyperpolarized 3He magnetic resonance imaging of ventilation defects in healthy elderly 
volunteers: initial findings at 3.0 Tesla. Acad Radiol. 2008;15(6):776-85. 
97.  Mathew L, Evans A, Ouriadov A, Etemad-Rezai R, Fogel R, Santyr G, et al. 
Hyperpolarized 3He magnetic resonance imaging of chronic obstructive pulmonary 
disease: reproducibility at 3.0 tesla. Acad Radiol. 2008;15(10):1298-311. 
168 
 
 
 
98.  Coxson HO, Quiney B, Sin DD, Xing L, McWilliams AM, Mayo JR, et al. Airway 
wall thickness assessed using computed tomography and optical coherence tomography. 
American journal of respiratory and critical care medicine. 2008;177(11):1201-6. 
99.  Woods JC, Choong CK, Yablonskiy DA, Bentley J, Wong J, Pierce JA, et al. 
Hyperpolarized 3He diffusion MRI and histology in pulmonary emphysema. Magn 
Reson Med. 2006;56(6):1293-300. 
100.  Yablonskiy DA, Sukstanskii AL, Woods JC, Gierada DS, Quirk JD, Hogg JC, et al. 
Quantification of lung microstructure with hyperpolarized 3He diffusion MRI. J Appl 
Physiol. 2009;107(4):1258-65. 
101.  Saam BT, Yablonskiy DA, Kodibagkar VD, Leawoods JC, Gierada DS, Cooper JD, 
et al. MR imaging of diffusion of (3)He gas in healthy and diseased lungs. Magn Reson 
Med. 2000;44(2):174-9. 
102.  Edelman RR, Hatabu H, Tadamura E, Li W, Prasad PV. Noninvasive assessment of 
regional ventilation in the human lung using oxygen-enhanced magnetic resonance 
imaging. Nat Med. 1996;2(11):1236-9. 
103.  Ohno Y, Koyama H, Nogami M, Takenaka D, Matsumoto S, Obara M, et al. 
Dynamic oxygen-enhanced MRI versus quantitative CT: pulmonary functional loss 
assessment and clinical stage classification of smoking-related COPD. AJR Am J 
Roentgenol. 2008;190(2):W93-9. 
104.  Minino AM, Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2008. Natl 
Vital Stat Rep. 2011;59(10):1-126. 
105.  Iwamoto H, Yokoyama A, Kitahara Y, Ishikawa N, Haruta Y, Yamane K, et al. 
Airflow limitation in smokers is associated with subclinical atherosclerosis. American 
journal of respiratory and critical care medicine. 2009;179(1):35-40. 
106.  Kim SJ, Yoon DW, Lee EJ, Hur GY, Jung KH, Lee SY, et al. Carotid 
atherosclerosis in patients with untreated chronic obstructive pulmonary disease. Int J 
Tuberc Lung Dis. 2011;15(9):1265-70, i. 
107.  van Gestel YR, Flu WJ, van Kuijk JP, Hoeks SE, Bax JJ, Sin DD, et al. Association 
of COPD with carotid wall intima-media thickness in vascular surgery patients. Respir 
Med. 2010;104(5):712-6. 
108.  Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et al. 
The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in 
chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005-12. 
109.  Zvezdin B, Milutinov S, Kojicic M, Hadnadjev M, Hromis S, Markovic M, et al. A 
postmortem analysis of major causes of early death in patients hospitalized with COPD 
exacerbation. Chest. 2009;136(2):376-80. 
169 
 
 
 
110.  Sidney S, Sorel M, Quesenberry CP, Jr., DeLuise C, Lanes S, Eisner MD. COPD 
and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente 
Medical Care Program. Chest. 2005;128(4):2068-75. 
111.  Rasmussen T, Kober L, Pedersen JH, Dirksen A, Thomsen LH, Stender S, et al. 
Relationship between chronic obstructive pulmonary disease and subclinical coronary 
artery disease in long-term smokers. Eur Heart J Cardiovasc Imaging. 2013. 
112.  Matsuoka S, Yamashiro T, Diaz A, Estepar RS, Ross JC, Silverman EK, et al. The 
relationship between small pulmonary vascular alteration and aortic atherosclerosis in 
chronic obstructive pulmonary disease: quantitative CT analysis. Acad Radiol. 
2011;18(1):40-6. 
113.  McAllister DA, MacNee W, Duprez D, Hoffman EA, Vogel-Claussen J, Criqui 
MH, et al. Pulmonary function is associated with distal aortic calcium, not proximal 
aortic distensibility. MESA lung study. COPD. 2011;8(2):71-8. 
114.  van den Hout RJ, Lamb HJ, van den Aardweg JG, Schot R, Steendijk P, van der 
Wall EE, et al. Real-time MR imaging of aortic flow: influence of breathing on left 
ventricular stroke volume in chronic obstructive pulmonary disease. Radiology. 
2003;229(2):513-9. 
115.  Wells JM, Washko GR, Han MK, Abbas N, Nath H, Mamary AJ, et al. Pulmonary 
arterial enlargement and acute exacerbations of COPD. N Engl J Med. 2012;367(10):913-
21. 
116.  Zureik M, Kauffmann F, Touboul PJ, Courbon D, Ducimetiere P. Association 
between peak expiratory flow and the development of carotid atherosclerotic plaques. 
Arch Intern Med. 2001;161(13):1669-76. 
117.  Engstrom G, Hedblad B, Valind S, Janzon L. Asymptomatic leg and carotid 
atherosclerosis in smokers is related to degree of ventilatory capacity: longitudinal and 
cross-sectional results from 'Men born in 1914', Sweden. Atherosclerosis. 
2001;155(1):237-43. 
118.  Frantz S, Nihlen U, Dencker M, Engstrom G, Lofdahl CG, Wollmer P. 
Atherosclerotic plaques in the internal carotid artery and associations with lung function 
assessed by different methods. Clin Physiol Funct Imaging. 2012;32(2):120-5. 
119.  Hofman A, van Duijn CM, Franco OH, Ikram MA, Janssen HL, Klaver CC, et al. 
The Rotterdam Study: 2012 objectives and design update. Eur J Epidemiol. 
2011;26(8):657-86. 
120.  Takaya N, Yuan C, Chu B, Saam T, Underhill H, Cai J, et al. Association between 
carotid plaque characteristics and subsequent ischemic cerebrovascular events: a 
prospective assessment with MRI--initial results. Stroke. 2006;37(3):818-23. 
170 
 
 
 
121.  Barr RG, Mesia-Vela S, Austin JH, Basner RC, Keller BM, Reeves AP, et al. 
Impaired flow-mediated dilation is associated with low pulmonary function and 
emphysema in ex-smokers: the Emphysema and Cancer Action Project (EMCAP) Study. 
American journal of respiratory and critical care medicine. 2007;176(12):1200-7. 
122.  Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, et al. 
Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol. 
2002;156(9):871-81. 
123.  Chae EJ, Seo JB, Oh YM, Lee JS, Jung Y, Lee SD. Severity of systemic calcified 
atherosclerosis is associated with airflow limitation and emphysema. J Comput Assist 
Tomogr. 2013;37(5):743-9. 
124.  Dransfield MT, Huang F, Nath H, Singh SP, Bailey WC, Washko GR. CT 
emphysema predicts thoracic aortic calcification in smokers with and without COPD. 
COPD. 2010;7(6):404-10. 
125.  Eichenberger AC, Schwitter J, McKinnon GC, Debatin JF, von Schulthess GK. 
Phase-contrast echo-planar MR imaging: real-time quantification of flow and velocity 
patterns in the thoracic vessels induced by Valsalva's maneuver. J Magn Reson Imaging. 
1995;5(6):648-55. 
126.  Maclay JD, McAllister DA, Mills NL, Paterson FP, Ludlam CA, Drost EM, et al. 
Vascular dysfunction in chronic obstructive pulmonary disease. American journal of 
respiratory and critical care medicine. 2009;180(6):513-20. 
127.  Cinarka H, Kayhan S, Gumus A, Durakoglugil ME, Erdogan T, Ezberci I, et al. 
Arterial stiffness measured by carotid femoral pulse wave velocity is associated with 
disease severity in chronic obstructive pulmonary disease. Respir Care. 2013. 
128.  Sabit R, Bolton CE, Edwards PH, Pettit RJ, Evans WD, McEniery CM, et al. 
Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. American 
journal of respiratory and critical care medicine. 2007;175(12):1259-65. 
129.  Burgel PR, Paillasseur JL, Caillaud D, Tillie-Leblond I, Chanez P, Escamilla R, et 
al. Clinical COPD phenotypes: a novel approach using principal component and cluster 
analyses. The European respiratory journal. 2010;36(3):531-9. 
130.  Burgel PR, Paillasseur JL, Peene B, Dusser D, Roche N, Coolen J, et al. Two 
distinct chronic obstructive pulmonary disease (COPD) phenotypes are associated with 
high risk of mortality. PLoS One. 2012;7(12):e51048. 
131.  Marsh SE, Travers J, Weatherall M, Williams MV, Aldington S, Shirtcliffe PM, et 
al. Proportional classifications of COPD phenotypes. Thorax. 2008;63(9):761-7. 
132.  Pike D, Parraga G. Chronic obstructive pulmonary disease: more imaging, more 
phenotyping...better care? Can Respir J. 2013;20(2):90. 
171 
 
 
 
 
 
172 
 
 
 
APPENDIX B – Pulmonary Imaging Abnormalities in an 
Adult Case of Congenital Lobar Emphysema 
Appendix B reports pulmonary imaging findings in a rare case of congenital lobar 
emphysema in an adult.  While imaging of congenital pulmonary disorders is not the 
focus of this thesis, data from this Case Report highlights how imaging measurements of 
airway morphology and emphysema can be used to identify and characterize bullous 
emphysema which is a phenotype of chronic obstructive pulmonary disease.  The contents 
of Appendix B have been previously published in the Journal of Radiology Case Reports 
and permission to reproduce the article was granted by Dr. Roland Talanow, MD, PhD 
(editor-in-chief) and is provided in Appendix D. 
D Pike, S Mohan, W Ma, JF Lewis and G Parraga.  Pulmonary Imaging Abnormalities in 
an Adult Case of Congenital Lobar Emphysema.  The Journal of Radiology Case 
Reports; DOI: 10.3941/jrcr.v9i2.2048 2015 
 
Pulmonary Imaging Abnormalities in an Adult Case of 
Congenital Lobar Emphysema 
D Pike, S Mohan, W Ma, JF Lewis and G Parraga 
Congenital lobar emphysema (CLE) is a rare pulmonary abnormality that is typically 
detected in the neonatal period, although rare cases have been reported in early adulthood 
(1).   CLE is commonly associated with bronchial abnormalities/obstruction and vascular 
dysfunction, resulting in ventilation-perfusion mismatch, hyperinflation and dyspnea (2).  
Diagnosis is often based on x-ray computed tomography (CT) findings of hyperlucent 
and/or hyperinflated lung lobes along with malformations of the pulmonary vasculature 
or mediastinum.  Here, we used imaging to quantitatively evaluate the function and 
morphology of alveolar and airway structures in a young adult with acute breathlessness 
and chest pain.  
A twenty-year-old female with a one-year, five-cigarette/day smoking history and no 
previous chronic respiratory disease presented with severe chest pain and shortness of 
breath.  Chest x-ray showed localized left upper lobe (LUL) hyperlucency whereupon she 
provided written informed consent to a Health Canada and local ethics board approved 
research protocol.  The subject underwent two visits, 75 days apart that included 
spirometry, plethysmography and hyperpolarized 
3
He magnetic resonance imaging (MRI) 
to evaluate regional pulmonary ventilation as well as parenchymal morphology using the 
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3
He apparent diffusion coefficient (ADC) – a surrogate measurement of emphysema (3).  
MRI was performed in breath-hold after inhalation of a 1L 
3
He/N2 gas mixture from 
functional residual capacity (FRC) using a fast-gradient-recalled-echo (FGRE) sequence, 
previously described (4).  
3
He MRI ventilation images were quantified to generate 
ventilation defect percent (VDP) (4) which is the volume of the lung not participating in 
ventilation, normalized to total lung volume.  For the generation of 
3
He ADC, diffusion-
weighted images were acquired as previously described (4).  To evaluate parenchymal 
microstructure, we adapted a method (3) whereby    and    were defined as the 
longitudinal and transverse diffusion coefficients in the acinar ducts respectively with R 
representing the outer radius and h the depth of the intra-acinar duct.  
Thoracic CT was acquired once within twenty minutes of MRI using a 64-slice 
Lightspeed VCT scanner (GEHC, Milwaukee, WI, USA) as previously described (4).  
Pulmonary Workstation 2.0 (VIDA Diagnostics, Iowa City, IA, USA) was used to 
generate emphysema measurements including the relative area of the lung with 
attenuation values <-950HU (RA950), low attenuation clusters (LAC), and as well airway 
measurements including airway wall area percent (WA%) and lumen area (LA).   
Spirometry, plethysmography and diffusing capacity of carbon monoxide (DLCO) 
measurements showed there was modestly abnormal forced expiratory volume in one 
second (FEV1, V1:V2 70%:75%), and highly abnormal residual volume (RV, V1:V2 
125%:150%), and airways resistance (Raw, V1:V2 185%:180%), but normal DLCO 
(V1:V2 100%:115%).  Figure 1 shows CT low attenuating area (LAA) and low 
attenuation clusters (LAC) and 
3
He MRI ventilation imaging with a large LUL ventilation 
defect spatially coincident with the CT- and 
3
He MRI-defined emphysematous region.  
3
He MRI morphometric maps (higher intensity representing greater acinar duct 
dimensions) are also shown for the intra-acinar duct outer radius (R), depth (h), and inner 
radius (R-h).  Quantitative LUL measurements showed abnormal RA950  (LUL: 13%, 
other lobes: 0%), LAC (LUL: -1.5, other lobes: -2.3 to -1.8) and VDP (LUL: 29%, other 
lobes: 1%-7%).  For the LUL, acinar outer and inner radii were markedly abnormal 
(490µm and 310µm respectively) compared to the other lung lobes (300-310µm and 130-
140µm respectively).  CT airway measurements for the subsegmental bronchus leading to 
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the LUL were abnormal (WA%: 50%, LA: 19mm
2
) compared to other airways of the 
same generation (WA%: 57%-66%, LA: 10mm
2
- 16mm
2
).   
 
Figure 1: Thoracic CT and 
3
He MRI measurements, co-registration and analysis in the 
axial, sagittal and coronal planes for the 20 year-old female with congenital lobar 
emphysema presented in this case. 
CT LAA: CT low attenuation area (LAA, in red, attenuation <-950HU) with the thoracic 
CT as the background (in grey-scale), CT LAC: 3D low attenuation clusters (LAC) 
analysis generated using VIDA Pulmonary Workstation 2.0, 
3
He MRI-CT:  
3
He MRI 
static ventilation image (in blue) registered to thoracic CT (in grey-scale), 
3
He MRI 
ADC: 
3
He MRI apparent diffusion coefficient (ADC) maps for b=1.6cm
2
/s, where 
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brighter yellow-green represents higher ADC values, R:intra-acinar duct outer radius 
generated from 
3
He MRI co-registered with thoracic CT (in grey-scale), h: intra-acinar 
duct depth generated from 
3
He MRI co-registered with thoracic CT (in grey-scale), R-h: 
intra-acinar duct inner radius co-registered with thoracic CT (in grey-scale). 
In Figure 2, the CT-derived airway tree is shown in yellow co-registered with the 
3
He 
MRI ventilation image with the hyperlucent region outlined in white and the fissure 
between the LUL and LLL shown in black.  The left upper subsegmental bronchus is 
abnormally terminated with the proximal end apparently disconnected from the rest of the 
airway tree.  Relative dimensions for this abnormal airway and a similar generation 
normal airway are shown in schematic along with acinar duct morphological 
measurements for normal and abnormal LUL parenchyma estimated using 
3
He MRI and 
the Weibel model (5) assumptions.   
Figure 2: Registered CT airway tree with 
3
He MRI and CT for the 20 year-old female 
with congenital lobar emphysema presented in this case.  The white contour outlines the 
emphysematous region in the left upper lobe (LUL), the black contour outlines the entire 
LUL.  There is a noticeable mediastinal shift onto the contralateral right lung due to 
hyperinflation in the LUL.  The subsegmental bronchus feeding into the LUL was 
abnormally terminated and not connected to the rest of the airway tree and dimensions of 
the resulting airway segment were abnormal (top panel).  Acinar duct schematics for the 
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abnormal LUL parenchyma (middle panel) and normal parenchyma (bottom panel) are 
shown to scale and were estimated using Weibel model assumptions.  
 
DISCUSSION 
Albeit a rare diagnosis in adults, CLE is an important differential for unilateral 
hyperlucent lung.  The number of adult diagnoses has recently increased due to incidental 
radiological findings, but to our knowledge, this is the first report of quantitative, non-
invasive regional measurements of airway morphology, parenchymal microstructure and 
3
He ventilation.  Thoracic CT showed that the hyperlucent region was highly localized, 
with a mediastinal shift to the contralateral right side likely related to LUL over-inflation 
- a common finding in CLE.  Interestingly, we also observed focal obliteration of the 
proximal aspect of the tertiary bronchi serving the LUL apico-posterior segment (the 
LUL-LB1+2 bronchus).  This leads to a lack of connection between this segment and the 
central airways although there was no evidence of localized endobronchial mucus 
plugging, foreign body or other masses resulting in extra-luminal compression.  The 
distal segment of the apico-posterior bronchus was present but highly abnormal with a 
thinner wall (decreased WA%) and widening of the lumen (high LA) compared to similar 
airways in other regions, consistent with an occult atretic bronchus.  The precise 
relationship between bronchial atresia and CLE is unknown although the timing and level 
of embryofetal airway obstruction may explain the variety of congenital lung lesions.  
We also observed a markedly elevated (worse) LUL VDP compared to the other lobes 
and a heterogeneous pattern of 
3
He signal filling inwards from the edges of the 
emphysematous region of the apico-posterior region.  We propose collateral ventilation 
into the emphysematous area as a potential mechanism for this finding, first described in 
excised emphysematous lungs (6) and COPD patients (7).  In emphysema, there is lower 
resistance to collateral flow that may involve the 1-2 micrometer pores of Kohn, the 30 
micrometer channels described by Lambert, or the 80-150 micrometer interbronchiolar 
paths described by Martin (8).   
In contrast to healthy lung tissue in the unaffected lobes, there was an elevated outer and 
inner radius of the LUL acinar ducts as previously shown in patients with emphysema.  
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There was also an elevated acinar duct sleeve depth and this is a novel finding that 
contrasts with results in emphysema ex-smokers where decreased alveolar duct sleeve 
depths were reported.  
Finally, although we observed significant airway and parenchymal abnormalities, airflow 
limitation was mild and DLCO was normal in this adult patient.  There was evidence of 
gas trapping and very high airways resistance, both of which may be related to the atretic 
bronchus and slower time constants for LUL emptying which may have been worsened 
by collateral ventilation.  The increased airways resistance may also be driving collateral 
ventilation into the emphysematous lobe and hyperinflation– a potential source of severe 
symptoms in this patient.  Other pathologies that should be considered when 
encountering hyperlucencies on x-ray or CT that resemble CLE (in infants or adults) 
include; bronchial atresia, congenital pulmonary airway malformations (CPAM) and 
spontaneous or traumatic pneumothorax.   
Bronchial atresia is generally asymptomatic and most commonly diagnosed incidentally 
using x-ray or CT, similar to CLE.  CLE often coexists with bronchial atresia making it 
difficult to differentiate these pathologies independently.  In adult cases, both bronchial 
atresia and CLE show locally hyperinflated/emphysematous regions however, bronchial 
atresia patients exhibit mucoceles (club-like or rounded shape pathologies at the proximal 
ends of segmental or subsegmental bronchi) which are easily visualized on thoracic CT.  
Further investigation with bronchoscopy after the location of mucoceles may then 
identify blind-ending bronchi characteristic of bronchial atresia.  
Congenital pulmonary airway malformations (CPAMs) appear on CT as cysts attached to 
segmental bronchi and are frequently observed concomitant with other congenital lung 
lesions such as bronchopulmonary sequestration or bronchial atresia.  The diagnoses of 
CPAM typically occurs in the neonatal period and is sub-categorized into one of five 
subtypes with “type 3 CPAM” being the most similar to CLE because it affects at least 
one entire lobe.  In prenatal cases, ultrasound most often identifies the presence of CPAM 
as hyperechoic lesions with microcystic patterns.  If these malformations are not detected 
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until adulthood, recurrent pulmonary infections are the most common finding that 
subsequently may result in incidental chest x-ray or CT findings. 
Finally, CLE may resemble pneumothorax on chest x-ray and/or CT as evidenced by a 
prominent mediastinal shift opposite the hyperlucent lobe.  However, CLE and 
pneumothorax can be differentiated using conventional chest x-ray where the absence of 
bronchovascular abnormalities indicates pneumothorax and not CLE.  Pneumothorax is 
more easily differentiated from other diagnoses of localized hyperlucency because these 
cases most frequently report to urgent care following trauma to the thorax, when the 
possibility of congenital lesions can be ruled out.   
It is important to note that with the increasing use of chest CT, all these pulmonary 
pathologies may be observed in young adults and frequently, the exact genesis of the 
malformations may never be determined.  In summary, quantitative thoracic imaging 
provides a way to definitively diagnose and quantify the critical structure-function 
relationships in an adult case of CLE in whom established measurements of pulmonary 
function (DLCO, FEV1) do not. 
 
 
TEACHING POINT 
In a 20 year old with acute, severe chest pain and dyspnea, thoracic CT and 
3
He MRI 
revealed an abnormal atrectic bronchus leading to a left upper lobe (LUL) congenital 
lobar emphysema with acinar duct morphologies that were very different from smoking-
related emphysematous bullae.  There was also functional imaging evidence of collateral 
ventilation leaking from the fissure into the LUL, providing an explanation for severe 
symptoms in this adult in whom pulmonary function (Diffusing capacity of carbon 
monoxide (DLCO), Forced expiratory volume in one second (FEV1)) measurements do 
not. 
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TABLES 
Table 1:  Summary Table for Congenital Lobar Emphysema (CLE) 
Etiology 
 Characterized by compression of lung tissue – emphysema, 
that is usually localized to one but can be several lung lobes 
 Usually the upper lobes are affected (>50% of cases) 
 Trapped gas within the localized emphysematous region 
causes displacement of the mediastinum into the opposite 
lung 
Incidence 
 Prevalence of 1 in 20,000 to 1 in 30,0000 
Gender Ratio 
 Affects males more than females 3:1 
Age Predilection 
 Nearly all cases present within the first year after birth but 
rare cases have been diagnosed in adulthood 
Risk Factors 
 Prenatal vascular abnormalities 
 Congenital heart disease (ventricular septal defects, ductus 
arteriosus) 
Treatment 
 Lobectomy is the accepted treatment for CLE 
 In older patients conservative management may be effective  
 In infants and neonates an emergency thoracotomy is 
sometimes performed  
Prognosis 
 Following surgical intervention, patients generally develop 
normal lung function without respiratory impairment in 
follow-up (>1 year)    
Findings on Imaging 
 Localized hyperlucency or regions of reduced density (<-
950HU) on x-ray computed tomography (CT) scans 
 Mediastinal shift towards the opposite lung from the 
affected lobe 
 Tracheo-bronchial and abnormalities  
 Localized abnormalities to the pulmonary vasculature in the 
affected lung lobe 
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ABBREVIATIONS 
CLE:  Congenital lobar emphysema 
CPAM:  Congenital pulmonary airway malformations 
LUL:  Left upper lobe 
LLL:  Left lower lobe 
3
He MRI:  Hyperpolarized helium-3 magnetic resonance imaging 
FGRE:  Fast gradient recalled echo sequence 
CT:  Computed tomography 
VDP:  Ventilation defect percent 
ADC:  Apparent diffusion coefficient 
RA950:  Relative area of the lung with attenuation values <-950HU 
LAA:  Low attenuation areas 
LAC:  Low attenuation clusters 
WA:  Airway wall area 
LA:  Airway lumen area 
FEV1:  Forced expiratory volume in one second 
Raw:  Airways resistance 
DLCO:  Diffusing capacity of the lung for carbon monoxide 
FRC:  Functional residual capacity 
DL:  Longitudinal diffusion coefficient of acinar ducts 
DT:  Transverse diffusion coefficient of the acinar ducts 
R:  Outer radius of the intra-acinar ducts 
h: Depth of the intra-acinar ducts 
KEYWORDS 
Congenital Lobar Emphysema, Bronchial Atresia, Hyperpolarized 
3
He, Magnetic 
Resonance Imaging, Computed Tomography, Emphysema, Airways Disease 
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Pulmonary Magnetic Resonance Imaging and CT Parametric Response Mapping 
Phenotypes in Ex-smokers with and without Chronic Obstructive Pulmonary 
Disease.  Imaging Network Ontario Symposium 2015.  London, ON, Canada 
 
5. N Zha, DPI Capaldi, D Pike, DG McCormack, IA Cunningham and G Parraga.  
Principal component analysis of the CT density histogram to generate parametric 
response maps of COPD.  Imaging Network Ontario Symposium. London, ON, 
Canada 
 
6. N Zha, DPI Capaldi, D Pike, DG McCormack, IA Cunningham and G Parraga.  
Principal Component Analysis of the CT Density Histogram to Generate 
Parametric Response Maps of COPD.  The International Society for Optical 
Engineering Annual Scientific Meeting 2015, Orlando, FL, USA 
 
7. S Svenningsen, G Paulin, D Pike, S Mohan, DG McCormack and G Parraga.  
Pulmonary Functional Imaging of Bronchiectasis: A First Look at Ventilation 
Abnormalities and their Relationship with Pulmonary Function and Symptoms. 
The London Health Research Day Symposium 2014, London, ON, Canada 
 
8. S Svenningsen, G Paulin, D Pike, S Mohan, DG McCormack and G Parraga.  
Pulmonary Functional Imaging of Bronchiectasis: A First Look at Ventilation 
Abnormalities and their Relationship with Pulmonary Function and Symptoms.  
The American Thoracic Society Annual Scientific Meeting 2014, San Diego, CA, 
USA 
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9. F Guo, D Pike, S Svenningsen, HO Coxson, JJ Drozd, J Yuan, A Fenster and G 
Parraga. Development and Applications of Pulmonary Structure-Function 
Registration Methods.  The International Society for Optical Engineering Annual 
Scientific Meeting 2014, San Diego, CA, USA 
 
10. D Pike, M Kirby, F Guo, DD Sin, HO Coxson, DG McCormack and G Parraga. 
Sex, Airways Disease and Emphysema in Ex-smokers with and without Airflow 
Limitation.  Imaging Network of Ontario Symposium 2014, Toronto, ON, 
Canada 
 
11. D Pike, M Kirby, S Svenningsen, HO Coxson, NAM Paterson, DG McCormack 
and G Parraga.  Are Hyperpolarized 
3
He Magnetic Resonance Imaging 
Ventilation Defects Clinically Relevant in Ex-smokers without Airflow 
Limitation? Radiological Society of North America Annual Scientific Meeting 
2013, Chicago, IL, USA 
Associated Award (International):  The Radiological Society of North 
America Research Trainee Prize, $1000 
 
Peer Reviewed Poster Presentations and Conference Proceedings (33)  
 
1. E Lessard, A Ouriadov, D Pike, DG McCormack and G Parraga.  Longitudinal 
Three-Year Decline in Alpha-1 Antitrypsin Deficiency: Regional Worsening in 
Emphysema and Ventilation.  The American Thoracic Society Annual Scientific 
Meeting 2016, San Francisco, CA, USA  
 
2. D Pike, DPI Capaldi, S Mattonen, F Guo, A Ward, DG McCormack and G 
Parraga.  Second-Order Texture Analysis of Hyperpolarized 
3
He MRI – Beyond 
the Ventilation Defect.  The International Society of Magnetic Resonance in 
Medicine Annual Scientific Meeting 2015, Toronto, ON, Canada 
 
3. DPI Capaldi, N Zha, D Pike, K Sheikh, DG McCormack, G Parraga. 3He MRI 
and CT Parametric Response Mapping of Small Airways Disease: The Battle-
Ground for Ground Truth. The International Society of Magnetic Resonance in 
Medicine Annual Scientific Meeting 2015, Toronto, ON, Canada 
 
4. DPI Capaldi, K Sheikh, S Svenningsen, D Pike, DG McCormack, G Parraga. 
MRI Measurements of Regional Ventilation Heterogeneity: Ventilation Defect 
Clusters.  The International Society of Magnetic Resonance in Medicine Annual 
Scientific Meeting 2015, Toronto, ON, Canada 
 
5. D Pike, A Ouridov, S Mohan, DG McCormack and G Parraga.  Evaluation of 
Emphysema in Alpha-1 Antitrypsin Deficiency Patients using 
3
He MRI – A 
Potential Tool for Monitoring Response to Augmentation Therapy.  The 
American Thoracic Society Annual Scientific Meeting 2015, Denver, CO, USA  
 
203 
 
 
 
6. D Pike, M Kirby, D Capaldi, N Zha, DG McCormack, HO Coxson and G 
Parraga.  Differences in Pulmonary Ventilation in Ex-smokers with and without 
COPD after Three years:  Longitudinal Results of the TINCan Cohort. The 
American Thoracic Society Annual Scientific Meeting 2015, Denver, CO, USA 
 
7. C Davis, D Pike, S Svenningsen, DG McCormack, D O’Donnell, JA Neder, G 
Parraga, Ventilation Heterogeneity in Older Never-Smokers and GOLD stage I-
IV COPD: Poorly Communicating Fraction and MRI Ventilation defects in the 
TINCan Cohort. The American Thoracic Society Annual Scientific Meeting 2015, 
Denver, CO, USA 
 
8. D Pike, M Kirby, D Capaldi, N Zha, DG McCormack, HO Coxson and G 
Parraga.  Differences in Pulmonary Ventilation in Ex-smokers with and without 
COPD after Three years:  Longitudinal Results of the TINCan Cohort.  London 
Health Research Day 2015, London, ON, Canada 
 
9. D Pike, M Kirby, D Capaldi, N Zha, DG McCormack, HO Coxson and G 
Parraga.  Differences in Pulmonary Ventilation in Ex-smokers with and without 
COPD after Three years:  Longitudinal Results of the TINCan Cohort.  Imaging 
Network Ontario Symposium 2015, London, ON, Canada 
 
10. C Davis, D Pike, S Svenningsen, DG McCormack, D O’Donnell, JA Neder, G 
Parraga, Ventilation Heterogeneity in Older Never-Smokers and GOLD stage I-
IV COPD: Poorly Communicating Fraction and MRI Ventilation defects in the 
TINCan Cohort. London Health Research Day 2015, London, ON, Canada 
 
11. DPI Capaldi, N Zha, D Pike, K Sheikh, DG McCormack and G Parraga.  
Pulmonary Magnetic Resonance Imaging and CT Parametric Response Mapping 
Phenotypes in Ex-smokers with and without Chronic Obstructive Pulmonary 
Disease.  Imaging Network Ontario Symposium 2015, London, ON, Canada 
 
12. N Zha, DPI Capaldi, D Pike, DG McCormack, IA Cunningham and G Parraga.  
Principal component analysis of the CT density histogram to generate parametric 
response maps of COPD.  London Health Research Day 2015, London, ON, 
Canada 
 
13. S Svenningsen, G Paulin, A Wheatley, D Pike, J Suggett, DG McCormack and 
G Parraga.  Oscillating Positive Expiratory Pressure (oPEP) Therapy in Chronic 
Obstructive Pulmonary Disease and Bronchiectasis.  European Respiratory 
Society Congress 2014, Munich, Germany 
 
14. D Pike, TL Lindenmaier; LM Mielniczuk, DG McCormack and G Parraga.  An 
Airways Disease Phenotype is related to Pulmonary Artery Abnormalities in 
COPD.  The American Thoracic Society Annual Scientific Meeting 2014. San 
Diego, CA, USA 
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15. D Pike, M Kirby, F Guo, DD Sin, HO Coxson, DG McCormack and G Parraga.  
Sex, Airways Disease and Emphysema in Ex-smokers with and without Airflow 
Limitation.  The American Thoracic Society Annual Scientific Meeting 2014. 
San Diego, CA, USA 
 
16. D Pike, M Kirby, S Svenningsen, DD Sin, DG McCormack, HO Coxson and G 
Parraga. Pulmonary Computed Tomography and 
3
He Magnetic Resonance 
Imaging of GOLD Unclassified Ex-smokers:  Does Imaging Matter? The 
American Thoracic Society Annual Scientific Meeting 2014. San Diego, CA, 
USA 
 
17. D Pike, M Kirby, DD Sin, DG McCormack, HO Coxson and G Parraga. 
Pulmonary Imaging of Chronic Obstructive Pulmonary Disease in Ex-smokers: 
Thoracic Imaging Network of Canada (TINCan) Cross-sectional Evaluation.  
The American Thoracic Society Annual Scientific Meeting 2014. San Diego, CA, 
USA 
Associated Award (International):  American Thoracic Society Respiratory 
Structure and Function Scholarship, $500 
 
18. W Ma, K Sheikh, D Pike, S Svenningsen, HO Coxson, DG McCormack and G 
Parraga.  Conventional Pulmonary MRI and CT of Bronchiectasis and 
Emphysema: Tissue density measurements and relationship to pulmonary 
function tests.  The American Thoracic Society Annual Scientific Meeting 2014. 
San Diego, CA, USA 
 
19. D Pike, M Kirby, DD Sin, DG McCormack, HO Coxson and G Parraga. 
Thoracic Imaging Network of Canada (TINCan): Answering Clinically 
Relevant Pulmonary Structure-Function Questions Through Imaging.  Imaging 
Network of Ontario Symposium 2014, Toronto, ON, Canada 
 
20. D Pike, M Kirby, S Svenningsen, DD Sin, DG McCormack, HO Coxson and G 
Parraga.  Imaging Global Initiative for Chronic Obstructive Pulmonary Disease 
(GOLD) Unclassified Ex-smokers: A Hyperpolarized 
3
He MRI and Thoracic 
CT Investigation.  Imaging Network of Ontario Symposium 2014, Toronto, ON, 
Canada 
 
21. F Guo, D Pike, S Svenningsen, HO Coxson, JJ Drozd, J Yuan, A Fenster and G 
Parraga. Deformable Pulmonary Structure-Function Registration Methods: 
Towards Pulmonary Image-Guidance Methods for Improved Airway Targeted 
Therapies and Outcomes.  Imaging Network of Ontario Symposium 2014, 
Toronto, ON, Canada 
 
22. D Pike, M Kirby, DD Sin, DG McCormack, HO Coxson and G Parraga. 
Pulmonary Imaging of Chronic Obstructive Pulmonary Disease in Ex-smokers: 
Thoracic Imaging Network of Canada (TINCan) Cross-sectional Evaluation.  
The London Health Research Day Symposium 2014, London, ON, Canada 
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23. F Guo, D Pike, S Svenningsen, HO Coxson, JJ Drozd, J Yuan, A Fenster and G 
Parraga. Deformable Pulmonary Structure-Function Registration Methods: 
Towards Pulmonary Image-Guidance Methods for Improved Airway Targeted 
Therapies and Outcomes.  The London Health Research Day Symposium 2014, 
London, ON, Canada  
 
24. S Mohan, D Pike, W Ma, JF Lewis and G Parraga.  Pulmonary Imaging 
Abnormalities in an Adult Case of Congenital Lobar Emphysema.  The London 
Health Research Day Symposium 2014, London, ON, Canada 
 
25. W Ma, K Sheikh, D Pike, S Svenningsen, HO Coxson, DG McCormack and G 
Parraga.  Conventional Pulmonary MRI and CT of Bronchiectasis and 
Emphysema: Tissue density measurements and relationship to pulmonary 
function tests.  The London Health Research Day Symposium 2014, London, 
ON, Canada 
 
26. D Pike, M Kirby, A Wheatley, D. McCormack and G Parraga. Evaluation of 
Airway Morphology in Chronic Obstructive Pulmonary Disease of 
Hyperpolarized Helium-3 Magnetic Resonance Imaging and Computed 
Tomography. International Society for Magnetic Resonance in Medicine 2013, 
Salt Lake City, UT, USA 
Associated Award (International):  International Society for Magnetic 
Resonance in Medicine Abstract Scholarship, $450 
 
27. D Pike, M Kirby, K Sheikh, D Buchanan, C Neron, J.D. Spence, N.A. 
Paterson, H.O. Coxson, D.G. McCormack and G Parraga.  Airways Disease in 
Asymptomatic Ex-smokers without Airflow Limitation: Relationship to 
Carotid Atherosclerosis.  The American Thoracic Society Annual Scientific 
Meeting 2013, Philadelphia, PA, USA 
 
28. D Pike, M Kirby, K Sheikh, D Buchanan, C Neron, JD Spence, NAM 
Paterson, HO Coxson, DG McCormack and G Parraga.  On the Relationship 
Between Carotid Atherosclerosis and Airways Disease in Ex-smokers without 
Airflow Limitation. Imaging Network Ontario 2013, Toronto, ON, Canada 
 
29. D Pike, M Kirby, A Wheatley, DG McCormack and G Parraga. Airway 
Morphology in Chronic Obstructive Pulmonary Disease using Hyperpolarized 
3
He Magnetic Resonance Imaging and x-ray Computed Tomography.  London 
Imaging Discovery Day 2013, London, ON, Canada 
 
30. D Pike, M Kirby, A Wheatley, DG McCormack and G Parraga. Evaluation of 
Airway Morphology in Chronic Obstructive Pulmonary Disease of 
Hyperpolarized Helium-3 Magnetic Resonance Imaging and Computed 
Tomography. London Health Research Day 2013, London, ON, Canada 
 
206 
 
 
 
31. M Kirby, D Pike, A Wheatley, NAM Paterson, D.G. McCormack and G 
Parraga.  Hyperpolarized Helium-3 Magnetic Resonance Imaging Phenotypes 
of Chronic Obstructive Pulmonary Disease: Relationship to Exacerbations.  
American Thoracic Society 2013, Philadelphia, PA, USA 
 
32. M McDonald, M Mannion, D Pike, K Lewis, M Browne, M Rise and V Booth. 
High Resolution Structures and Structure-Function Relationships in Histidine-
Rich Antimicrobial Peptides from Cod.  Biophysical Society Annual Scientific 
Meeting 2013, Philadelphia, PA, USA 
 
33. D Pike, M Morrow and V Booth. Characterizing Membrane Interactions of 
Antimicrobial Peptide MSI-78 Using 
31
P Nuclear Magnetic Resonance. 
Memorial University of Newfoundland Research Symposium 2012, St. John’s, 
NL, Canada 
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ACADEMIC CONFERENCES WITH PROCEEDINGS FEATURED 
2016 American Thoracic Society Conference, San Francisco, CA, International 
 National Student Research Forum, Galveston, TX, International 
 Memorial University Medical Research Conference, St. John’s, NL, Provincial 
 
2015    International Society of Magnetic Resonance in Medicine (ISMRM) Conference, 
Toronto, ON, International  
American Thoracic Society Conference, Denver, CO, International  
Imaging Network of Ontario, Toronto, ON, National 
London Health Research Day, London, ON, Provincial 
 
2014    International Society of Magnetic Resonance in Medicine Conference (ISMRM), 
Milan, ITA, International 
American Thoracic Society Conference, San Diego, CA, International 
Imaging Network of Ontario, Toronto, ON, National 
London Imaging Discovery Day, London, ON, Provincial 
London Health Research Day, London, ON, Provincial 
 
2013    Radiological Society of North America (RSNA), Chicago, IL, International 
International Society of Magnetic Resonance in Medicine (ISMRM) Conference, 
Salt Lake City, UT, International 
American Thoracic Society Conference, Philadelphia, PA, International 
Imaging Network of Ontario, Toronto, ON, National 
London Imaging Discovery Day, London, ON, Provincial 
London Health Research Day, London, ON, Provincial 
 
 
 
PROFESSIONAL MEMEBERSHIPS 
 
  
Feb. 2016 – present  
Jan. 2016 – present 
Sep. 2015 - present 
Jan. 2013 – present 
Canadian Interventional Radiology Association (CIRA) 
Clinician Investigator Training Association of Canada (CITAC) 
Canadian Medical Association (CMA) 
Radiological Society of North America (RSNA) 
Jan. 2013 – present  American Thoracic Society (ATS) 
Jan. 2013 – present Canadian Thoracic Society (CTS) 
Jan. 2012 – present  
 
International Society of Magnetic Resonance in Medicine (ISMRM) 
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RESEARCH EDUCATION DEVELOPMENT 
 
2015  Medical Resident Research Trainee Supervision 
  Resident (PGY-3 Internal Medicine): Michael Mitar, MD 
Project:  Longitudinal Evaluation of Emphysema in Alpha-1 Antitrypsin 
Deficiency Patients using Diffusion-weighted 
3
He MRI:  Monitoring 
Response to Augmentation Therapy 
Abstract:  Evaluation of Emphysema in Alpha-1 Antitrypsin Deficiency 
Patients using 
3
He MRI – A Potential Tool for Monitoring Response to 
Augmentation Therapy.   
 
2015  Medical Resident Research Trainee Supervision  
  Resident (PGY-2 Internal Medicine): Chris Davis, MD  
Manuscript:  C Davis, K Sheikh, D Pike, S Svenningsen, DG McCormack, 
D O’Donnell, JA Neder and G Parraga. Ventilation Heterogeneity in 
Never-smokers and COPD: Comparison of Pulmonary Functional 
Magnetic Resonance Imaging with Poorly Communicating Fraction 
derived from Plethysmography.  Academic Radiology; DOI:  
10.1016/j.acra.2015.10.022 
 
2014  Medical Student Research Trainee Supervision  
  Pre-clerkship MD Candidate:  Nanxi Zha, BEeng 
Manuscript:  N Zha, D Pike, S Svenningsen, DPI Capaldi, DG 
McCormack and G Parraga.  Second-Order Texture Measurements of 
3
He 
Ventilation MRI: Proof of Concept Evaluation of Asthma Bronchodilator 
Response. Academic Radiology DOI:  10.1016/j.acra.2015.10.010 
 
2013  Medical Resident Research Trainee Supervision  
  Resident (PGY-2 Internal Medicine): Sindu Mohan, MD  
Manuscript:  D Pike, S Mohan, W Ma, JF Lewis and G Parraga.  
Pulmonary Imaging Abnormalities in an Adult Case of Congenital Lobar 
Emphysema.  The Journal of Radiology Case Reports; DOI: 
10.3941/jrcr.v9i2.2048 2015 
 
2012  Undergraduate Summer Student Supervision  
  Student: William Alexander, Faculty of Engineering, Memorial University 
  6 Week Project: Differential Scanning Calorimetry of Bacterial 
Membranes 
 
2011  Undergraduate Summer Student Supervision  
  Student: Kathleen O’Grady, Faculty of Engineering, Memorial University 
6 Week Project: 
31
P Solid State Nuclear Magnetic Resonance of Dynamic 
Systems 
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RELEVANT GRADUATE COURSEWORK 
Conceptual Magnetic Resonance Imaging (Instructor:  Charles McKenzie PhD) – 93% 
Principles of Medical Imaging (Instructors:  David Holdsworth  PhD, Maria Drangova 
PhD, Keith St. Lawrence PhD, Ting Yim-Lee PhD) – 80% 
Nuclear Magnetic Resonance (Instructor:  Blaine Chronik PhD) – 84% 
Vascular Imaging (Instructor:  Aaron Fenster PhD, FCCPM) – 99% 
Research Ethics and Biostatistics (Instructor:  Aaron Fenster PhD, FCCPM) – 94% 
Inferencing From Data Analysis (Instructor:  Yves Bureau PhD) – 85% 
Scientific Communications (Instructor:  Terry Thompson PhD) – 94% 
Digital Image Processing (Instructor:  Hanif Ladak PhD, P. Eng) – 92% 
Imaging Principles (Instructor:  Ian Cunningham PhD, FCCPM, FAAPM) – 90% 
 
LEADERSHIP, VOLUNTEER AND COMMUNITY ACTIVITIES 
 
2016 Volunteer, Memorial University Faculty of Medicine Clinical Research 
Interest Group – Co-founder and President 
Volunteer, Memorial University Faculty of Medicine Undergraduate (MD) 
Research Representative  
Volunteer, Memorial University Faculty of Medicine Undergraduate (MD) 
Radiology Representative  
 
2015 Volunteer, Memorial University Faculty of Medicine Medical Doctor 
(MD) Research Representative  
Volunteer, Memorial University Faculty of Medicine Medical Doctor 
(MD) Radiology Representative  
Volunteer, Memorial University Faculty of Medicine Medical Doctor 
(MD) Research Representative  
Volunteer, Camp Delight Oncology Camp Counsellor and Mentor 
 Volunteer, Memorial University Faculty of Medicine Monte Carlo 
Fundraiser  
Volunteer, Schulich Medicine and Dentistry Society Medical Biophysics 
Graduate Recruitment Committee 
Member, London Ontario Soccer League 
Volunteer, Track 3 Ski School Instructor  
Volunteer, Schulich Medicine and Dentistry Society Medical Biophysics 
Graduate Representative 
 
2014 Volunteer, Schulich Medicine and Dentistry Society Medical Biophysics 
Graduate Recruitment Committee 
Volunteer, Schulich Medicine and Dentistry Society Medical Biophysics 
Graduate Representative 
 Participant/Member, MEC Charity Road Race Series (London, Ontario) 
Member, London Ontario Soccer League 
Volunteer, Track 3 Ski School Instructor  
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  Member, Network of Imaging Students (NOISe) 
 
2013  Participant/Member, Forest City Road Race Series (London, Ontario) 
Member, London Ontario Soccer League 
Volunteer, Track 3 Ski School Instructor  
  Member, Network of Imaging Students (NOISe)   
 
2012 Participant, Forest City Road Race Series Half-Marathon (London, 
Ontario) 
Participant, MEC Charity Road Race Series (London, Ontario) 
Member, Network of Imaging Students (NOISe)  
Volunteer, Canadian Ski Patrol (Nationwide On-hill Certification), St. 
John’s, NL 
  Volunteer, Memorial University Campus Foodbank, St. John’s Campus  
Member, Hockey Newfoundland and Labrador, Provincial Goaltending 
Development Committee  
  Member, Memorial University Faculty of Biochemistry Vice President of 
  Athletics 
Volunteer, Hockey Newfoundland and Labrador Midget AAA 
Goaltending Coach  
 
2011 Volunteer, Canadian Ski Patrol (Nationwide On-hill Certification), St. 
John’s, NL 
  Volunteer, Memorial University Campus Foodbank, St. John’s Campus  
  Volunteer, Women in Science and Engineering (WISE), Mentor 
Member, Hockey Newfoundland and Labrador, Regional Goaltending 
Development Committee  
Volunteer, Hockey Newfoundland and Labrador Midget AAA 
Goaltending Coach  
 
2010 Volunteer, Canadian Ski Patrol (Nationwide On-hill Certification), St. 
John’s, NL 
  Volunteer, Memorial University Campus Foodbank, St. John’s Campus 
  Volunteer, Memorial University Science Matters, Career Development  
  Programme 
Member, Hockey Newfoundland and Labrador, Regional Goaltending 
Development Committee  
Volunteer, Hockey Newfoundland and Labrador Midget AAA 
Goaltending Coach  
 
2009 Volunteer, Canadian Ski Patrol (Nationwide On-hill Certification), St. 
John’s, NL 
  Volunteer, Memorial University Campus Foodbank, St. John’s Campus 
Member, Hockey Newfoundland and Labrador, Regional Goaltending 
Development Committee  
 
